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Zusammenfassung
Das Ziel dieser Arbeit war es mit Hilfe eines Zellkulturmodells, basierend auf der hu-
manen Colonkrebszellline LS180, und einer Kombination von Methoden der Proteom-
und Metabolomanalyse sowie der Molekularbiologie, die molekularen Mechanismen
fu¨r die gastrointestinale (gastrointestinal, GI) Toxizita¨t der Mycophenolsa¨ure (my-
cophenolic acid, MPA) aufzukla¨ren.
Im ersten Schritt wurde das Zellkultursystem validiert. Hierbei wurde die Sta-
bilita¨t von wichtigen Transportern und pharmakametabolisierenden Enzymen u¨ber
13 Passagen durch Westernblotanalyse besta¨tigt. Außerdem wurde sichergestellt,
dass die zu untersuchenden Pharmaka in den getesteten Konzentrationen nicht
zelltoxisch waren. Insgesamt wurde besta¨tigt, dass LS180-Zellen ein geeignetes
Modell sind, um die molekularen Gru¨nde fu¨r MPA-induzierte GI Nebenwirkungen
aufzuzeigen. In Kombination mit Metabolom- und Proteomanalysen durch nukleare
magnetische Resonanz (nuclear magnetic resonance, NMR)- und Massenspektrome-
trie (mass spectrometry, MS)-Messungen, die eine schnelle und umfassende analy-
tische Strategie darstellen, Vera¨nderungen in biochemischen Stoffwechselwegen und
Toxizita¨tsmechanismen aufzukla¨ren, bildete diese schnell wachsende und einfach zu
handhabende Zellline eine optimale Grundlage fu¨r unsere NMR- und MS-basierten
Experimente.
Anfangs wurden die Effekte von MPA, des MPA-Derivats Mycophenolat Mofetil
(mycophenolate mofetil, MMF), des MMF-Esterrests 4-(2-Hydroxyethyl)morpholin
und MPA in Kombination mit 4-(2-Hydroxyethyl)morpholin auf LS180-Zellen un-
tersucht. Das Zellkulturmodell wurde in Hinsicht auf Anreicherung des Zellkultur-
mediums mit fo¨talem Ka¨lberserum und Guanosin (um MPA-induzierte Effekte auf-
zuheben) und auf die Auswirkungen auf Zelllebensfa¨higkeit und Proliferation weiter
untersucht, um optimale und physiologisch sinnvolle Bedingungen fu¨r die folgenden
Experimente sicherzustellen. MPAs antiproliferativer Effekt konnte durch Zugabe
von Guanosin zum Zellkulturmedium ru¨ckga¨ngig gemacht werden, jedoch lediglich
u¨ber einen Zeitraum von 72 Stunden. Da sich das Epithel des Magen-Darm-Trakts
1
Zusammenfassung
alle 3-5 Tage vollsta¨ndig erneuert, wurden die Effekte u¨ber 5 Tage beobachtet, wobei
sich ein signifikanter Einbruch der Proliferation (p<0.001) nach 5 Tagen Inkuba-
tionszeit zeigte. Die Effekte der Guanosinzugabe wurden mit Hilfe zweier anderer
Zelllinien kreuzvalidiert.
Messung von Nukleotidkonzentrationen und Nukleotidenergieniveaus mittels Hoch-
leistungsflu¨ssigkeitschromatographie (high performance liquid chromatography,
HPLC)-MS in LS180-Zellen nach Behandlung mit MPA mit und ohne Guanosin-
beigabe zeigte eine gravierende Verarmung der LS180-Zellen an Guanosinnukleoti-
den. Trotz Anreicherung und wiederholter Dosierung der Zellen mit der maximalen
Guanosinkonzentration (1000µM) waren Guanosinmono-, Guanosindi- und Guano-
sintriphosphatniveaus auf etwa 40% der Kontrollwerte gesenkt (p<0.001). Erho¨hte
Uridin- und Cytidinnukleotidkonzentrationen, verursacht durch die Verarmung an
Guanosinnukleotiden, waren ebenfalls nicht durch Zugabe von Guanosin zu nor-
malisieren. Dieses Ungleichgewicht ko¨nnte beispielsweise Einfluss auf den Glyko-
sylierungsstatus von Proteinen haben, wie er auch spa¨ter in den Proteomanalysen
sichtbar wurde. Intrazellula¨re Konzentrationen von zyklischem Adenosinmonophos-
phat und zyklischem Guanosinmonophosphat waren jedoch nicht betroffen, wie
durch Enzymimmuntests sichergestellt wurde.
Um intrazellula¨re Medikamenten- und Metabolitenkonzentrationen und Konzen-
trationen in LS180-Zellkulturmedien messen zu ko¨nnen, wurde eine HPLC-MS-
Methode fu¨r MPA, MMF und ihre Metabolite entwickelt. Der Versuch, diesen Assay
zu validieren, scheiterte an Matrixeffekten, die die Analytstabilita¨ten, vor allem der
Metabolite, gravierend beeintra¨chtigten. Diese Effekte wurden bis jetzt noch nicht in
der Literatur beschrieben. Da diese Matrixeffekte ho¨chstwahrscheinlich von der An-
wesenheit und Konzentration von bestimmten Serumproteinen und dem pH-Wert
der Probe abha¨ngen, ko¨nnte unsere Beobachtung ebenfalls eine Relevanz fu¨r die
Messung klinischer Blut- und Urinproben haben.
Proteomanalyse von LS180-Zellen nach MPA-Behandlung durch stabile Isotopen-
markierung durch Aminosa¨uren in Zellkultur (stable isotope labeling by amino acids
in cell culture, SILAC) und gelbasierte Flu¨ssigkeitschromatographie (GeLC)-MS
zeigte, dass die Expression von 35 Proteinen signifikant vera¨ndert war. Datenanalyse
mit Hilfe verschiedener online-Programme und Datenbanken zeigte, dass insbeson-
dere Proteine des Lipidmetabolismus und strukturelle Proteine, die an der Bildung
von Gap Junctions beteiligt sind und damit die epitheliale Integrita¨t garantieren,
2
betroffen waren. Ebenso waren Prozesse, die guanosinnukleotidabha¨ngig sind, sig-
nifikant beeintra¨chtigt. Die Kreuzvalidierung von schon publizierten Daten (Rat-
tenmodell und humane Zelllinien ohne Krebsursprung) mit den MPA-induzierten
Proteomvera¨nderungen in LS180-Zellen war erfolgreich und besta¨tigte nochmals
die Eignung von LS180-Zellen als Modell. Weitere Datenanalyse, die auf der Bil-
dung von Proteinnetzwerken basiert und fu¨r die verschiedene Datenbanken verwen-
det wurden, deutete auf eine Beeintra¨chtigung weiterer Proteine hin, die jedoch
durch Westernblotanalysen widerlegt wurde. Teilweise uneinheitliche Ergebnisse
von MS- und Westernblotanalysen ließen auf MPA-induzierte Vera¨nderungen von
post-translationalen Modifikationen schliessen, insbesondere da bekannt ist, dass
MPA die Glykosylierung von Proteinen beeintra¨chtigt und Glykoproteinsynthese
Uridin- und Cytidintriphosphat abha¨ngig ist.
Die direkte Identifizierung von Proteintargets durch kovalente Modifikation der Pro-
teine durch MPA und MPA-Metabolite, insbesondere durch das Mycophenolsa¨ure--
acylglucuronid (mycophenolic acid acyl glucuronide, AcMPAG), mit Hilfe eines anti-
MPA/AcMPAG-Antiko¨rpers schlug fehl, obwohl der Ansatz ausreichend validiert
worden war und in der Literatur bekannt ist. Wa¨hrend in der Literatur nur Pro-
teinmodifikationen durch AcMPAG in Betracht gezogen wurden, wurden hier auch
andere mo¨gliche Addukte beru¨cksichtigt, die u¨ber a¨hnliches Toxizita¨tspotential wie
AcMPAG-Addukte verfu¨gen ko¨nnten.
Metabolomanalyse durch 1H-NMR-Messungen besta¨tigte Vera¨nderungen im Lipid-
metabolismus, wie sie auch schon in der Proteomanalyse gesehen wurden. MPA
steigerte die Synthese von Cholesterol, freien Fettsa¨uren und Phosphatidylcholin.
Ungleichgewichte in Konzentrationen dieser wichtigen Membranbestandteile ko¨nnte
eine Beeintra¨chtigung der intestinalen Barrierefunktion zur Folge haben.
Keine Beeintra¨chtigung des Kohlenhydratmetabolismus war messbar. Versuche mit
markierter Glukose und 13C-NMR-Messungen zeigten keine A¨nderungen in oxida-
tivem versus anaplerotischem Glukosestoffwechsel, lediglich ein Trend zu einem
gesteigerten oxidativen Metabolismus war sichtbar (statistisch nicht signifikant).
Diese Daten decken sich weitgehend mit den Ergebnissen aus den zuvor beschriebe-
nen Proteomicsexperimenten. Die krebsartige Natur der LS180-Zellen und eine
vera¨nderte Metabolisierung von Glukose, auf den die 1D- und 2D-NMR-Daten hin-
weisen, spiegelten sich in unseren Daten wahrscheinlich wieder.
Ein in vitro-Darmentzu¨ndungsmodell aus LS180- und RAW 264.7-Zellen wurde ba-
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sierend auf einem schon existierenden Modell aus Caco-2- und RAW 264.7-Zellen
entwickelt, um Entzu¨ndungsreaktionen, die mo¨glicherweise durch MPA und/oder die
Metabolite ausgelo¨st werden, zu untersuchen. Das Modell basierte auf der Freiset-
zung von Zytokinen von RAW 264.7-Zellen durch Stimuli wie Medikamente oder
Lipopolysaccharid. Fu¨r MPA und die MPA-Metabolite wurde keine Zytokinfreiset-
zung gemessen, wa¨hrend die positive Kontrolle eine starke Reaktion hervorrief. Da
die Testsubstanzen keine Zytokinfreisetzung von RAW 264.7-Zellen auslo¨sten, wur-
den keine Folgeexperimente ausgefu¨hrt. Mit geringfu¨gigen A¨nderungen, z.B. Kokul-
tivierung beider Zelltypen in der selben Zellkulturschale, ko¨nnte dieses andernfalls
vielversprechende Modell weitere Einsichten in die Toxizita¨tsmechanismen von MPA
geben.
Zusammenfassend beweisen unsere Studien die Eignung des LS180-Zellkulturmodells
und zeigen sogar Vorzu¨ge gegenu¨ber den oft verwendeten Caco-2-Zellen auf.
MPA beeintra¨chtigte insbesondere nukleotidabha¨ngige Prozesse, die Expression
struktureller Proteine, sowie den Fettsa¨ure- und Lipidmetabolismus in LS180-Zellen.
Diesen Ergebnissen nach, kann die GI Toxizita¨t zum Teil einer eingeschra¨nkten Bar-
rierefunktion des durch MPA kompromittierten Epitheliums zugeschrieben werden,
wie auch vera¨nderten Konzentrationen an essentiellen Proteinen und Membranbe-
standteilen. Unsere Studien beru¨cksichtigen daru¨ber hinaus wichtige Aspekte der
Validierung von Modellsystemen und Assays. Ein umfassender Einblick in die Me-
chanismen MPAs molekularer Toxizita¨t konnte mit Hilfe der vielfa¨ltigen Methoden,
die im Rahmen dieser Arbeit zum Einsatz kamen, gewonnen werden.
In Abbildung 0.1 sind die hier vorgeschlagenen Toxizita¨tsmechanismen von MPA
in Abha¨ngigkeit voneinander und die verwendeten Methoden dargestellt.
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Abb. 0.1: Vorgeschlagene Mechanismen der GI Toxizita¨t von MPA aufgekla¨rt
durch das LS180-Zellkulturmodell in Kombination mit den verwendeten
Methoden. Die erwa¨hnten MPA-abha¨ngigen Effekte wurden mit Hilfe des LS180-
Zellkulturmodells erkla¨rt mit Ausnahme von “Kovalente Modifizierung von Proteinen
durch MPA und MPA-Metabolite”. Dieses Experiment lieferte keine sinnvollen Ergeb-
nisse, jedoch wurden kovalente Proteinmodifikationen zuvor in der Literatur beschrieben.
Das LS180-RAW 264.7-Kokulturmodell, wie es von uns eingesetzt wurde, zeigte keine
Immunreaktion gegen MPA oder MPA-Metabolite. Ein modifiziertes Kokulturmodell,
wie es in spa¨teren Abschnitten diskutiert wird, ko¨nnte Informationen hinsichtlich Im-
munreaktionen gegen modifizierte Proteine liefern. FBS: fo¨tales Ka¨lberserum (fetal
bovine serum), GeLC: gelbasierte Flu¨ssigkeitschromatographie, HPLC: Hochleistungs-
flu¨ssigkeitschromatographie (high performance liquid chromatography), MPA: Mycophe-
nolsa¨ure (mycophenolic acid), MS: Massenspektrometrie (mass spectrometry), NMR:
nucleare magnetische Resonanz (nuclear magnetic resonance), SILAC: stabile Isotopen-
markierung durch Aminosa¨uren in Zellkultur (stable isotopic labeling by amino acids in
cell culture).
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Summary
The objective of this thesis was the elucidation of the molecular mechanisms of the
gastrointestinal (GI) toxicity of mycophenolic acid (MPA) using a cell culture model
based on the human colon cancer cell line LS180 and a combination of methods of
proteome and metabolome analysis as well as molecular biology methods.
In a first step the cell culture system was validated. The stability of important
transporters and drug-metabolizing enzymes was ensured by western blot analysis
over 13 passages. It also was assured that the test drugs did not show cytotoxicity
within the tested concentration ranges. Overall it was confirmed that LS180 cells are
an appropriate model to clarify the molecular mechanisms of MPA-induced GI side
effects. In combination with proteome and metabolome analyses by nuclear mag-
netic resonance (NMR) and mass spectrometry (MS) measurements, which provide
a fast and comprehensive approach to explain changes in metabolic pathways and
mechanisms of toxicity, this fast-growing and easily manageable cell line constituted
an optimal basis for our NMR- and MS-based studies.
The effects of MPA, the MPA-derivative mycophenolate mofetil (MMF), the MMF
ester residue 4-(2-hydroxyethyl)morpholine, and MPA in combination with 4-(2-hy-
droxyethyl)morpholine on LS180 cells were examined. The cell culture model was
further investigated in terms of supplementation of the cell culture medium with
fetal bovine serum and guanosine (to reverse MPA-induced effects) and the effects
on cell viability and proliferation to guarantee optimal and physiologically reason-
able conditions for the following experiments. MPA’s antiproliferative effects were
reversed by supplementation of the cell culture medium with guanosine, but only
over a period of 72 hours. Since the epithelium of the GI tract is renewed every
3-5 days, the effects were monitored over 5 days whereupon a significant decrease in
proliferation appeared after 5 days of incubation (p<0.001). The effects of guano-
sine supplementation were cross-validated with two other cell lines.
Measurement of nucleotide concentrations and nucleotide energy levels using high
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performance liquid chromatography (HPLC)-MS in LS180 cells after MPA treat-
ment with and without guanosine supplementation resulted in marked depletion of
guanosine nucleotides in LS180 cells. Despite supplementation and redosing of cells
with the maximal guanosine concentration (1000µM) levels of guanosine mono-, di-,
and triphosphates decreased to about 40% of control values (p<0.001). Elevated uri-
dine and cytidine nucleotide concentrations, triggered by the depletion of guanosine
nucleotides, were not reversible by supplementation with guanosine either. These
imbalances could influence the glycosylation status of proteins as it was apparent in
later conducted proteome analyses. On the other hand intracellular concentrations
of cyclic adenosine monophosphate and cyclic guanosine monophosphate were not
affected as evaluated by enzyme-linked immunosorbent assays.
To measure intracellular drug and metabolite concentrations and concentrations in
LS180 cell culture media, an HPLC-MS assay for MPA, MMF, and their metabolites
was developed. The attempt to validate this assay failed due to matrix effects which
severely compromised analyte stabilities, especially the stability of the metabolites.
These effects had not been described in the literature before. Since these matrix
effects very likely depended on the presence and concentration of certain serum
proteins and a sample’s pH value, our observations might be relevant for the mea-
surement of clinical blood and urine samples.
Proteome analysis of LS180 cells after MPA treatment by stable isotopic label-
ing by amino acids in cell culture (SILAC) and gel-based liquid chromatography
(GeLC)-MS showed that the expression of 35 proteins was significantly affected.
Data analysis using several online programs and databases revealed that especially
proteins of lipid metabolism, structural proteins that are involved in the formation of
gap junctions and guarantee epithelial integrity, are compromised. Cross-validation
of already published data (rat model and human cell lines of non-cancerous ori-
gin) with MPA-induced proteome changes in LS180 cells was successful and again
confirmed the applicability of LS180 cells as model system. Further data analysis,
which was based on the construction of protein networks and for which different
databases were used, pointed towards disturbance of additional proteins. Partly in-
consistent results of MS and western blot analyses indicated MPA-induced changes of
post-translational modifications, especially since MPA is known to affect the glyco-
sylation of proteins and glycoprotein synthesis is dependent on uridine and cytidine
triphosphate.
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The direct identification of covalent modification of proteins by MPA and MPA
metabolites, especially by the mycophenolic acid acyl glucuronide (AcMPAG) metabo-
lite, using an anti-MPA/AcMPAG antibody failed although the approach had been
thoroughly validated and is known throughout the literature. While in the literature
only protein modifications by AcMPAG are considered, here other possible adducts,
that should exhibit a similar potential of toxicity as AcMPAG adducts, were taken
into account as well.
Metabolome analysis by 1H NMR measurements confirmed changes in lipid meta-
bolism as they were seen in proteome analyses before. MPA increased the synthesis
of cholesterol, free fatty acids, and phosphatidylcholine. Imbalances in concentra-
tions of these important membrane constituents could compromise intestinal barrier
function.
No impairment of carbohydrate metabolism was measureable. Experiments with
marked glucose and 13C NMR measurements did not show changes in oxidative
versus anaplerotic glucose metabolism, just a trend towards increased oxidative
metabolism was observed (not statistically significant). These data corresponded
to the results of the previously described proteomics experiments. The cancerous
nature of LS180 cells and a changed glucose metabolism, which is indicated by 1D
and 2D NMR data, is most likely reflected in our data.
An in vitro gut inflammation model based on LS180 and RAW 264.7 cells was
developed by modification of an already existing model of Caco-2 and RAW 264.7
cells to include inflammatory processes possibly triggered by MPA and/or MPA
metabolites. The model is based on the liberation of cytokines from RAW 264.7
cells by stimuli such as drugs or lipopolysaccharide. No release of cytokines was
seen for MPA and MPA metabolites, whereas the positive control triggered a strong
reaction. Since the test compounds did not cause cytokine release from RAW 264.7
cells, no further experiments were conducted. With marginal changes, e.g. coculture
of both cell types in the same cell culture dish, this otherwise promising model could
provide further insight in MPA’s mechanisms of toxicity.
Overall our studies demonstrated the applicability of the LS180 cell culture model
and even show advantages over the often used Caco-2 cells.
MPA especially compromised nucleotide-dependent processes, the expression of struc-
tural proteins, as well as fatty acid and lipid metabolism in LS180 cells. According
to these results, MPA’s GI toxicity is partly attributable to an impaired barrier
9
Summary
function of the MPA-compromised epithelium, but also to changed concentrations
of essential proteins and membrane components. Moreover, our studies considered
important aspects in terms of the validation of model systems and assays. Compre-
hensive insight in the mechanisms of MPA’s molecular toxicity was gained by the
multifaceted methods used within the scope of this thesis.
In Figure 0.2 the proposed molecular mechanisms of MPA’s toxicity are summa-
rized in context of the used methods.
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Fig. 0.2: Proposed molecular mechanisms of MPA’s GI toxicity elucidated using
the LS180 cell culture model and various methods. The listed MPA-dependent
effects were determined using the LS180 cell culture model except for “Covalent mod-
ification of proteins by MPA and MPA metabolites”. This experiment did not yield
analyzable results, but covalent modifications of proteins have been described in the
literature before. The LS180-RAW 264.7 cell coculture model as it was used by us did
not show immune reactions to MPA or MPA metabolites. A modified coculture model
as discussed in later sections could provide information about immune reactions to modi-
fied proteins and/or intra- and extracellular parameters. FBS: fetal bovine serum, GeLC:
gel-based liquid chromatography, HPLC: high performance liquid chromatography, MPA:
mycophenolic acid, MS: mass spectrometry, NMR: nuclear magnetic resonance, SILAC:
stable isotopic labeling by amino acids in cell culture.
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1 Introduction
1.1 Immunosuppression and mycophenolic acid
Over 25,000 organ transplants are performed annually in the United States of Amer-
ica with another 100,000 patients waiting for a transplant [1, 2]. To minimize the
discrepancy between demand and supply, the improvement of transplantation out-
comes is fundamental.
Any immunosuppressive treatment, crucial for graft maintenance, needs to be bal-
anced between drug efficacy and tolerability [1, 3]. Nowadays a broad range of im-
munosuppressive drugs are available to customize regimens. Most commonly used
are steroids, calcineurin inhibitors such as cyclosporine and tacrolimus, mammalian
target of rapamycin inhibitors such as sirolimus (rapamycin), and other agents, e.g.
antiproliferatives such as mycophenolic acid (MPA). Most regimens feature MPA in
combination with calcineurin inhibitors and steroids due to diminished major side
effects despite well maintained immunosuppression [4].
1.1.1 History and success of MPA
MPA was discovered as a product of different Penicillium species and first extracted
from Penicillium stoloniferum in the 1890’s by Bartolomeo Gosio [5, 6]. Within the
following decades it was found to have antiviral, antifungal [7], and antineoplas-
tic [8, 9] effects and became the first comprehensively characterized antibiotic in
history. Another valuable property of MPA is its immunosuppressive nature [10].
Until the end of the 20th century the antiproliferative drug of choice in combination
therapies was 6-mercaptopurine, which was primarily marketed as its prodrug aza-
thioprine (AZA) [11]. The preference for AZA as an antiproliferative lapsed when
findings in animal models of transplantation [12–16] and first clinical trials around
1990 [16–19] led to the approval of mycophenolate mofetil (MMF), the morpholi-
noethyl ester prodrug and first formulation of MPA for kidney transplantation in
1995. Within a few years, MMF became the most frequently used antiproliferative
agent in immunosuppressive drug regimens for kidney, pancreas, liver, and heart
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transplantation [20]. Today, instead of AZA, MMF is commonly administered in
transplant regimens combined with cyclosporine and corticosteroids [4, 11, 21, 22],
exhibiting superior performance and safety profiles [23, 24].
1.1.2 The two formulations of MPA
Currently MPA is available in two formulations [25]. The conventional mycopheno-
late mofetil (MMF, CellCept R©, International Union of Pure and Applied Chemistry
(IUPAC) name: 2-(morpholine-4-yl)ethyl(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-
oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate; Roche Pharmaceuticals,
Basel, Switzerland; approved in 1995 [20]) is immediately released after drug in-
take. The alternate, tentatively advanced formulation enteric-coated mycophenolate
sodium (EC-MPS, myfortic R©, sodium salt of (4E)-6-(4-hydroxy-6-methoxy-7-me-
thyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; Novartis Pharma
AG, Basel, Switzerland; approved in 2005 [21]) delays the release of the pharma-
cologically active component MPA until more distal portions of the small intestine
to diminish upper gastrointestinal (GI) side effects. Structures, sum formulas, and
molecular weights of MPA, EC-MPS, MMF, and the ester moiety 4-(2-hydroxy-
ethyl)morpholine (subsequently called morpholinoethanol) are shown in Figure 1.1.
1.1.3 Benefits and adverse effects of MPA and their
consequences
Amongst other reasons for the success of MPA is that it neither possesses cardiovas-
cular nor renal toxicity [4, 20, 25]. The former is of major interest considering that
the main cause of death in renal transplant patients is of cardiovascular origin, the
latter taking into account that calcineurin inhibitor adverse effects (especially renal
toxicity) contribute to chronic allograft dysfunction and potentially graft loss.
Additional benefits are a lack of diabetogenic potential due to the fact that MPA
is mainly metabolized by glucuronidation [20], superiority to AZA in diminishing
incidence and severity of acute rejection episodes, which are a main reason for graft
loss during the first year after kidney and heart transplantation [26, 27], as well as
reduced dyslipidemia, improved wound healing [28, 29], and increased patient and
graft survival as long-term benefits [30, 31]. Another favorable attribute of MPA
immunosuppression is the possibility of reduction or withdrawl of the combination
drugs (cyclosporine and corticosteroids) [32].
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Fig. 1.1: Chemical structures, sum formulas, and molecular weights of
mycophenolic acid, enteric-coated mycophenolate sodium, mycophenolate
mofetil, and 4-(2-hydroxyethyl)morpholine.
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The main concern about MPA typically is GI intolerability which tends to be more
severe than GI side effects occurring in patients on other immunosuppressive drug
regimens [20, 25, 33–35]. These, yet not fully elucidated disorders, are mainly at-
tributed to MPA itself, MPA’s acyl glucuronide metabolite (AcMPAG), and im-
paired immunity under immunosuppressive therapy. Other very common side effects
associated with MPA therapy resemble those of AZA such as hematologic disorders,
e.g. anemia, thrombocytopia, leucopenia, and malignancy [25, 34, 36, 37].
1.1.4 Pharmacodynamic properties: Mechanism of
immunosuppression
Inosine monophosphate dehydrogenase inhibition
The enzyme inosine monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) cat-
alyzes the nicotinamide adenine dinucleotide (NAD)-dependent oxidation of ino-
sine 5’-monophosphate (IMP) to xanthosine 5’-monophosphate (XMP) and reduced
nicotinamide adenine dinucleotide (NADH):
IMP + NAD+ + 2H2O ⇀↽ XMP
− + NADH + 2H+.
A cross-linked position in metabolism makes IMPDH a popular target for sev-
eral classes of drugs, i.e. for anticancer (tiazofurin), antiviral (ribavirin, thiazole-
4-carboxamide adenine dinucleotide), and immunosuppressive (MPA, mizorbine)
therapy [38, 39]. IMPDH can either be inhibited by modification of the substrate
site (ribavirin, mizorbin) or NAD-binding site (MPA, thiazole-4-carboxamide ade-
nine dinucleotide).
MPA is a non-competitive reversible non-nucleoside inhibitor of IMPDH, the rate-
limiting enzyme in the de novo pathway of purine synthesis [4, 20, 40]. In most
cell types a salvage pathway is utilized for purine synthesis additionally to the de
novo pathway to replenish purine pools. Lymphocytes, in contrast to other cells,
are almost fully dependent on purine de novo generation [41]. Unrestrained de novo
synthesis of purines as precursors for building blocks of deoxyribonucleic acid (DNA)
is therefore critical for lymphocyte proliferation [4, 40].
Pathways of guanosine nucleotide synthesis
Studies of genetic defects elucidated the above described lymphocyte-specific condi-
tion and suggested immunemodulatory potential [16, 22, 42, 43]. Children suffering
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from Lesch-Nyhan syndrome, a deficiency in hypoxanthine-guanine phosphoribosyl-
transferase (HGPRT, E.C. 2.4.2.8, enzyme of the salvage pathway), show mental
defects while having normal numbers of T and B lymphocytes and a properly work-
ing immune system. The salvage pathway and HGPRT seemed to be crucial for
brain cell development and function, while lymphocytes seemed to be unaffected
and therefore independent of the salvage pathway. Adenosine deaminase deficiency
on the other hand leads to a decrease in number and function of T and B lym-
phocytes, but neither brain function nor numbers of neutrophils, erythrocytes, or
platelets are affected. Since brain and other cell types are capable of de novo guano-
sine synthesis their proliferation is, unlike lymphocyte proliferation, unaffected.
Pathways of adenosine and guanosine nucleotide (purine nucleotide) biosynthesis
are explained in Figure 1.2. Key substrate for the generation of purine as well
as pyrimidine nucleotides is phosphoribosyl pyrophosphat (PRPP) which is synthe-
sized from ribose 5-phosphate (Ribose 5P) from the pentose phosphate pathway and
adenosine triphosphate (ATP) [42, 43]. Several steps lead to IMP, which can either
be transformed to adenosine monophosphate (AMP) or guanosine monophosphate
(GMP). GMP is generated by de novo (blue arrows in Figure 1.2) or salvage (green
arrows) synthesis. De novo GMP is formed by conversion of IMP to XMP; intermedi-
ates of the salvage pathway are hypoxanthine, xanthine, and guanine. MPA inhibits
IMPDH and shuts down the de novo route of GMP synthesis, thereby depleting the
GMP pool of lymphocytes selectively and suppressing responses to antigenic or mi-
togenic stimulation. Shortly, MPA immunotherapy leads to a lack of key substrates
for DNA and ribonucleic acid (RNA) sythesis (absence of GMP leading to a shortage
of guanosine triphosphate (GTP) and deoxyguanosine triphosphate (dGTP)) as it
occurs in the case of genetic mutations in adenosine deaminase-deficient individu-
als (absence of AMP leading to a shortage of ATP and deoxyadenosine triphosphate
(dATP)).
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Fig. 1.2: Pathways of purine biosynthesis and immunosuppressive mechanism of
MPA. MPA antagonizes IMPDH and therefore the de novo pathway of purine synthesis.
Lymphocytes do not feature the salvage pathway which makes them strongly dependent
on GMP production via IMPDH for synthesis of deoxyribonucleic acid (DNA) and ribonu-
cleic acid (RNA) and susceptible for inhibition of cell proliferation by MPA. AMP: adeno-
sine monophosphate, ATP: adenosine triphosphate, dATP: deoxyadenosine triphosphate,
dGTP: deoxyguanosine triphosphate, GMP: guanosine monophosphate, GTP: guanosine
triphosphate, HGPRT: hypoxanthine-guanine phosphoribosyltransferase, IMP: inosine
5’-monophosphate, IMPDH: inosine monophosphate dehydrogenase, MPA: mycopheno-
lic acid, PRPP: phosphoribosyl pyrophosphate, Ribose 5P: ribose 5-phosphate, XMP:
xanthosine 5’-monophosphate. Adapted from [20, 44, 45], modified.
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Additional advantages of MPA’s mechanism of immunosuppression
Throughout the literature, many minor immunosuppressive actions of MPA in ad-
dition to the main effect of IMPDH inhibition are described [20, 42, 43, 46]. A few
examples are listed below.
• Allosteric regulation of other key enzymes
Blocking of IMPDH manipulates the nucleotide-dependent allosteric regulation of
PRPP synthetase (Ribose 5P + ATP ⇀↽ PRPP + AMP) and ribonucleotide re-
ductase (deoxyguanosine triphosphate + H+ + reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) ⇀↽ deoxyguanosine triphosphate + nicotinamide ade-
nine dinucleotide phosphate (NADP+), e.g. guanosine diphosphate (GDP) ⇀↽ de-
oxyguanosine diphosphate, adenosine diphosphate (ADP)⇀↽ deoxyadenosine diphos-
phate) in lymphocytes [43, 47]. While PRPP synthetase is inhibited by AMP and
ADP, activation occurs by high levels of GMP, GDP, and GTP. Ribonucleotide re-
ductase activity is impaired by dATP, but dGTP on the other hand stimulates the
enzyme and results in ADP reduction. High abundance of adenosine nucleotides
and/or low abundance of guanosine ribonucleotides lowers PRPP levels by inhibit-
ing PRPP synthetase. High levels of dATP and/or low levels of dGTP inhibit ri-
bonucleotide reductase, depleting deoxyribonucleotide triphosphate pools and DNA
synthesis. While guanosine and deoxyguanosine nucleotides stimulate lymphocyte
proliferation, high levels of adenosine and deoxyadenosine nucleotides inhibit pro-
liferation. This ensures inhibition of DNA synthesis after the initial depletion of
guanosine pools by IMPDH inhibition by MPA.
• Isoforms of IMPDH
Two different isoforms of IMPDH exist [40, 43, 48, 49]. MPA acts on human IMPDH
isoform II with about four times greater specificity than on isoform I [40]. Type II
IMPDH is strongly upregulated in stimulated lymphocytes [50], which collaterally
increases MPA’s antiproliferative effects and suppression of clonal expansion of T
and B cells.
• Inhibition of glycosylation and expression of adhesion molecules
A lack of GTP diminishes fucose and mannose transfer to glycoproteins [42]. As gly-
cosylation of adhesion molecules is pivotal for the attachment of leukocytes (integrin-
mediated sticking through selectins) to the endothelium, recruitment of lymphocytes
and monocytes into areas of inflammation/graft rejection is inhibited [42, 43, 46].
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1.1.5 Pharmacokinetic properties
The main site of MPA metabolism is the liver [20], but organs such as the kidney
and intestine contribute significantly and play an important role in drug degradation
and transformation [4, 42, 51].
Differences in pharmacokinetic properties of formulations
MMF’s solubility in water at neutral pH is low (43µg/mL at pH 7.4) [52], but it
increases with decrease of pH (4.27mg/mL at pH 3.6). Orally administered MMF
is dissolved in the stomach at pH values of 1-3 (Fig. 1.6). In the stomach and even
in oral/pregastric regions of the digestive tract, esterases acting on aromatic and
aliphatic ester bonds are ubiquitous [53–56]. Carboxylesterases convert MMF to
MPA (Fig. 1.3) and morpholinoethanol [57]. MMF is rapidly de-esterified in the
stomach [58] and MPA is absorbed partly in the stomach and partly in the proximal
small intestine [59]. Orally administered MMF is also absorbed by the wall of the
GI tract directly and is intracellularly hydrolyzed by esterases in tissue and plasma
to MPA and morpholinoethanol [57].
The alternative formulation EC-MPS offers an enteric coating that dissolves at pH
values > 5.5 (Fig. 1.3), as it is present in the small intestine [59] (Fig. 1.6). Release
of MPA is thereby delayed until entry and disintegration of the EC-MPS capsule
in the duodenum. The gavage of MPA as a salt enhances solubility and absorption
compared to administration as an acid.
In the past it was assumed that pharmacokinetic (PK) properties differ only slightly
between the two MPA formulations [3, 25]. The aberrant metabolism was thought
to primarily be due to a delayed release of the pharmacologically active component
MPA resulting in a delayed Tmax (time of maximal concentration after administra-
tion, 1 hour for MMF [20] versus 2-3 hours for EC-MPS [60]). Formulations were
considered equivalent [3, 20, 25] as studies showed that MMF yields a bioavailability
of MPA of 94% [20, 61]. More recent and more diligent publications deny bioequiva-
lence of MMF and EC-MPS mainly because of severely diverging concentration-time
profiles [60, 62]. Formulations should, due to differences in multiple PK parameters,
not be considered equivalent as agreed on in a consensus meeting about MPA thera-
peutic drug monitoring held in 2008 [60]. In addition the comparison of PK proper-
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ties of formulations is hindered by a lack of information on EC-MPS metabolism and
disposition, while PK attributes of MMF have been studied extensively for different
types of transplants, healthy controls, adults and pediatric patients [20, 60, 63, 64].
General PK characteristics of MPA
Uptake of a wide variety of substrates is mediated by organic anion-transporting
polypeptides (OATPs), which are encoded by solute carrier organic anion trans-
porter genes. Hepatocellular and intestinal uptake of MPA is promoted by OATP1B1
(formerly OATP2), OATP1B3, and OATP2B1 located in the basolateral cell mem-
brane [65] as depicted for an intestinal cell in Figure 1.4. Intracellularly MPA is
extensively metabolized by glucuronidation by 5’-uridine diphosphate glucurono-
syltransferase (UGT) enzymes (Fig. 1.3) imbedded in the membrane of the endo-
plasmatic reticulum (ER) [20, 66] (Fig. 1.4). About 80% of the drug is converted
to its major metabolite, the phenolic mycophenolic acid glucuronide (MPAG, β-D-
glucuronide, 7-O-glucuronide; for labeling routine in the MPA molecule please see
comments in Section 2.7.2), which reaches its Cmax (maximum concentration a drug
reaches after administration prior to administration of a second dose) about 1 hour
after the MPA Cmax and is pharmacologically inactive [20, 67]. MPAG is mainly
generated by UGT isoforms UGT1A8, UGT1A9, and UGT1A10 (phase II enzymes),
of which UGT1A8 and UGT1A10 are only expressed in the GI tract. The minor
glucuronide metabolite AcMPAG constitutes about 10% of the MPA-AUC0−12 (area
under the curve/integral of the concentration-time curve over 12h after drug admin-
istration), peaks 1 hour after the MPA Cmax as well, but is pharmacologically active
and adds to the immunosuppressive potential of MPA. UGT2B7 is almost entirely
responsible for AcMPAG formation and to a smaller extent also UGT1A8.
In addition the two glucuronides two glucoside metabolites, a phenolic (MPA-GS,
7-O-glucoside; for labeling routine in the MPA molecule please see comments in
Section 2.7.2) and an acyl glucoside (AcMPA-GS), have been identified [51, 68].
MPA-GS constitutes about 10% of the AUC of the respective MPA-AUC, while
AcMPA-GS is only prominent in trace amounts and cannot be determined due to
detection limits of the methods used [20]. The glucoside metabolites are formed by
phase II transformation via UGT enzymes as well (Fig. 1.3).
Other minor metabolites of unclear clinical significance include 6-O-desmethyl-MPA
(DM-MPA, formerly named M-3; 12h-AUC of 0.3-2.8% of 12h-MPA-AUC) and two
related glucuronides, DM-MPA-6-O-phenyl glucuronide (DM-MPA-6G, 0.6-3.5%)
and DM-MPA-4-O-phenyl glucuronide (DM-MPA-4G, 0.4-1.1%) [69]. DM-MPA is
produced by cytochrome P450 oxidase (CYP, phase I enzymes) isoforms CYP3A4
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and CYP3A5 and possibly to a minor extend by CYP2C8 (Fig. 1.3) [69]. CYP
enzymes are located in the membrane of the ER (Fig. 1.4) [70].
After uptake and possibly conjugation inside a hepatocyte or intestinal cell (or an-
other metabolizing tissue, e.g. the placenta), MPA and conjugates can be excreted
into bile or back into the intestinal lumen (enterohepatic recirculation) or the blood
stream respectively (Fig. 1.4). Export is mediated by eﬄux pumps, namely mul-
tidrug resistance-associated protein (MRP) 1 and 2, multidrug resistance protein
1 (MDR1, also known as P-glycoprotein/P-gp), and breast cancer resistance pro-
tein (BCRP) [65, 71]. Glucuronides can enzymatically and non-enzymatically be
hydrolysed back to MPA and glucuronic acid [20].
More than 90% of an MPA dose (mainly in form of MPAG) can be recovered from
urine (active tubular secretion) within 3 days [20, 67]. While MPA and the above
described metabolites have been detected in urine in minor amounts, MMF has
never been found. 5.5% of a given MMF dose can be recovered in the feces. The
ester moiety released by de-esterification of MMF is metabolized as well and almost
completely excreted in urine within 1 day [20].
Inter- and intrapatient variablility in MPA exposure is striking and, as commonly
seen in PK profiles of drugs, multiple parameters such as renal function, coadmin-
istered drugs (for MPA especially cyclosporine) [21, 72], albumin levels, genetic fac-
tors, meal times, or disease can affect all elements of MPA metabolism, e.g. absorp-
tion, enterohepatic circulation, metabolite formation, and bioavailability [20, 21].
Major efforts have been undertaken to clarify the role of genetic polymorphisms in
enzymes involved in MPA metabolism [20].
In terms of MPA GI toxicity, it should be mentioned that effects on MPA metabolism
by food ingestion have been found to be minor, as plasma MPA-AUC of fed and
fasted state are equivalent [73]. If taken with food, Tmax is delayed by 1 hour [34, 67].
Although Cmax is significantly decreased [34, 67], no adjustment of intake or dosage
is required [67].
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Fig. 1.3: Metabolism of EC-MPS and MMF. Location of named enzymes in the GI tract wall is shown in Figure 1.4.
AcMPAG: mycophenolic acid acyl glucuronide, CYP: cytochrome P 450 oxidases, DM-MPA: 6-O-desmethyl mycophenolic
acid, DM-MPA-4/6G: 6-O-desmethyl mycophenolic acid-4/6-O-phenyl glucuronide, EC-MPS: enteric-coated mycophenolate
sodium, MMF: mycophenolate mofetil, MPA: mycophenolic acid, MPAG: mycophenolic acid glucuronide, UGT: 5’-uridine
diphosphate glucuronosyltransferase.
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Fig. 1.4: MPA disposition. Metabolic transformations of MPA to MPA metabolites
catalyzed by the named enzymes is depicted in Figure 1.3. BCRP: breast cancer resis-
tance protein, CYPs: cytochrome P 450 oxidases, MDR1: multidrug resistance protein 1,
MRP1/2: multidrug resistance-associated protein 1/2, UGTs: 5’-uridine diphosphate
glucuronosyltransferases.
1.2 The GI tract and GI toxicity of MPA
1.2.1 Impact of MPA GI side effects
GI intolerability is the main reason for an MMF/EC-MPS dose change or even dis-
continuation [33, 35, 74–77]. Over 50% of renal transplant patients were found to
be subject to these adjustments [77]. Consequences negatively affect short- and
long-term graft outcomes due to suboptimal dosing (risk of underdosing to avoid GI
symptoms or withdrawl) as can be clearly seen when correlating incidences of graft
loss, GI symptoms, and MMF dose reduction/discontinuation (Fig. 1.5) [77].
As GI symptoms vary widely in terms of nature and severity, as well as the patient’s
perception of wellness and constraints in daily life [35], assessment of GI symptom
burden is difficult [25]. Insufficient comparability among studies and differences in
assessment of data are other pitfalls in clinical trials trying to clarify the clinical
impact of MPA GI toxicity [25, 35].
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Another important factor in reviewing MPA GI toxicity is the financial distress
that is placed on healthcare systems by MPA due to GI complications (e.g. hos-
pitalization in 20% of patients) and subsequent actions such as dose reduction or
discontinuation [75].
Fig. 1.5: Correlation of GI events, MMF discontinuation, and graft survival.
Graft survival over 3 years in patients with or without gastrointestinal complications (GI)
after the first year dependent on as to whether MMF was continued or discontinued.
Graft survival was significantly lower in the “GI/MMF discontinued” group (70.2%,
p<0.0001) and the “GI/MMF continued” group (83%, p=0.001) versus patients without
GI complications in whom MMF was continued (87.1%). Graft survival was 82.3% in
the group with GI complications who continued MMF (p=0.091%). Graph and caption
taken from [35] and [77], unmodified.
1.2.2 Parts, functions, and features of the GI tract
The GI tract consists of the mouth, pharynx (most parts), esophagus, stomach,
small intestine, and large intestine [78, 79] (Fig. 1.6). Associated digestive organs
are teeth, tongue, salivary glands, liver, gallbladder, and pancreas. Since it is the
goal to discuss MPA’s intestinal side effects, this section focuses on the physiology
of the small and large intestine.
25
1 Introduction
Fig. 1.6: GI tract and supporting organs. pH values are given for the stomach and
portions of the small and large intestine [78–80]. Liver, gallbladder, and pancreas connect
to the GI tract. They assist in the digestive process and influence drug metabolism and
disposition. Drawing adapted from [81], modified.
The small intestine
The small intestine is divided into the duodenum, jejunum, and ileum [80, 82]
(Fig. 1.6). Absorption mainly takes place in the first portion of the small intes-
tine, the duodenum. Pancreatic and mucosal enzymes break down food compo-
nents/(pro)drugs for absorption. The products of this process include monosaccha-
rides, amino acids, di- and tripeptides, monoacylglycerols, free fatty acids, vitamins,
water, and/or drugs. To be absorbed, material has to pass the mucus layer of the
intestine, the epithelium, the lamina propria, and the endothelial cells of the capil-
laries to reach the blood stream [82]. Products reach the liver via the portal vein
where they are metabolized further and distributed or excreted.
As depicted in Figure 1.7 the intestinal tube is made up of the tunica serosa, a
coat of longitudinal muscle fibers, the myenteric plexus (Auerbach’s plexus), a coat
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of circular muscle fibers, the submucous plexus (Meissner’s plexus), the muscularis
mucosa and the lamina propria covered by epithelial cells (Fig. 1.7). Nerves, blood
vessels, and lymph vessels span the layers of the small intestine. Kercking’s folds,
villi, and enterocytic microvilli (brush border) increase the intestinal surface by 300-
1600 times.
Enterocytes are responsible for absorption of nutrients and drugs [78, 80]. Inbetween
the enterocytes goblet cells secrete mucus to protect and lubricate. Undifferentiated
cells in the intestinal glands (crypts of Lieberkuehn) differentiate into villous cells,
mucous cells, endocrine and paracrine cells, and immune cells. From the crypts
of Lieberkuehn the epithelium of the small intestine is continously replaced every
3-5 days.
Fig. 1.7: Structure of the small intestine. Drawing adapted from [80], modified.
The large intestine
The large intestine consists of the cecum, colon, and rectum [78, 80] (Fig. 1.6). The
main functions include storage of intestinal contents and the absorption of water
and electrolytes. Water removal reduces the volume of digestive matter significantly,
playing a pivotal role in fluid balance e.g. the development of diarrhea.
Another feature of the large intestine worth mentioning is its bacterial colonization,
which is more pronounced than in upper regions of the intestine due to the low pH of
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the stomach acting as a barrier against pathogens (upper small intestine 0-104/mL,
ileum 106/mL, large intestine up to 1012/mL) [83].
1.2.3 Mechanisms and modulation of intestinal inflammation
and repair
Similarity of Crohn’s disease and MPA GI side effects
Crohn’s disease is a chronic inflammation of the gut wall provoked by an inadequate
immune response to the commensal microflora [84] and is among the main types of
inflammatory bowel disorders (IBD) [85, 86]. Genetic, immunologic, and environ-
mental factors contribute to IBD pathogenesis. MPA GI adverse events generally
manifest as Crohn’s disease-like enterocolitis (inflammation of the small intestine
and the colon) [34, 42, 58, 75, 77]. Diarrhea, abdominal pain, mucosal changes such
as ulcers, and submucosal inflammation are some of the frequently occurring char-
acteristics of MPA GI toxicity that are seen in Crohn’s disease as well [84]. Crohn’s
disease can affect all areas of the GI tract but is most commonly located in the
terminal ileum [84]. As MPA GI side effects show a pattern very similar to Crohn’s
disease.
Mucosal epithelial barrier and flora
The alimentary tract possesses remarkable potential to maintain and restore in-
tegrity of the mucosal epithelial barrier despite aggressive conditions such as the
presence of low pH values, proteolytic enzymes, and noxious substances within the
intestinal lumen [87, 88]. Injury to the mucosa/epithelium is frequently occurring
even under physiologic conditions (e.g. diet, disease, GI flora, proteases). Fast re-
generation is guaranteed by a network of factors involving epithelial restitution (cell
migration), proliferation, differentiation, regulatory peptides (growth factors and cy-
tokines), non-peptide molecules (e.g. phospholipids, short-chain fatty acids, adenine
nucleotides, trace elements) [87], and other key mediators (nitric oxide, polyamides,
eicosanoids) [89].
The bacterial content of the small and large intestine accounts for up to 106 and
1012 bacteria/mL, respectively [80, 83]. In healthy individuals a viscous mucus layer
spanning the epithelium eliminates contact of epithelial cells and these bacteria [83].
Patrolling leukocytes within the layer and probiotic strains growing on the outside
offer additional protection of the mucosa. Only in case of a defective mucus layer and
compromised mucus barrier function, like in IBD, inflammatory responses occur due
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to bacterial (polymicrobial) invasion of the epithelium. The reasons for chronically
compromised barrier function in IBD is not known. Factors such as lifestyle, diet,
use of detergents and emulsifiers, genetic background etc. seem to influence disease
development and progression [83].
Immunological factors of Crohn’s disease
Crohn’s disease results from an inappropriate immune response of the mucosa to
the gut flora [84]. Genetic predisposition and factors that have not been fully deter-
mined nor understood have to coincide. Occurance of intestinal lesions in Crohn’s
disease can be explained as results of a broadly accepted inflammatory cascade
shown in detail in Figure 1.8. Damage of the epithelium allows paracellular transit
of bacterial antigens and gut contents to reach the lamina propria (1 in Figure 1.8).
Macrophages present antigens to T cells, which become activated and start to release
pro-inflammatory cytokines (2). Even without passage, bacteria can be caught by
dendritic cells through intracellular spaces or toll-like receptors (TLRs) expressed
on epithelial cells (3) and lead to activation of T cells (polarization into Th1 and
Th17 cells, 4). Different cytokines are involved in the pathogenesis of Crohn’s disease
among them interferon-γ (INF-γ; production of interleukin (IL)-12 by macrophages,
activation of T cells by IL-12). Neutrophils are recruited by TLRs interacting with
luminal antigens and IL-8, which is secreted by the epithelium after stimulation by
IL-17 (5). Activated macrophages secrete tumor necrosis factor-α (TNF-α), leading
to upregulation of adhesion molecules, aiding more immune cells to access the area of
inflammation from the blood vessels (6) and formation of fistulae by overproduction
of matrix metalloproteinases (7). TNF-α can also damage the epithelium directly
inducing de-epithelization and ulceration (7).
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Fig. 1.8: Immune response of the mucosa to the gut flora. IFN-γ: interferon-γ, IL: interleukin, MHC: major histocom-
patibility complex, MMPs: matrix metalloproteinases, TLR: toll-like receptor, TNF-α: tumor necrosis factor-α, numbers are
explained in the text. Drawing adapted from [84], modified.
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1.3 Hypothesis, aims of the study, and research
strategies
It is hypothesized that MPA promotes GI inflammation by disrupting the GI barrier
and allowing bacterial toxins and proteins to penetrate the mucosa as described in
Section 1.2.3 in the context of the pathogenesis of Crohn’s disease. Luminal and/or
intracellular proteins might additionally get covalently modified by MPA and/or
MPA metabolites and act as immunogens.
Objectives of the present study were
1. assessment of the potential of LS180 cells as a model for studies on MPA/MMF
GI toxicity concerning protein expression and stability of expression over pas-
sage numbers,
2. assessment of time- and dose-dependent effects of MPA on the metabolome
and proteome of colonic epithelial cells (LS180 cells),
3. assessment of direct toxic effects of MPA and MPA metabolites (especially
AcMPAG) on colonic epithelial cells,
4. determination of inflammatory parameters involved in MPA GI toxicity and
their direct effects on colonic epithelial cells.
1.3.1 LS180 cell culture model and its qualification
LS180 colonic epithelial cells (adenocarcinoma) were chosen as a model over Caco-2
cells, which is the most commonly used colon carcinoma cell line to study GI
drug metabolism and effects [90]. Although LS180 cells are not well character-
ized [91] they feature expression of pregnane X receptor (PXR) [91, 92], which
induces drug metabolizers (CYP3A4) [91] and transporters (MDR1) [91]. Caco-2
cells on the other hand are PXR-deficient [91, 92]. LS180 cells, likewise the Caco-2
cell line [93, 94] express mucin genes [95], which make it possible to include drug
treatment effects on certain traits of the GI tract’s mucus layer, e.g. epithelial bar-
rier integrity, in LS180 studies if necessary.
Since toxicity of AcMPAG was a central question of this study and LS180 cells turned
out to provide a stable and high content of AcMPAG-producing UGT2B7 (Sec. 2.2.1),
this cell line was used to investigate MPA-induced effects on cell function and
metabolism in detail.
31
1 Introduction
1.3.2 Biomarkers, proteomics, and metabolomics
A biomarker is “a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or pharmacologic re-
sponse to therapeutic intervention” [96, 97]. For this study a proteo-metabolomic
profiling strategy was employed which is generally used for the search of biomark-
ers to identify disease processes. Within the last decade non-targeted screening
technologies and tools in the fields of genetic profiling (transcriptomics), protein
profiling (proteomics), and biochemical profiling (metabolomics) have developed
rapidly [97, 98]. A combination of these tools was used to gain insight into mecha-
nisms of GI toxicity of MPA on a systematic and comprehensive basis.
While metabolomics is defined as “the quantitative measurement of the time-related
multi-parametric metabolic response of living systems to pathophysiological stim-
uli or genetic modification” [99] proteomics relates to the response of the proteome
i.e. “the systematic analysis of all the proteins in any defined biologic compart-
ment” [100] (Fig. 1.9). Metabolic profiling mainly employs techniques such as nu-
clear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) [101],
proteomic studies usually rely on MS-dependent approaches [100] followed by con-
firmation of results by immunoblotting [97]. Poor correlation of transcriptomic data
and actual changes on the metabolite and/or protein level promotes examination of
metabolome and proteome directly without relying on assumptions of transferabil-
ity of changes determined on the messenger ribonucleic acid (mRNA) level to the
metabolite/protein level.
NMR-based studies also provide the possibility to use labeled tracers to exam-
ine abnormal metabolic fluxes induced by e.g. drug treatment, toxins, or disease
state [102, 103]. Concentrations of small molecule metabolites, lipids, phosphates,
and isotopomers can be assessed and provide clues on impairment of metabolic
pathways, severeness of medical conditions, mechanisms of toxicity, and related
questions. Another advantage of NMR spectroscopy is its non-invasiveness.
MS-based studies on the other hand allow for higher throughput than NMR mea-
surements or RNA micro array tools. MS is also superior in terms of sensitivity
than NMR spectroscopy [97]. Scanning the entire metabolome and proteome of a
given organism for drug-induced changes is an immense undertaking which has been
made possible by improvements in biological MS and bioinformatics over the last 20
years.
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Fig. 1.9: Relationship between transcriptomics (genomics), proteomics, and
metabolomics. Adapted from [97], modified.
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2 Results and Discussion
2.1 Determination of cell culture treatment
conditions
2.1.1 Drug treatment
Oral dosing of drugs is likely to create high local concentrations of the administered
compound in the gut lumen [104]. Therefore LS180 cells were treated with com-
pound concentrations from 0.01µM up to 250µM. Considering that 1-1.5g of MPA
are given twice daily, dependent on the formulation, even much higher concentrations
may occur locally for certain periods of time (1g MPA/L = 3.1217mM = 3121.7µM,
MMPA = 320.34g/mol). While an MMF tablet is likely to dissolve in the stom-
ach already and to release less concentrated MMF suspension into the duodenum,
the enteric coating of an EC-MPS capsule dissolves rapidly in the small intestine
(Sec. 1.1.5), releases its contents and exposes the epithelium to a high amount of
MPA. Due to limited solubility of MMF and MPA in the cell culture medium when
spiked from more concentrated stocks in dimethyl sulfoxide (DMSO), 250µM was
chosen to be the maximum concentration used in most experiments.
For experiments initially conducted, LS180 cell cultures were treated not only with
MPA but with MMF, MPA + morpholinoethanol (in combination), and morpholi-
noethanol as well to cover for all possible variations of drug-induced effects. Neither
the metabolic capacity of LS180 cells for MPA and associated compounds was known
nor was literature available for differences in metabolism/toxicity of compounds, i.e.
MPA versus MMF, in cell culture.
Although tertiary amines are often used as prodrugs to increase a drug’s water sol-
ubility [105, 106] the morpholinoethanol moiety of MMF seems to be rarely used
as most literature on morpholinoethanol prodrugs refers to MMF/MPA. Morpholi-
noethanol and MPA + morpholinoethanol were therefore included in first exper-
iments, i.e. proliferation assays (Sec. 2.4) and measurements of intracellular nu-
cleotide levels (Sec. 2.5).
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Since the effects on LS180 cells induced by MPA, MMF, and MPA + morpholi-
noethanol showed consistently the same profiles and no effects on LS180 cells were
seen after morpholinoethanol treatment, only MPA treatment was persued to gain
insight into MPA-related mechanisms of toxicity.
Due to very limited stability of the AcMPAG metabolite described in the litera-
ture [107], especially under cell culture conditions (37◦C, neutral pH, long incubation
times up to 72h; please see Section 2.6 for further explanation and preliminary sta-
bility studies), in most experiments AcMPAG was not tested directly. Assessment
of effects of AcMPAG was a major aim of this study, so that sufficient formation
of AcMPAG by LS180 cells was essential. Since LS180 cells were proven to provide
a high and stable amount of the UGT2B7 enzyme, via which AcMPAG is formed,
incubation of cells was restricted to incubation with MPA.
The MPAG metabolite is universally described as non-toxic [60, 108] (the possi-
bility of covalent modifications of proteins by MPAG is discussed at the end of
Section 2.7.2). As MPAG is very polar and only crosses cell membranes erratically
no experiments were conducted applying MPAG directly in cell cultures.
2.1.2 Guanosine treatment
After assessment of the first data such as IC50 values (Sec. 2.4) and nucleotide levels
(Sec. 2.5) in LS180 cells, the LS180 cell culture model for elucidation of MPA GI
toxicity was promoted in terms of mimicking physiological conditions by addition of
guanosine to the culture medium. Epithelial cells within the GI tract are known to
import nucleotides from the intestinal lumen [109, 110]. Thus, effects of MPA linked
to guanosine nucleotide depletion and cell cycle arrest can be reversed by exogenous
guanosine [109, 110]. After determination of the most appropriate guanosine con-
centration, most experiments were conducted by addition of 1000µM guanosine to
culture media.
2.2 Validation of the LS180 cell culture model
Human cell lines are a popular model to study in vitro biotransformation and trans-
port of drugs [111], especially since it is difficult to discriminate between liver and ex-
trahepathic tissue contribution in vivo [112]. For screening of intestinal metabolism,
commercially available colon carcinoma cell lines are widely used besides other cell
intact systems (e.g. biopsies, precision-cut slices) and subcellular fractions (e.g. mi-
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crosomes) [112, 113].
Human Caco-2 cells are the most commonly used cells to study intestinal drug
metabolism and effects [90], followed by LS180 cells [112]. Both cell lines are human
colon adenocarcinoma-derived.
Caco-2 cells polarize and differentiate until they form a monolayer with tight junc-
tions and are considered the more physiological model, especially for drug transport
and absorption studies [112, 113]. On the other hand expression levels of important
drug-metabolizing enzymes and drug transporters differ extremely between Caco-2
cells and the in vivo situation present in the small intestine and colon (e.g. low levels
for CYP3A4, other CYP enzymes, and MDR1), so that transfection is required to
justify the use of Caco-2 cells for prediction of drug metabolism [90, 112, 114]. Low
levels [113] or absence [115] of nuclear PXR, which is important for induction of
enzymes of low abundance such as MDR1 and CYP3A4, is reported as well [116].
Another significant issue with Caco-2 cells is inter- and intra-laboratory reproducibil-
ity [112]. Expression levels of drug-metabolizing enzymes and drug transporters
inbetween passage numbers [112, 117] and during cultivation [112, 118] are highly
unstable (e.g. 4-fold increase in CYP3A4 expression levels inbetween low and high
passage numbers [112, 117]). The long culture time of about 20 days until con-
fluency and morphological and functional differentiation, as well as deficiency of a
mucus layer of Caco-2 cells are drawbacks of an otherwise simple and extensively
used model for drug screening.
LS180 cells are not as extensively characterized in terms of expression of drug-
metabolizing enzymes and drug transporters as Caco-2 cells [112, 113], but some
characterization has been published [91, 92, 95, 111–113, 115]. While expression
levels of enzymes as CYP3A4 and MDR1 seem to be similar in LS180 and Caco-2
cells, BCRP expression is lower [112]. Overall there seem to be certain advantages
and disadvantages for each of the two popular culture models looking at metabolic
capacities and comparability to the in vivo situation. A very prominent aspect of
choice for the appropriate cell culture system was the fact that only the LS180 line
offers PXR expression [112, 113] and provides the potential to upregulate/induce
expression of important enzymes by PXR as it occurs in vivo [113, 116].
It needs to be kept in mind that LS180 as well as Caco-2 cells are of cancerous origin
and reveal certain characteristics of cancer tissue such as over/underexpression of
certain proteins and a deviant metabolism [113, 119] (Sec. 2.8.2). A major concern is
the overexpression of export pumps and metabolizing enzymes in cancer cells estab-
lishing drug resistance or at least diminished metabolism of drugs and endogenous
compounds [113, 120].
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Other intestinal cell lines such as Caco-2 TC7 (Caco-2 cells that have been exposed
to methotrexate) or (non-cancerous) lines from the small intestine such as IEC-
6 (rat duodenum), IEC-18 (rat ileum), HUTU 80 (human duodenum), HCT 8 (hu-
man ileum/cecum), and FHS 74 (human fetal small intestine) have been used as
well [112, 121]. All of these cell lines lack one or more crucial characteristic to
guarantee general applicability. While insufficient/contradictory biochemical char-
acterization in only a few published studies seems to be an ubiquitous problem, de-
ficiency of important metabolizers and transporters (for IEC-6, IEC-18, HUTU 80,
and HCT 8 cells) constituted another criterion for not considering these cell lines
for the present study.
Based on a comprehensive literature review, LS180 cells seemed the best model for
achieving our study aims. Thus, the first step was a validation of the LS180 cell
model to confirm that it can be considered adequate.
2.2.1 Dependency of protein expression on passage number of
LS180 cells
Although LS180 cells are well characterized concerning the expression of enzymes/
mRNA of enzymes linked to the metabolism of xenobiotics [113, 122–124], enzyme
stability over a certain amount of passage numbers has never been assessed for this
cell line. In terms of MPA metabolizing enzymes, LS180 cells have been described to
provide mRNA and protein expression of all involved UGTs, CYPs, and transportes
as well as PXR [113, 122–124].
To ensure LS180 cells are suitable for the studies of MPA transport and metabolism,
cells were characterized in terms of the expression of MPA-metabolizing enzymes
(UGT1A7/8/9/10, UGT2B7, CYP3A4/5), import transporters (OATP1B1,
OATP1B3, OATP2B1), export pumps (MRP1/2, MDR1, BCRP) as well as PXR
and IMPDH isoforms 1 and 2, by western blot.
LS180 cells (American Type Culture Collection, ATCC) of unknown passage num-
ber N were subcultured and were extracted in passage numbers N+7, N+11, N+15,
and N+19 (subsequently referred to as passage numbers 7, 11, 15, and 19) and sub-
jected to western blot or quantitative polymerase chain reaction (QPCR) analysis.
Western blots and the expression levels of MPA metabolizing enzymes are shown
in Figure 2.1 and Figure 2.2, respectively. Expression levels of MPA transporting
enzymes and pharmacodynamic target proteins of MPA are shown in Figure 2.3 -
Figure 2.6. UGT1A8 stability could not be assured directly, but mRNA levels be-
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tween passages were compared. For BCRP neither enzyme nor mRNA stability
could be ensured, due to unsatisfying results in western blots (lack of an appropri-
ate antibody) and QPCR data (most likely due to not optimally designed primers).
Since all other enzymes where stable over passage numbers, BCRP content was as-
sumed to be stable over checked passages as well and not investigated further.
Cell proliferation assays for MPA, MMF, MPA + morpholinoethanol, and morpholi-
noethanol were carried out using cells in passage numbers 7 and 23, respectively,
to ensure that no apparent alterations in drug metabolism in LS180 cells occur
due to age of the cell culture (data for passage number 7 shown in Figure 2.14 in
Section 2.4, data for passage number 23 not shown). Proliferation of cells of low
passages compared to high passages did not show profund differences.
Stabilities of cell lines over passage numbers has often been evaluated, but is not
always a routine procedure to validate a cell culture model. While certain cell
lines are characterized over a long period of time/multiple passage numbers (e.g. up
to 150 [126]), others (especially primary cultures) can only be surveyed for shorter
periods (e.g. 10 or even less passage numbers [127]). Here, LS180 cells were evaluated
over 12 passages to establish stability for the experiments performed. The relatively
short time of evaluation of 12 passages makes it difficult to compare results to Caco-2
cells. Passage numbers termed “high” and “low” generally span a longer time frame
(with passage numbers around 30 typically considered low, around 100 high [112,
128]). Changes occurring in Caco-2 cells over time affect cell morphology [112,
128], as well as diffusion characteristics and most problematic for studies on drug
transport and drug metabolism, transporters, and other enzymes expressed in the
brush border [128]. Their faster proliferation rate (Sec. 3.2.1), time until confluency
of the culture (about 3 days for LS180 cells versus about 20 days for Caco-2 cells
after subcultivation), and less distinct morphological and functional differentiation
during cultivation [112], makes it easier to maintain homogenity of LS180 than of
Caco-2 cells during experiments.
2.2.2 Influence of MPA treatment on expression levels of
enzymes involved in MPA metabolism in LS180 cells
A standard parameter of evaluating a drug’s properties in terms of absorption, dis-
tribution, metabolism, and excretion in vivo involves screening of the drug’s impact
on transporters and conjugating enzymes as drug-induced changes can significantly
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Fig. 2.1: Western blots for determination of expression levels of MPA-
metabolizing enzymes in LS180 cells in passages 7, 11, 15, and 19. Bands
are shown with their respective β-actin bands (N=3). Relative intensities as deter-
mined by densitometry analysis normalized based on β-actin are shown in Figure 2.2.
M: molecular weight, ∗: difference between actual and predicted band size probably due
to post-translational modifications, post-translational cleavage, splice variants, relative
charge or multimerization [125], ∗∗: due to cutting/stripping of the membrane the same
β-actin band served for the normalization of multiple proteins.
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Fig. 2.2: Expression levels of MPA-metabolizing enzymes in LS180 cells in
passages 7, 11, 15, and 19 as determined by densitometry analysis. Intensities
were normalized based on β-actin (N=3). Western blots with their respective β-actin
bands are shown in Figure 2.1. No statistically significant differences in expression levels
were found among passage numbers as determined using one-way ANOVA in combination
with Scheffe’s post − hoc test.
change PK properties, efficacy, and toxicity [129].
LS180 cells were treated with increasing concentrations of MPA as described in
Section 2.1.1 in detail. As the here presented induction studies were performed at
the beginning of the project, for these experiments cell culture media were not sup-
plemented with guanosine.
Western blots (not shown) of LS180 lysates were performed after 24h of MPA
treatment for drug-metabolizing enzymes directly involved in MPA metabolism
(UGT1A7/9/10, CYP3A4/5, except for UGT1A8), eﬄux pumps (MRP1/2, MDR1,
except BCRP), and IMPDH isoform 1 and 2.
Expression levels did not change significantly after 24h of MPA treatment, although
many xenobiotics frequently induce proteins necessary for their detoxification in
normal and especially in cancer tissue [130]. After 24h a trend towards increased
IMPDH2 expression (p=0.192) was observed. As IMPDH1 is prevalent in most
normal tissues, IMPDH2 is predominant and constantly upregulated in neoplas-
tic and fast replicating tissue [40]. The trend towards overexpression of isoform 2
might be attributable to the cancerous nature of LS180 cells or guanosine nucleotide
depletion which has been reported to lead to upregulation of IMPDH gene expres-
sion [131, 132].
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Fig. 2.3: Western blots for determination of expression levels of transporters
of potential relevance for MPA in LS180 cells in passages 7, 11, 15, and
19. Bands are shown with their respective β-actin bands (N=3). Relative intensities as
determined by densitometry analysis normalized based on β-actin are shown in Figure 2.4.
M: molecular weight, ∗: difference between actual and predicted band size probably due
to post-translational modifications, post-translational cleavage, splice variants, relative
charge or multimerization [125], ∗∗: due to cutting/stripping of the membrane the same
β-actin band served for the normalization of multiple proteins.
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Fig. 2.4: Expression levels of transporters of potential relevance for MPA in
LS180 cells in passages 7, 11, 15, and 19 as determined by densitometry
analysis. Intensities were normalized based on β-actin (N=3). Western blots with their
respective β-actin bands are shown in Figure 2.1. No statistically significant differences
in expression levels were found among passage numbers as determined using one-way
ANOVA in combination with Scheffe’s post − hoc test.
Fig. 2.5: Western blots for determination of expression levels of pharmaco-
dynamic target proteins of MPA in LS180 cells in passages 7, 11, 15, and
19. Bands are shown with their respective β-actin bands (N=3). Relative intensities
as determined by densitometry analysis normalized to β-actin are shown in Figure 2.6.
M: molecular weight, ∗: difference between actual and predicted band size probably due
to post-translational modifications, post-translational cleavage, splice variants, relative
charge or multimerization [125].
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Fig. 2.6: Expression levels of pharmacodynamic target proteins of MPA in
LS180 cells in passages 7, 11, 15, and 19 as determined by densitometry
analysis. Intensities were normalized based on β-actin (N=3). Western blots with their
respective β-actin bands are shown in Figure 2.1. No statistically significant differences
in expression levels were found among passage numbers for the studied target proteins
as determined using one-way ANOVA in combination with Scheffe’s post − hoc test.
Fig. 2.7: Change in UGT1A8 message in LS180 cells in passages 7, 11, 15,
and 19. Message measured using QPCR was normalized based on β-actin (N=3).
No statistically significant differences in mRNA levels were found among passages for
UGT1A8 as determined using one-way ANOVA in combination with Scheffe’s post − hoc
test.
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Fig. 2.8: Expression levels of MPA-metabolizing enzymes in LS180 cells after
24h of MPA treatment as determined by densitometry analysis. Intensities were
normalized based on β-actin (N=3). Western blots with their respective β-actin bands
are not shown. There were no statistically significant differences in expression levels of
the studied MPA-metabolizing enzymes after 24h of MPA treatment as determined using
one-way ANOVA in combination with Scheffe’s post − hoc test.
Additional western blots (not shown) were performed after 72h treatment (single
dose of MPA) for eﬄux transporters such as MRP1/2 and MDR1 that are known
to be frequently upregulated in tissues exposed to xenobiotics (such as drugs or tox-
ins). After 72h MDR1 expression was significantly upregualted by almost 3.5-fold
after treatment with single doses of 100µM and 250µM MPA (334.0 ± 59.0% and
343.6 ± 33.6%) and a gradual increase could be seen for smaller doses as shown in
Figure 2.10. No such changes were found for MRP1 or MRP2.
A marked upregulation of MDR1 protein expression or mRNA expression can be
seen often in epithelial in vitro models treated with MDR1 substrates [104, 130].
An upregulation in LS180 cells has been observed before in the presence of many
other drugs such as rifampicin, phenobarbital, clotrimazole, reserpine, and isosafrole
before potentially decreasing their intracellular residence time [130, 133]. Upregula-
tion of MDR1 is also commonly observed in vivo [134], in other in vitro models, as
well as PK computational models [135].
In conclusion, LS180 cells are stable over the tested passage numbers including all
drug-metabolizing enzymes, drug transporters, and pharmacodynamic target pro-
teins relevant for the present study. Based on these results and the literature on
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Fig. 2.9: Expression levels of MPA eﬄux transporters and IMPDH isoform 1
and 2 in LS180 cells after 24h of MPA treatment as determined by densitometry
analysis. Intensities were normalized based on β-actin (N=3). Western blots with their
respective β-actin bands are not shown. There were no statistically significant differences
in expression levels of the studied transporters after 24h of MPA treatment as determined
using one-way ANOVA in combination with Scheffe’s post − hoc test.
Fig. 2.10: Expression levels of MPA eﬄux transporters MRP1, MRP2, and
MDR1 in LS180 cells after 72h of MPA treatment as determined by densit-
ometry analysis. Intensities were normalized based on β-actin (N=3). Western blots
with their respective β-actin bands are not shown. Differences in expression levels of
the studied transporters after 24h of MPA treatment were determined using one-way
ANOVA in combination with Scheffe’s post − hoc test with ∗: p<0.05).
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LS180 cells, these cells were considered a valid model to study MPA metabolism
and toxicity over the passages tested.
2.3 Cytotoxicity of MPA
Incubating cells with a compound that possibly has cytotoxic properties, two differ-
ent mechanisms of cell death can occur [136, 137]. Necrosis, the “accidential” cell
death is defined by alterations in plasma membrane permeability, i.e. spontanous
cell lysis and extrusion of intracellular compounds. Apoptosis, the “normal” cell
death removes unwanted or old cells in a controlled way.
To rule out major cytotoxic effects of the MPA concentrations used the necrotic and
apoptotic potential of MPA on LS180 cells was determined individually.
2.3.1 Necrotic potential of MPA
During necrosis cell damage and lysis occur. The soluble enzyme lactate dehydroge-
nase (LDH) is released from the cytosol into the cell culture medium. LDH activity
measurement can be used to indicate the amount of necrosis in a cell culture [138].
To determine necrotic effects of MPA on LS180 cells were incubated with 0.01,
0.1, 0.5, 1, 5, 10, 50, 100, and 250µM MPA. Assays were carried out for 24h, 48h,
and 72h for comparison with cell proliferation assays (described in Section 2.4 and
Section 3.2.2) and to provide the opportunity to adjust proliferation assay data in
case of cytotoxic potential of MPA. For one set of cytotoxicity assays, cells were
not redosed for potentially released LDH to accumulate in the cell culture media for
24h, 48h, and 72h, respectively. A second set of assays was run for which cells were
redosed every 24h to test if a second/third dose puts additional stress on LS180 cells
as measured by LDH leakage. For this set values represent the amount of LDH that
leaked into the cell culture supernatants in the time period from 24h to 48h after
the second dose of MPA after 24h (48h redosed) and in the time period from 48h
to 72h after the third dose of MPA after 48h (72h redosed). Results calculated as
percentages of controls (% control in figures/graphs) are shown in Figure 2.11 for
the five different experiments.
Cell numbers were not compromised by morpholinoethanol in the CyQUANT NF
Cell Proliferation Assays (Sec. 2.4), which would have revealed cytotoxic properties
of morpholinoethanol. Thus, no further cytotoxicity assay was run for this com-
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pound. For the same reason no cytotoxicity assays were run for MMF and MPA +
morpholinoethanol as their proliferation profiles matched the profile of MPA.
Fig. 2.11: LDH activity in cell culture media of LS180 cells after treatment
with a single dose and multiple doses of MPA for 24h, 48h (single dose and
redosed every 24h), and 72h (single dose and redosed every 24h). Values are
given as means of % of controls with standard deviations (N=6). Significance was
determined using one-way ANOVA combined with Scheffe’s post − hoc test with ∗:
p<0.05; ∗∗: p<0.005; ∗∗∗: p<0.001 versus controls. Values were calculated from LDH
activities and normalized to fuorescence intensities (cell numbers) as measured using the
CyQUANT NF Cell Proliferation Assay.
As shown in Figure 2.11 LDH activity values in culture media of LS180 cells were
<100% of values of controls for all MPA concentrations in all five experiments, al-
though LDH activities were normalized to cell content per well measured by the
CyQUANT NF Cell Proliferation Assay. Assays were run without addition of fetal
bovine serum (FBS) to the culture media to avoid interference since FBS contains
LDH. Withdrawl of FBS is generally used to growth arrest cultured cells [139]. LDH
activities ranged from 7mU/mL (controls) to 3mU/mL for 24h assays and assays
that were redosed every 24h, while values ranged from 28mU/mL to 18mU/mL for
48h and 72h for single dose assays. Proliferation rates were widely unaffected due
to growth arresting LS180 cells by FBS withdrawl. Only in case of the redosed 72h
assays, proliferation rates dropped from 100±3.5% (controls) to 91.4±4.6% (250µM
MPA, not statistically significant versus controls).
The decreased LDH activities in LS180 culture media after MPA treatment with low
and high concentrations are most likely caused by growth inhibition via IMPDH in-
hibition by MPA (cells get arrested in the S phase of the cell cycle [140]). Control
cells, without IMPDH inhibitor, keep multiplying with a demand for nutrients usu-
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ally provided by addition of 10% FBS to the culture media. Although withdrawl
of FBS is widely used for growth arresting, a slight increase of necrosis due to FBS
withdrawl cannot be ruled out completely. It was not possible to assess the effects
of FBS withdrawl on LS180 cells using this specific cell culture assay due to the
interference of FBS with the assay. No changes between different MPA concentra-
tions, especially in comparison with changes occurring between controls and low
MPA concentrations, were seen. Thus, MPA does not seem to induce necrosis in
LS180 cells within the time and dose ranges used for subsequent experiments. This
was further confirmed by the fact that no dead cells/cell debris were observed in the
culture media at any time throughout the experiments.
Dependent on species, tissue, cell type, exposure time, and dose in vitro data on
MPA cytotoxicity (and effects generally) differ widely. Another fact complicating
comparison of the present data with the current literature is the limited amount
of research and publications on MPA and MPA toxicity in cultured cells. Concen-
trations used in most studies were within or slightly above the therapeutic range
of MPA (up to 10µM) [109, 110, 139, 141]. Concentrations as high as expected
in the vicinity of mucosa cells and tested in our studies are relatively rarely de-
scribed. While in many studies significantly decreased cell survival can be seen
with fairly low concentrations of MPA, addition of guanosine to the cell culture
media reverses effects of MPA and MPA’s cytotoxic effects that can be attributed
to depletion of guanosine nucleotides [109, 110]. Guanosine depletion due to MPA
obviously has a less fatal effect on LS180 cells than on other cell types. This might
be partly attributable to LS180 cells not being primary cells as no cytotoxic effects
were seen in other immortalized cell lines before [141, 142]. Changes in metabolism
and drug transport due to the cancerous origin of LS180 cells (p53 inactivation in
cancers and MDR1 overexpression as described in Sec. 2.2.2 leading to selective
drug resistance) could be a reason as well [143]. Kaczmarek et al. also did not find
any evidence for cytotoxic effects of MPA at concentrations as high as 250µg/mL
(=780µM) in another human epithelial cell line (human retinal pigment epithelial
cells, ARPE19) after 24h and 72h incubation using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay to test antiproliferative and cytotoxic
effects of MPA [142].
2.3.2 Apoptotic potential of MPA
Cleavage of caspase-3 is crucial in programmed cell death (apoptosis) and activated
p17 and p12 fragments resulting from cleavage of caspase-3 show induction of apop-
tosis [144]. Western blots using a caspase-3 antibody detecting full length caspase-3
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of 35kDa and the 17kDa and 19kDa fragments were employed to assess apoptotic
properties of MPA on LS180 cells.
LS180 cell lysates from previously performed experiments of cultures incubated with
increasing concentrations of MPA (0.1, 1, 5, 10, 100, 250µM MPA and controls in-
cubated with 0.5% DMSO) and 1000µM guanosine and no FBS for 3h, 24h, and
72h (redosed every 24h) were used for caspase-3 western blots. These conditions
were chosen after evaluation of the LS180 cell culture model in terms of addition of
guanosine, redosing with MPA and guanosine, and MPA as described in the previ-
ous section. Additional lysates of cultures treated with 500µM and 1000µM MPA
(control incubated with 2% DMSO) were prepared for the 3h incubation to also test
high local concentrations potentially occurring for short time periods in the duode-
num after administration of EC-MPS.
Caspase-3 western blots are shown in Figure 2.12 and the corresponding densit-
ometry analysis is shown in Figure 2.13. After incubation with MPA for 3h only full
length caspase-3 was present in LS180 lysates (Fig. 2.13). The amount of caspase-3
covered about 100% of the values of controls for all samples even for concentrations
of 500µM and 1000µM MPA. After 24h and 72h p17 and p12 fragments of caspase-3
were visible in western blots. For cleavage of caspase-3 occurring in controls as well
as in treated samples, relative intensities were expressed as % of controls. Ratios of
cleaved to total (cleaved + uncleaved) caspase-3 are presented as well (also shown
as % of controls).
None of the changes in uncleaved or cleaved caspase-3 levels or ratios of cleaved to
total caspase-3 reached statistical significance. All values were elevated (full length
and cleaved caspase-3 as well as the ratio uncleaved/total caspase-3; except for
10µM MPA 72h cleaved and uncleaved/total caspase-3 which were <100% of con-
trol values) with peak values around 150% of controls for MPA concentrations in the
medium range (for cleaved and uncleaved/total caspase-3 after 24h and 27h treat-
ment). 3h values for full length caspase-3 ranged from 100±2.1% and 100±15.8%
for controls (0.05% and 2% DMSO, respectively) to 112.0±15.1% for 1000µM MPA.
Although no statistically significant change was found, a trend towards increased
expression of full length caspase-3 can be seen after 3h incubation with MPA. This
trend was observed after 24h and 72h as well, but less pronounced. Very distinct
trends towards increases in cleaved caspase-3 levels were detected for 17kDa and
19kDa fragments after 24h and 72h (Fig. 2.12).
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As for data on MPA-induced necrosis, almost no literature can be found for MPA-
induced apoptosis in human intestinal cell lines. No data on LS180 or Caco-2 cells
is available. Findings in examined cell lines (often lymphocytes [145] or other blood
cells [146], that are dependent on de novo guanosine synthesis and cannot utilize
exogenous guanosine as efficently as other cell types) differ widely and are hard to
compare to findings in the LS180 cell model.
Many publications report induction of apoptosis by MPA in vitro in cells of non-
cancerous [145, 146] and cancerous origin, e.g. neuroblastoma [147, 148] and leukemia
cells [149]. The common cause of induction seems to be guanosine nucleotide de-
pletion [148, 149]. Very few publications are available that report no apoptotic
potential of MPA [150] (article in Chinese, only abstract in English).
The lack of MPA-induced apoptosis can be caused by multiple factors or by an in-
terplay of factors. LS180 cells were supplemented with 1000µM guanosine, which is
often neglected in in vitro experiments [148, 149]. Although intracellular nucleotide
concentrations in LS180 cells are unbalanced despite supplementation with 1000µM
guanosine of the growth medium (please see Section 2.5.2), 1000µM guanosine may
have had an ameliorating effect on the induction of apoptosis. FBS depletion of the
culture media most likely had no effect on LS180 cells treated with MPA, as de-
scribed and depicted in Section 2.3.1. Another reason might be the cancerous origin
of LS180 cells. Overexpression of MDR1 leading to multidrug resistence (already
described in Section 2.2.2 and Section 2.3.1), which was specifically shown for LS180
cells treated with a single dose of MPA for 72h (Sec. 2.2.2), could diminish apop-
totic potential of MPA in LS180 cells. Overexpression of OATP1B3, with increases
up to 100-fold in colorectal cancers [120], may have antiapoptotic effects due to
altered p53-dependent pathways [120] and could enhance cell survival as well. Ad-
ditionally an antiapoptotic effect of PXR was found in human colon cancer cells as
well as normal mouse colon epithelium, which may occur in LS180 cells as well [151].
Cytotoxicity tests showed very little to no cytotoxic effects of MPA concentrations
up to 250µM (in case of short term apoptosis studies even up to 1000µM) on LS180
cells under the different conditions tested (no use of FBS, no necrosis even with-
out supplementation with exogenous guanosine, no significant apoptosis/cleavage of
caspase-3 compared to controls with 1000µM exogenous guanosine).
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Fig. 2.12: Western blots for determination of expression levels of caspase-3
and levels of cleaved caspase-3 in LS180 cells after treatment with increasing
concentrations of MPA and 1000µM guanosine for 3h (8 MPA concentrations),
24h, and 72h (6 MPA concentrations). Caspase-3 gave a band at 35kDa, cleaved
caspase-3 gave bands at 17kDa and 19kDa. Bands are shown with their respective β-
actin bands (N=3). Relative intensities as determined by densitometry analysis were
normalized based on β-actin and calculated as % of controls are shown in Figure 2.13.
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Fig. 2.13: Expression levels of caspase-3 and levels of cleaved caspase-3
in LS180 cells after treatment with increasing concentrations of MPA and
1000µM guanosine for 3h (8 MPA concentrations), 24h, and 72h (6 MPA con-
centrations) as assessed using densitometry of western blots. Values are given
as means of % of controls of relative intensities as determined by densitometry analysis
normalized based on β-actin for uncleaved caspase-3 (35 kDa), cleaved caspase-3 (sum
of intensities of bands at 17 and 19 kDa), and the ratio of uncleaved to total caspase-3
(sum of intensities of bands at 17, 19, and 35 kDa) (N=3). Western blots with their
respective β-actin bands are shown in Figure 2.12. No statistically significant differences
in caspase-3 expression levels versus controls were found in LS180 cells after treatment
with increasing concentrations of MPA and supplementation with 1000µM guanosine for
3h, 24h, and 72h as determined using one-way ANOVA in combination with Scheffe’s
post − hoc test.
2.4 Antiproliferative properties
Cell proliferation of LS180 cells exposed to increasing concentrations of MPA, MMF,
MPA + morpholinoethanol, and morpholinoethanol was measured using
CyQUANT NF Cell Proliferation Assays. This assay relies on a fluorescent dye
that binds to cellular DNA, the amount of which is closely related to cell number,
and allows to assess proliferation rates by measuring flurescence intensities.
Since the CyQUANT NF Cell Proliferation Assay estimates cell numbers by mea-
suring DNA content of a sample, it identifies impairment of cell populations caused
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by cell proliferation inhibition as well as cytotoxicity. A contribution of necrosis or
apoptosis to decreases in cell numbers, that may be caused by MPA’s antiprolifera-
tive properties, was evaluated and widely ruled out by LDH assays and measurement
of caspase-3 and cleaved caspase-3 levels (Sec. 2.3). The assay outcome should there-
fore depend on cell proliferation exclusively.
LS180 cells were incubated with MPA, MMF, MPA + morpholinoethanol, and mor-
pholinoethanol at concentrations of 0, 0.01, 0.1, 0.5, 1, 5, 10, 50, 100, and 250µM.
Two sets (single dose and redosed every 24h) were run for 48h and 72h incubations.
Incubation times of at least 48h were chosen for first experiments to reliably allow
for detecting differences in data for LS180 cell proliferation rates (doubling time of
51.1±2.7 hours for LS180 cells, Sec. 3.2.1). Fluorescence readings were calculated
as % of controls.
Data for single dose studies are shown in Figure 2.14. Data for studies in which cells
were redosed every 24h are shown in Section 2.4.1 for cells treated with and without
exogenous guanosine and MPA (Fig. 2.16).
Since decreases in cell proliferation occured during exposure to MPA, MMF, MPA +
morpholinoethanol (discussed below) while morpholinoethanol treatment alone did
not show any significant effects, data shown in Figure 2.16 in Section 2.4.1 were
collected for MPA treatment only.
Figure 2.14 shows significant decreases in cell proliferation after a single dose of
MPA, MMF, and MPA + morpholinoethanol for concentrations ≥1µM after 48h (all
p-values > 0.001). After 72h, drug concentrations ≥5µM significantly decreased
proliferation, while 1µM drug concentrations did not affect proliferation. This shift
might result from glucuronidation/metabolism of MPA/MMF as it often occurs for
many drugs in tumor cells (one mechanism of drug resistance) [152] and from LS180
cells adapting to MPA exposure (Sec. 2.2.2).
Half maximal inhibitory concentration (IC50) values were calculated for incubation of
LS180 cells for 48h and 72h with single doses of MPA, MMF, and MPA + morpholi-
noethanol. IC50 values ranged around 2µM, with IC50 (MPA, 48h, single dose) =
2.59µM, IC50 (MMF, 48h, single dose) = 1.15µM, IC50 (MPA + morpholinoethanol,
48h, single dose) = 2.44µM, IC50 (MPA, 72h, single dose) = 1.73µM, IC50 (MMF,
72h, single dose) = 2.13µM, and IC50 (MPA + morpholinoethanol) = 1.24µM. For
24h incubations (Sec. 2.4.1) an IC50 (MPA, 24h) = 2.25µM was determined, as well
as values for redosed cell cultures for 48h and 72h incubations of IC50 (MPA, 48h,
redosed) = 2.28µM and IC50 (MPA, 72h, redosed) = 4.40µM.
Comparing IC50 values for LS180 cells for different incubation times after single
MPA doses, no apparent changes in values were observed. An increase in IC50 val-
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Fig. 2.14: Effects of drug treatment (single dose) on LS180 cell proliferation
after 48h and 72h. Values are given as means of % of controls (N=6). Values were
calculated from fluorescence intensities using the CyQUANT NF Cell Proliferation Assay.
Due to the 96-well plate format of the assay, a set of controls was run for each drug
individually. Significance was determined using one-way ANOVA combined with Scheffe’s
post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
ues could have been expected due to the increasing drug inactivation over time due
to glucuronidation/metabolism of the parent drug as already mentioned above [152].
While after single MPA doses the IC50 doses after different incubation periods
were consistant, after repeat doses and 72h incubation, the IC50 values approxi-
mately doubled to 4.4µM. This about 2-fold higher IC50 value may be due to LS180
cells adapting to MPA as mechanism of drug resistance (described above and in
Sec. 2.2.2). Overexpression of enzymes and transporters linked to MPA metabolism,
i.e. MRP1 (significantly upregulated after 72h of MPA treatment, Fig. 2.10), as well
as of enzymes linked to pharmacodynamics of MPA, i.e. IMPDH 2 (trend towards
upregulation after only 24h of MPA treatment, Fig. 2.9), in LS180 cells was ob-
served and is discussed in context of these studies in Section 2.2.2 already. Slight
differences in experimental conditions (most likely cell density at the start of the
experiment) and conditions during the experiment (media renewal ensuring optimal
growth conditions for cells) may also contribute to the increase of the IC50 values
for cells treated with repeated doses of MPA over 72h.
The necessity to redose for sufficient guanosine supplementation of the media for
follow-up experiments, the shift in proliferation profiles as shown in Figure 2.14,
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and redosing being the more physiologic approach, led us to the use of a repeated
dosing strategy with MPA and guanosine in subsequent experiments (Sec. 2.1.2).
Comparing the above findings to the currently available literature, it is ambigu-
ous that MPA depletes intracellular GTP and excerts its antiproliferative effects in
a strongly cell type-specific manner [153]. Lymphocytes respond to MPA in vitro
with IC50 values of proliferation inhibition of less than 0.1µM while cells such as
fibroblast or endothelial cells are less sensitive or unaffected by concentrations in
this concentration range (IC50 values ≈ 0.6 µM) [42, 43]. Evaluating effects of MPA
on the proliferation of different cancer cell lines for a duration of 48h, Franklin et al.
reported differences in IC50 values inbetween cell lines as well, although the exam-
ined lines had a cancerous origin in common [152]. While EMT6 (murine mammary
carcinoma) cells exhibited an IC50 for proliferation inhibition of 0.24µMMPA, HeLa
(human cervical carcinoma) cells showed an IC50 of 0.80µM MPA, and HT29 (hu-
man colorectal carcinoma) cells an IC50 of 12.9µM MPA. Yalowitz et al. found an
even higher IC50 of 21µM MPA for growth inhibition of HT29 cells by MPA [154].
The IC50 values found in LS180 cells (≈ 2µM MPA) correspond to the high IC50
values for HT29 cells and the low values for EMT6 and HeLa, which are all human
cancer cell lines. Especially values for HT29 show that even very high IC50 values
for human colon adenocarcinomas are resonable. Proliferation rates (and therefore
utilization of nucleotides) such as a doubling time of 1 day for HT29 cells in pres-
ence of FBS [155], about 1 day for HeLa cells [156], and about 2 days for LS180
cells (Sec. 3.2.1) do not seem to be directly affected by MPA exposure. Probable
reasons are cell type-dependent characteristica such as differences in utilization of
pathways of nucleotide synthesis (Sec. 1.1.4) as well as preconditions (Sec. 2.2.1)
and adaptation (Sec. 2.2.2).
2.4.1 Influence of exogenous guanosine on proliferation of
different cell types during MPA treatment
The influence of exogenous guanosine on MPA’s antiproliferative properties was as-
sessed for different time periods in LS180 cells and subsequently in two additional
cell types using the CyQUANT NF Cell Proliferation Assay as described above
(Sec. 2.4). For these experiments cells were redosed with MPA and guanosine every
24h to ensure sufficient availability of guanosine and to avoid insufficient exposure
to the parent drug due to drug inactivation by glucuronidation/metabolism.
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RAW 264.7 and CCD-18Co cells were employed as controls to check and verify
changes in proliferation patterns seen in LS180 cells, which are grade II tumor cells
and therefore bear abnormalities in metabolism (Sec. 2.2 and Sec. 2.8.2). Taken
higher proliferation rates/shorter doubling times of RAW 264.7 and CCD-18Co cells
into account (Sec. 3.2.1) and therefore eventually higher demand of guanosine, assays
determining effects of MPA and only 100µM guanosine were not carried out for these
cells types. As no cytotoxicity assays were conducted for these cells, contribution of
cell death cannot be fully ruled out in these studies. Arguing against the occurance
of necrosis in these two cell types is that no dead cells were observed during the
experiments.
Influence of exogenous guanosine on LS180 cells
LS180 cell proliferation under MPA and guanosine (0, 100, 200, 400 and 1000µM)
treatment was tested for 24h, 48h, 72h, and 5 days (5 days for 1000µM guanosine
only).
Figure 2.15 shows effects of treatment in LS180 cells within the first 72h. After 24h
LS180 cell proliferation was diminished for cells grown in culture medium contain-
ing 0µM and 100µM guanosine for MPA concentrations ≥5µM. Almost the same
changes were present for 48h and 72h (no changes for 100µM guanosine, but 200µM
guanosine) treatment. 1000µM guanosine antagonized the negative effects on prolif-
eration by MPA even at higher MPA concentrations. Compared to assays without
guanosine substitution this included higher proliferation rates for cells treated with
100µM MPA after 24h, 100 and 250µM MPA after 48h, and 10, 50, and 100µM
MPA after 72h.
Data shown in Figure 2.15 (arranged based on increasing guanosine concentrations)
is shown again in Figure 2.16, this time with data sorted based on incubation time
(for 0, 100, 200, and 400µM guanosine) and Figure 2.17 (for 1000µM guanosine).
Influence of exogenous guanosine on RAW 264.7 cells
Due to the relatively high proliferation rate of the murine macrophage cell line
RAW 264.7 (Sec. 3.2.1) proliferation assay duration was limited to 72h to guarantee
uncompromised proliferation of controls and treatment groups.
In Figure 2.18 RAW 264.7 data is sorted based on increasing guanosine concentra-
tions for 24h, 48h, and 72h. Significantly impaired cell growth was seen after 24h
and 48h only for RAW 264.7 cells grown in medium without guanosine and MPA
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Fig. 2.15: Effects on LS180 cell proliferation after 24h, 48h, and 72h of MPA treatment and supplementation
with 100, 200, 400, and 1000µM guanosine (redosed every 24h). Values are given as means of % of controls (N=6).
Significance was determined using one-way ANOVA combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005;
∗∗∗: p<0.001 versus controls. Values were calculated from fluorescence intensities using the CyQUANT NF Cell Proliferation
Assay. Due to the 96-well plate format of the assay a set of controls was run for each guanosine concentration individually.
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Fig. 2.16: Effects on LS180 cell proliferation after 24h, 48h, and 72h of MPA
treatment and supplementation with 0, 100, 200, and 400µM guanosine (re-
dosed every 24h). Values are given as means of % of controls (N=6). Significance
was determined using one-way ANOVA combined with Scheffe’s post − hoc test with
∗/ ♯: p<0.05; ∗∗/ ♯♯: p<0.005; ∗ ∗ ∗/ ♯♯♯: p<0.001 versus controls; ∗: significance
versus 24h values, ♯: significance versus 48h values of same MPA concentration. Values
were calculated from fluorescence intensities using the CyQUANT NF Cell Proliferation
Assay. Due to the 96-well plate format of the assay a set of controls was run for each
guanosine concentration individually.
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Fig. 2.17: Effects on LS180 cell proliferation after 24h, 48h, 72h, and 5d of
MPA treatment and supplementation with 1000µM guanosine (redosed every
24h). Values are given as means of % of controls (N=6). Significance was determined
using one-way ANOVA combined with Scheffe’s post − hoc test with ∗/ ♯/ ◦: p<0.05;
∗∗/ ♯♯/ ◦◦: p<0.005; ∗ ∗ ∗/ ♯♯♯/ ◦ ◦ ◦: p<0.001 versus controls; ∗: significance versus
24h values, ♯: significance versus 48h values of same MPA concentration, ◦: significance
versus 72h values of same MPA concentration. Values were calculated from fluorescence
intensities measured by a fluorescence microplate reader using the CyQUANT NF Cell
Proliferation Assay. Due to the 96-well plate format of the assay a set of controls was
run for each guanosine concentration individually.
concentrations ≥5µM. In most cases guanosine substitution ≥200µM was sufficient
to return proliferation rates back to normal as compared to controls. A comparison
of effects of MPA treatment and insufficient guanosine levels as shown in the first
graph in Figure 2.19 (0µM guanosine) shows significantly lower cell numbers (cal-
culated as % of controls) after 24h and 48h/72h of treatment.
Figure 2.19 shows the time course of RAW 264.7 proliferation changes over 72h
after supplementation with 0 (controls), 200, 400, and 1000µM guanosine. Supple-
mentation of cell culture media with 200, 400, and 1000µM guanosine reversed the
effects of MPA (except for significant decreases for concentrations of 400µM guano-
sine and 10-100µM MPA). Starting at 5µM MPA depleted RAW 264.7 cell numbers
for cells grown in 200µM guanosine-containing medium after 48h (p<0.001 for MPA
concentrations ≥5µM for 48h values versus 72h values). These changes were less
pronounced but still significant for cells exposed to higher guanosine concentrations.
For 400µM guanosine-treated cells p-values ranged between 0.05 and 0.01 for MPA
doses between 5µM and 100µM. There did not seem to be further improvement
over supplementation with 400µM guanosine as the effects of supplementation with
1000µM showed similar results.
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Fig. 2.18: Effects on RAW 264.7 cell proliferation after 24h, 48h, and 72h of
MPA treatment and supplementation with 0, 200, 400, and 1000µM guanosine
(redosed every 24h). Values are given as means of % of controls (N=6). Significance
was determined using one-way ANOVA combined with Scheffe’s post − hoc test with
∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls. Values were calculated from
fluorescence intensities using the CyQUANT NF Cell Proliferation Assay. Due to the 96-
well plate format of the assay a set of controls was run for each guanosine concentration
individually.
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Fig. 2.19: Effects on RAW 264.7 cell proliferation after 24h, 48h, and 72h of
MPA treatment and supplementation with 0, 200, 400, and 1000µM guanosine
(redosed every 24h). Values are given as means of % of controls (N=6). Significance
was determined using one-way ANOVA combined with Scheffe’s post − hoc test with
∗/ ♯: p<0.05; ∗∗/ ♯♯: p<0.005; ∗ ∗ ∗/ ♯♯♯: p<0.001 versus controls; ∗: significance
versus 24h values of same MPA concentration, ♯: significance versus 48h values of
same MPA concentration. Values were calculated from fluorescence intensities using the
CyQUANT NF Cell Proliferation Assay. Due to the 96-well plate format of the assay a
set of controls was run for each guanosine concentration individually.
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Influence of exogenous guanosine on CCD-18Co cells
CCD-18Co cells turned out to be more resistant to MPA-induced changes in pro-
liferation under treatment with exogenous guanosine than LS180 and RAW 264.7
cells. To follow growth profiles over a longer period of time assays were run for
24h, 48h, 72h, and additionally for 5 days after guanosine supplementation with 0
(controls), 200, 400, and 1000µM.
Figure 2.20 shows CCD-18Co cell proliferation with data sorted based on concentra-
tions of exogenous guanosine. After 24h only a trend towards lower cell numbers un-
der higher doses of MPA was seen for 0µM guanosine (250µM MPA: 90.8±19.6% of
control values), while in comparison after 24h statistically significant changes oc-
cured already for LS180 cells with p<0.01 versus controls and p<0.001 versus con-
trols for RAW 264.7 cells. For concentrations of 200-1000µM guanosine, pronounced
trends towards elevated proliferation of CCD-18Co cells under increasing doses of
MPA were detected (250µM MPA: 135.1±26.7% of control values for 200µM guano-
sine, 138.1±27.6% of control values for 400µM guanosine, 120.6±34.6% of control
values for 1000µM guanosine; please see 3D graph in Figure 2.20). Significant de-
creases in proliferation without guanosine supplementation was found after 48h with
significance levels increasing with incubation time. Significant decreases in CCD-
18Co cell numbers under guanosine treatment occured after 5 days for 400µM guano-
sine for 100µM and 250µM MPA.
Time courses of growth profiles of CCD-18Co cells are shown in Figure 2.21. With-
out guanosine supplementation, MPA reduced CCD-18Co cell numbers after 48h for
MPA concentrations ≥1µM and after 72h already for MPA concentrations ≥0.01µM,
which was also the lowest concentration used. Significant decreases in cell numbers
were seen for all MPA concentrations starting at 0.01µM when incubated for 48h or
72h as well. No changes were detected when cells were incubated without guanosine
supplementation for more than 72h.
Supplementation with 200µM and 400µM guanosine did not prevent reduction in
cell numbers after 5 days of treatment with 100µMMPA (200µM and 400µM guano-
sine) and 250µM MPA (400µM guanosine). Neither trends nor significant changes
were found in time-dependent proliferation patterns for CCD-18Co cells exposed to
1000µM guanosine at any of the MPA concentrations tested.
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Fig. 2.20: Effects on CCD-18Co cell proliferation after 24h, 48h, 72h, and 5d of
MPA treatment and supplementation with 0, 200, 400, and 1000µM guanosine
(redosed every 24h). Values are given as means of % of controls (N=6). Significance
was determined using one-way ANOVA combined with Scheffe’s post − hoc test with
∗: p<0.05; ∗∗: p<0.01; ∗ ∗ ∗: p<0.001 versus controls. Values were calculated from
fluorescence intensities using the CyQUANT NF Cell Proliferation Assay. Due to the 96-
well plate format of the assay a set of controls was run for each guanosine concentration
individually.
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Fig. 2.21: Effects on CCD-18Co cell proliferation after 24h, 48h, 72h and
5d of MPA treatment and supplementation with 0, 200, 400, and 1000µM
guanosine (redosed every 24h). Values are given as means of % of controls (N=6).
Significance was determined using one-way ANOVA combined with Scheffe’s post − hoc
test with ∗/ ♯/ ◦: p<0.05; ∗∗/ ♯♯/ ◦◦: p<0.005; ∗ ∗ ∗/ ♯♯♯/ ◦ ◦ ◦: p<0.001 versus
controls; ∗: significance versus 24h values, ♯: significance versus 48h values of same MPA
concentration, ◦: significance versus 72h values of same MPA concentration. Values
were calculated from fluorescence intensities using the CyQUANT NF Cell Proliferation
Assay. Due to the 96-well plate format of the assay a set of controls was run for each
guanosine concentration individually.
The literature supports that most negative MPA effects on cell proliferation, func-
tion, and metabolism can be antagonized by supplementation with guanosine [43,
110, 157]. While reversal of certain effects, e.g. the MPA-mediated negative effect on
the expression of certain proteins is not established [157], effects such as intra- and
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extracellular levels of signaling molecules and LDH [110] as well as DNA synthesis
can generally be restored to normal [43, 110, 157] or sometimes even supranormal
levels [157].
Restoration of proliferation to normal as well as even supranormal levels, as it was
described before [157] was seen. Looking at proliferation profiles over time for cells
in differently supplemented media has not been described in the literature yet. De-
creases in the capacity to utilize exogenous guanosine as seen in the three examined
cell types occurring after distinct incubation times leads to the question how the
divergent epithelial cell types, especially stem cells, constituting the intestinal bar-
rier along the crypt-villus axis [158, 159] are affected. If intestinal barrier function
was compromised by these disturbances, Crohn’s disease-like patterns of inflamma-
tion would result as they are seen in transplant patients receiving an MPA-based
immunosuppressive drug regimen (Sec. 1.2.3).
2.5 Effects on nucleotide levels and energy charge
Nucleotides (nucloeside mono-, di-, and triphosphates) are high-energy phosphates
that are essential for a multitude of biochemical processes within cells [131, 148, 160].
They determine a cell’s energy state, serve as coenzymes and as intermediates in
anabolic and catabolic pathways, and they are the building blocks of nucleic acids
constituting DNA (deoxyribonucleotides) and RNA (ribonucleotides) (Sec. 1.1.4,
Fig. 1.2). Cyclic nucleotides, especially cyclic adenosine monophosphate (cAMP)
and cyclic guanosine monophosphate (cGMP), serve as second messengers influ-
encing metabolism, gene transcription, cell morphology, and signal transduction
amongst many other crucial cellular actions [161]. Redox cofactors such as NAD+,
NADP+, and flavin adenine dinucleotide (FAD) are inevitable for maintaining func-
tions such as cellular respiration, oxidative phosphorylation, lipid synthesis, gluco-
neogenesis, post-translational modifications of proteins, and many others [78, 80].
Concentrations of high-energy phosphates (ATP, ADP, AMP, GTP, GDP, GMP,
UTP, UDP, UMP, CTP, CDP, CMP) as well as NAD+, NADP+, and FAD in ex-
tracts of drug-treated LS180 cell were assessed to investigate the influence of MPA
and its derivatives on nucleotide levels in LS180 cells in detail. Dependent on the
experiment cells were or were not supplemented with guanosine. After drug in-
cubation cells were extracted with perchloric acid (PCA) and a quantitative high
performance liquid chromatography (HPLC)-MS assay developed by Klawitter et
al. was used to measure nucleotide concentrations [160].
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2.5.1 Nucleotide levels and energy charge after single doses of
drugs without exogenous guanosine
To obtain concentration-dependent profiles and for comparison of drugs and drug
combinations, LS180 cells were incubated 12h, 24h, and 48h, respectively, with single
doses of drugs (MPA, MMF, MPA + morpholinoethanol, and morpholinoethanol) at
increasing concentrations (0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, 100, and 250µM) or 0.05%
DMSO for controls (N=4). As this was one of the first experiments performed, cells
were neither redosed nor were cell culture media supplemented with guanosine. Nu-
cleotide levels were measured quantitatively [160], normalized to amounts of protein
per sample and calculated as % of controls. The adenylate energy charge (AEC) of
treated LS180 cells was calculated according to the formula by Atkinson: AEC =
(ATP + 0.5*ADP)/(AMP + ADP + ATP) [162]. Respective energy charge values
for guanine (GEC), uridine (UEG), and cytidine (CEG) nucleotides were calculated
using the respective concentrations of nucleotide triphosphates (NTPs), nucleotide
diphosphates (NDPs), and nucleotide monophosphates (NMPs). The corresponding
equations are based on the equation for a general nucleotide energy charge (NEC):
NEC = (NTP + 0.5*NDP)/(NMP + NDP + NTP) [163].
Graphs of levels of nucleotide tri-, di-, and monophosphates (ATP, ADP, AMP,
GTP, GDP, GMP, UTP, UDP, UMP, CTP, CDP, CMP) as well as of redox cofac-
tors (FAD, NAD+, NADP+) and NECs (AEC, GEC, UEC, CEC) in LS180 cells after
12h, 24h, and 48h incubations with MPA, MMF, MPA + morpholinoethanol, and
morpholinoethanol are shown calculated as % of controls in the appendix (Fig. 4.1 -
Fig. 4.19).
Nucleotide ratios in LS180 cells were in normal ranges when compared to published
data on physiological nucleotide concentrations in predominantly mammalian cell
lines and fluids [164]. Traut et al. found the following average concentrations for the
four NTPs: ATP: 3152 ± 1698µM, GTP: 468 ± 224µM, UTP: 567 ± 460µM, CTP:
278 ± 242µM, with concentrations being elevated 1.2-5-fold in tumor cells compared
to normal cells [164]. As values are given in µM it is hard to compare Traut’s values
directly to our values due to the procedure used to measure nucleotides in our sam-
ples: After reconstitution of lyophylized cell extracts of LS180 cells in 500µL HPLC
grade H2O, 1:20 dilution, and measurement using HPLC-MS, absolute amounts of
compounds were calculated and normalized to protein contents of samples (unit:
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Table 2.1: Influence of MPA, MMF, and MPA + morpholinoethanol (ME) on
nucleotide levels and energy charge. Statistically significant changes (↑↓, num-
ber of displayed arrows reflects the most significant change within one treatment group
of increasing drug concentrations versus controls) and trends (↑↓, not statistically sig-
nificant) in compound concentrations versus controls are summarized, p<0.05: ↑/↓,
p<0.01: ↑↑/↓↓, p<0.001: ↑↑↑/↓↓↓.
MPA MMF MPA+ME
12h 24h 48h 12h 24h 48h 12h 24h 48h
ATP - ↓ ↑↑↑ - - ↑↑↑ - ↓ -
ADP - - ↑↑↑ - - ↑↑ - - -
AMP - - - - - - - - -
GTP ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓ ↓↓↓ ↓↓↓ ↓
GDP ↓↓↓ ↓↓↓ - ↓↓↓ ↓↓↓ - ↓↓↓ ↓↓↓ -
GMP ↓↓↓ ↓↓↓ - ↓↓↓ ↓↓↓ - ↓↓↓ ↓↓↓ -
UTP ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑
UDP ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑
UMP ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑
CTP ↑↑↑ ↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ -
CDP ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑
CMP ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑
NAD+ - - ↑↑↑ - - ↑↑ - ↑↑ -
NADP+ - - ↑↑↑ ↑ - ↑↑↑ ↑ - -
FAD - - ↑↑↑ - - ↑ - - ↑
AEC - - - - - - - - -
GEC ↓↓↓ - - ↓↓↓ - - ↓↓↓ - -
UEC - - - - - - - - -
CEC - - - - - - - - -
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nmol/mg protein). Results are given as % of control NTP values (nmol/mg pro-
tein). Representative examples of values for 72h cell extracts of LS180 cells not sup-
plemented with exogenous guanosine (control, 72h, 0µM guanosine) are as follows:
ATP: 3308.0 ± 172.8nmol/mg protein, GTP: 1448.8 ± 133.9nmol/mg protein, UTP:
447.4 ± 18.8nmol/mg protein, CTP: 2278.5 ± 95.7nmol/mg protein. The amount
of UTP seems relatively low compared to values for ATP, GTP, and CTP, but is
still reasonable when taking the high standard deviation found for UTP as reported
by Traut into account [164]. The same applies for CTP values which seem fairly
high even for a cancer cell line.
Overall nucleotide levels were not affected differently for MPA, MMF, or MPA +
morpholinoethanol and responses of LS180 cells showed closely matching profiles.
Adenosine nucleotide levels (Fig. 4.1 - Fig. 4.3) were largely unaffected after 12h,
24h, and 48h after single doses of drugs with exemption of a few elevated ATP
and ADP values after 48h (Fig. 4.1 and Fig. 4.2). Relative high-energy phosphate
concentrations were found for MPA and MMF in the range of 5-250µM, but also
for 5µM morpholinoethanol. These surprising elevations after 48h are likely to be a
stress response of LS180 cells after 48h of drug treatment (elevation only for higher
concentrations) and no exchange of culture media. Depletion of nutrients in culture
media seems to be a reason especially since imbalances in other nucleotide levels
are balanced after 48h compared to 12h and 24h. The AEC did not change for any
compound/compound combination after 12h, 24h, or 48h of treatment with a single
dose (Fig. 4.16).
Guanosine nucleotide levels (Fig. 4.4 - Fig. 4.6) were significantly reduced starting
at MPA concentrations of 0.5µM after 12h and 24h. After 48h only GTP levels
were still significantly affected at higher MPA concentrations. The amelioration of
MPA-induced effects between 24h and 48h is most likely due to drug metabolism
(Sec. 2.2.2). Figure 4.5 and Figure 4.6 show significantly decreased values with
p<0.001 for all concentrations >1µM after 12h and 24h with no significant de-
creases being obvious after 48h anymore. This pattern also occurs in the case of
uridine and cytidine nucleotides. The GEC is significantly affected after 12h for
concentrations >1µM (except for morpholinoethanol), with imbalances evened out
after 24h already.
Pyrimidine (uridine and cytidine) nucleotides were significantly higher for MPA,
MMF, and MPA + morpholinoethanol than for the controls at all time points as-
sessed starting at drug doses of 5µM (Fig. 4.7 - Fig. 4.12). This upregulation of
pyrimidine nucleotides is most likely caused by increased PRPP concentrations due
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to IMPDH inhibition by MPA [165], as PRPP is used in the synthesis of purines
as well as synthesis of uridine nucleotides, which are substrates for cytidine nu-
cleotides [166].
The rate of phosphorylation of the respective nucleotide did not seem to have influ-
ence on synthesis suppressing/elevating effects since mono-, di-, and trinucleotides
were equally affected for guanosine, uridine, and cytidine.
Concentrations of NAD+, NADP+, and FAD were found changed (Fig. 4.13, Fig. 4.14,
and Fig. 4.15, respectively).
The results discussed above are summarized in Table 2.1 (morpholinoethanol is not
listed in this summary, as incubation with morpholinoethanol did not induce any
significant changes in measured compounds).
Imbalances of nucleotide/ribonucleotide pools with increased synthesis of certain
uridine and cytidine nucleotides/ribonucleotides were observed in the 1970ies and
80ies already [167, 168]. Studies of the biological effects of inhibition of guanosine nu-
cleotide synthesis by MPA in cultured cells such as murine neuroblastoma cells [167],
murine leukemia L1210 cells [168], human umbilical vein endothelial cells [169], and
murine sarcoma 180 cells [170] showed similar effects as seen here in LS180 cells.
To mention in this context is a randomized PK study of MPA that did not show
significant effects of MPA on intracellular pools of deoxytriphosphates of cytidine
and guanosine in HIV-1-infected patients on MMF therapy compared to non-MMF
patients [171].
In Section 2.5.2 MPA’s effects on nucleotide levels in guanosine-supplemented LS180
cells are discussed in detail in the context of a more physiological experiment not
sacrificing the availability of exogenous guanosine.
2.5.2 Influence of exogenous guanosine on nucleotide levels and
energy charge
To reassess effects of perturbations of cellular guanosine nucleotide levels in the pres-
ence of exogenous guanosine, LS180 cells were incubated with 0, 0.1, 5, 100, and
250µM MPA in the presence of 0, 200, and 1000µM guanosine for 24h and 72h (re-
dosed every 24h), extracted with PCA, and high-energy phosphate concentrations
were measured using HPLC-MS.
Effects of the incubation conditions on adenosine, guanosine, uridine, and cytidine
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nucleotide levels are shown in Figure 2.22 - Figure 2.25, effects on NAD+, NADP+ ,
and FAD levels are shown in Figure 2.26, energy charges of all nucleotides are shown
in Figure 2.27. Effects of MPA and exogenous guanosine treatment on all measured
intracellular compounds in LS180 cells are summarized in Table 2.2.
While adenosine concentrations were relatively unaffected by a singe dose of MPA
(Sec. 2.5.1, Fig. 4.1 - Fig. 4.3), redosing of cells every 24h led to depletion of ATP,
ADP, and AMP to levels of 40.7 ± 8.3% of controls, 25.2 ± 4.2% of controls, and
9.4 ± 4.5% of controls, respectively (without guanosine supplementation, 250µM
MPA; Fig. 2.22). Adenosine nucleotide levels were largely restored by supplemen-
tation with 200µM and 1000µM guanosine.
Guanosine nucleotides were significantly lower for MPA concentrations ≥5µM for
all guanosine concentrations applied for 24h and 72h (Fig. 2.23). Even for LS180
cells treated with 1000µM exogenous guanosine GTP, GDP, and GMP levels ranged
around 30% of controls only. As described in Section 2.4.1 (Fig. 2.15), LS180 cell pro-
liferation was restored by 1000µM and drastically improved by 200µM and 400µM
guanosine. Restoration of proliferation rates does not reflect intracellular guanosine
nucleotide levels as nucleotide levels only slightly improved in the presence of high
guanosine concentrations but levels could neither be restored completely nor be el-
evated to control levels.
Addition of guanosine antagonized the changes of UMP and UDP levels after 72h
that occured without 200µM and 1000µM guanosine (Fig. 2.24). UTP levels on the
other hand were significantly higher for MPA concentrations ≥5µM in the presence
of 200µM and 1000µM guanosine (127.6 ± 8.3% of controls and 199.8 ± 12.3% of
controls for 250µM MPA after 24h and 72h).
Changes of cytidine nucleotide levels were reversed by supplementation with guano-
sine in most cases. The few slighly elevated values (GTP: 100µM MPA, 200µM and
1000µM guanosine; GMP: 100µM MPA, 1000µM guanosine) suggested imbalances
in cytidine nucleotide levels in LS180 cells despite of/due to heavy guanosine sup-
plementation of the cell culture media.
Disturbances in NAD+, NADP+, and FAD, which mainly occured after 72h for
higher MPA concentrations in the absence of guanosine supplementation, were sim-
ilar to control levels during supplementation with guanosine.
After 24h the GEC was significantly decreased (74.9 ± 4.2% of controls, i.e. 0.499 ±
0.005 for controls versus 0.374 ± 0.021 for 250µM MPA) in LS180 cells without
guanosine supplementation. The other NECs did not show any differences versus
controls after 24h (Fig. 2.27). After 72h treatment changes occured in AEC, GEC,
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and CEC without guanosine supplementation (AEC: 115.9 ± 1.0% of controls, i.e.
0.760 ± 0.018 for controls versus 0.862 ± 0.041 for 250µMMPA; GEC: 135.3 ± 5.5%
of controls, i.e. 0.502 ± 0.028 for controls versus 0.681 ± 0.024 for 250µM MPA;
CEC: 83.7 ± 2.9% of controls, i.e. 0.503 ± 0.030 for controls versus 0.422 ± 0.014 for
250µM MPA). The increase in UEC values after 72h of treatment with 250µM MPA
and 1000µM guanosine to 125.3 ± 5.0% of controls (i.e. 0.503 ± 0.041 for controls
versus 0.630 ± 0.025 for 250µM MPA, p>0.05) in consideration of imbalances in
pyrimidine nucleotide levels even under guanosine supplementation described above
is remarkable due to the magnitude and significance of metabolic roles of uridine
and cytosine nucleotides. GDP-, UDP-, and CDP-linked intermediates are involved
in e.g. lipid and protein glycosylation and membrane synthesis [166, 172]. Our find-
ings concerning nucleotide concentrations in LS180 cells during MPA and guanosine
treatment will be discussed further in later sections, i.e. Section 2.7 and Section 2.8
describing MPA-induced proteome and metabolome alterations in LS180 cells.
Again, MPA concentrations used in the literature were in lower ranges (e.g. 0.1µM -
5µM [165], 10µM [170]) than in our studies, accordingly guanosine concentrations
necessary to reverse MPA-induced effects typically ranged around 50µM - 100µM [165,
170].
2.5.3 Influence of MPA treatment on Na+-K+-ATPase
expression levels
Na+-K+-ATPase (sodium pump) is a membrane-bound enzyme that regulates Na+
and K+ gradients across plasma membranes in mammalian cells [173]. ATP is
hydrolyzed to ADP and Pi and drives the movement of ions against their concentra-
tion gradients. The enzyme plays a role in many essential cellular functions such as
maintaining cytoplasmic Na+ concentrations which regulate cell volume, cytoplas-
mic pH and Ca2+ concentrations (through Na+/H+ and Na+/Ca2+ exchangers), and
secondary transport processes (Na+-dependent glucose and amino acid transport).
Since water and Na+ absorption are dependent on each other, Na+-K+-ATPase is
crucial to water absorption in the intestine and closely linked to the pathophysiology
of diarrhea [173, 174], which is one of MPA’s most prominent side effects (Sec. 1.2.3).
Although ATP and AEC levels were only affected by MPA as long as cell culture
72
2.5 Effects on nucleotide levels and energy charge
Fig. 2.22: Adenosine nucleotide levels of LS180 cells after 24h and 72h (redosed
every 24h) of treatment with MPA and guanosine. Values are given as means of
% of controls (N=4). Significance was determined using one-way ANOVA combined
with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus
controls.
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Fig. 2.23: Guanosine nucleotide levels of LS180 cells after 24h and 72h (redosed
every 24h) of treatment with MPA and guanosine. Values are given as means of
% of controls (N=4). Significance was determined using one-way ANOVA combined
with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus
controls.
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Fig. 2.24: Uridine nucleotide levels of LS180 cells after 24h and 72h (redosed
every 24h) of treatment with MPA and guanosine. Values are given as means
of % of controls (N=4). Significance was determined using one-way ANOVA combined
with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus
controls.
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Fig. 2.25: Cytidine nucleotide levels of LS180 cells after 24h and 72h (redosed
every 24h) of treatment with MPA and guanosine. Values are given as means
of % of controls (N=4). Significance was determined using one-way ANOVA combined
with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus
controls.
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Fig. 2.26: NAD+, NADP+, and FAD levels of LS180 cells after 24h and 72h
(redosed every 24h) of treatment with MPA and guanosine. Values are given
as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001
versus controls.
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Fig. 2.27: Energy charges for adenosine (AEC), guanosine (GEC), uridine
(UEC), and cytidine (CEC) nucleotides in LS180 cells after 24h and 72h (re-
dosed every 24h) of treatment with MPA and guanosine. Values are given as
means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001
versus controls.
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Table 2.2: Influence of exogenous guanosine (Guo) on nucleotide levels and
energy charge. Statistically significant changes (↑↓, number of displayed arrows
reflects the most significant change within one treatment group of increasing MPA
concentrations versus controls) and trends (↑↓, not statistically significant) in com-
pound concentrations versus controls are summarized, p<0.05: ↑/↓, p<0.01: ↑↑/↓↓,
p<0.001: ↑↑↑/↓↓↓.
0 µM Guo 200 µM Guo 1000 µM Guo
24h 72h 24h 72h 24h 72h
ATP ↓↓↓ ↓↓↓ - - ↑ -
ADP - ↓↓↓ - ↓ - -
AMP - ↓↓↓ - ↓↓ - -
GTP ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓
GDP ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓
GMP ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓
UTP ↑↑↑ ↑↑↑ ↑ ↑↑↑ ↑↑↑ ↑↑↑
UDP ↑↑↑ ↓↓↓ - - - ↑↑
UMP ↑↑↑ ↑↑ - ↑ - -
CTP ↑↑↑ - - ↑ - ↑↑
CDP ↑↑↑ ↓↓↓ - - - ↑
CMP ↑↑↑ ↑↑ ↑ ↑ ↑ ↑↑↑
NAD+ - ↓↓↓ - ↓↓ - -
NADP+ ↑↑ ↓↓↓ - - - -
FAD - ↓↓ - - - -
AEC - ↓ ↓↓ ↓↓ - -
GEC ↓↓↓ ↑↑↑ - - - -
UEC - - - - - ↑
CEC - ↓↓↓ - - - -
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media were not supplemented with guanosine and values returned to control levels
under treatment with 200µM and 1000µM guanosine (Fig. 2.22 and Fig. 2.27), ex-
amination of Na+-K+-ATPase expression levels in MPA-treated LS180 cells seemed
valuable. Additionally ATPase α and β subunits were found by Asif et al. and Ship-
kova et al. to be covalently modified by the AcMPAG metabolite of MPA [175, 176].
To evaluate adenosine nucleotide and AEC levels in the context of Na+-K+-ATPase
expression levels, western blots for the determination of Na+-K+-ATPase expression
levels of lysates of LS180 cells treated with 0, 0.1, 1, 5, 10, 100, and 250µM MPA
and 0, 200, and 1000µM guanosine were run. Western blots are shown in Figure 2.28
and expression levels normalized based on β-actin and calculated as % of controls
in Figure 2.29.
There were no significant changes in Na+-K+-ATPase expression levels, although
a trend toward overexpression could be observed in LS180 cells treated with high
MPA concentrations and no guanosine for 24h (Fig. 2.29). After 72h or when cul-
ture media were supplemented with guanosine Na+-K+-ATPase expression returned
to control levels. In comparison to changes in ATP and ADP concentrations as
summarized in Table 2.2, decreases in ATP levels and normal levels of ADP after
24h MPA treatment (without guanosine) may at least partially be related to overex-
pression of Na+-K+-ATPase, although multiple reasons, e.g. decreases in oxidative
phosphorylation and/or tricarboxylic acid (TCA) cycle activity, may also contribute
to the decrease of ATP levels.
2.5.4 Influence of MPA treatment on cAMP and cGMP levels
While cAMP and cGMP are well-characterized in their functions as second messen-
gers roles of cUMP and cCMP as signaling molecules are still widely unknown [161].
cAMP and cGMP are synthesized from the cytosolic purine nucleotides ATP and
GTP by adenylyl and guanylyl cyclases, respectively [161, 179, 180]. cAMP and
cGMP are degraded by phosphodiesterases [180]. cAMP acts mostly but not ex-
clusively through activation of cAMP-dependent protein kinases. It influences cell
metabolism, morphology, gene transcription, and regulates functions of ion channels
and other proteins [161, 181]. cGMP also regulates fundamental processes within
cells such as gene expression, cell growth, and apoptosis. It is involved in contrac-
tion/relaxation of smoothe muscle [179] which is of special interest in the GI tract
regulating its muscle tone via the nitric oxide-cGMP signaling pathway [182].
To rule out depletion of cAMP and/or cGMP which could be expected from findings
described in Section 2.5.2; levels of both cyclic nucleotide monophosphates in LS180
cells under MPA treatment with and without exogenous guanosine supplementa-
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Fig. 2.28: Western blots for determination of expression levels of Na+-K+-
ATPase in LS180 cells after treatment with MPA and guanosine for 24h and
72h. Bands are shown with their respective β-actin bands (N=3). Relative intensities
normalized based on β-actin and calculated as % of controls are shown in Figure 2.29.
Na+-K+-ATPase gave a band at 120kDa (predicted 95kDa), difference between actual
and predicted band size probably due to post-translational modifications [125]; bands
for Na+-K+-ATPase at higher molecular weigths than the predicted have been reported
in the literature already (most likely due to phosphorylation or glycosylation state of the
protein) [177] and have been reported in product sheets for other available Na+-K+-
ATPase antibodies [178].
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Fig. 2.29: Expression levels of Na+-K+-ATPase in LS180 cells after treatment
with MPA and guanosine for 24h and 72h. Values are given as means of % of con-
trols of relative intensities normalized based on β-actin (N=3). Western blots with their
respective β-actin bands are shown in Figure 2.28. No statistically significant differences
in Na+-K+-ATPase expression levels versus controls were found after treatment with in-
creasing concentrations of MPA and guanosine for 24h and 72h (p=0.59 for 10µM MPA
versus control, 0µM guanosine, 24h).
tion were measured using enzyme-linked immunosorbent assays (ELISAs, Cyclic
AMP/GMP Competitive Enzyme Immunoassays Kit, Cayman Chemical). Aliquots
of cell lysates that were used for caspase-3 western blots (Sec. 2.3.2) and western
blots for validation of proteomics experiments (Sec. 2.7.1) were used.
Competitive enzyme immunoassays that are based on competition of free cAMP/
cGMP and a cAMP/cGMP-acetylcholinesterase conjugate (cAMP/cGMP tracer) for
a limited number of cAMP/cGMP-specific antibody binding sites were used. Depen-
dent on a sample’s amount of cAMP/cGMP, only a proportion of the tracer is able
to bind to the antibody. The tracer-antibody complex is bound to a second antibody
immobilized on the ELISA plate. Providing the substrate for acetylcholinesterase,
an enzymatic reaction is initiated. The reaction’s yellow-colored product strongly
absorbs at 412nm. Color intensity is proportional to the amount of tracer bound
which is inversely proportional to the sample’s cAMP/cGMP concentration.
As can be seen in Figure 2.30 cAMP concentrations after 24h treatment are unaf-
fected for all combinations of MPA and guanosine. After 72h a trend towards ele-
vated cAMP levels in LS180 cells not supplemented with guanosine occured. cAMP
levels in cells supplemented with 200µM guanosine increased with MPA concentra-
tion. The increases were rather small and seemed to reach statistical significance
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Fig. 2.30: cAMP and cGMP levels in LS180 cells after treatment with MPA
and guanosine for 24h and 72h. Values are given as means of % of controls (N=3).
Measurement of absorbance using a cAMP/cGMP standard allowed calculation of the
absolute amount of cAMP/cGMP as well as calculation of the values as % of controls.
Statistically significant differences in cAMP levels versus controls were only found after
treatment with increasing concentrations of MPA and 200µM guanosine after 72h for
the four highest MPA concentrations used (due to relatively small standard deviations of
this set of samples). A statistically significant difference in cGMP levels versus controls
was only found after treatment with increasing concentrations of MPA and without
guanosine supplementation after 24h for the highest MPA concentration.
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only due to very small standard deviations of this set of samples. Most impor-
tantly cells treated with 1000µM guanosine did not show changes in cAMP levels
incubated with MPA. cGMP levels of LS180 cells were not affected significantly by
MPA treatment, except for 250µMMPA without guanosine supplementation. These
data emphasized once more the importance of guanosine supplementation for these
experiments.
Only little research on the influence of MPA on cAMP or cGMP concentrations in
vitro and in vivo has been performed. The available literature is not consistent and
described effects are cell type-dependent. Studying the reduction in β-adrenergic
response of C6 glioma cells (rat glioma) Franklin et al. measured decreased cAMP
responses to (+/-)isoprenaline, used as β-adrenergic stimulant, after MPA treat-
ment [183]. Responses were restored by addition of guanine (intermediate of the
salvage pathway of purine synthesis, conversion by HGPRT to GMP directly, or
conversion to guanosine by purine nucleoside phosphorylase and consecutive con-
version to GMP by guanosine kinase/5’-nucleotidase) along with MPA (after 3h,
31µM MPA, 166µM guanine). In another study the ability of prostaglandin E1 and
isoproterenol to elevate intracellular cAMP concentrations in cultured normal rat
kidney cells was decreased by MPA (20-100µM) by 50-70% with the response being
maximal after 2h [184].
While Naor et al. found basal and hormone-induced cGMP concentrations decreased
to undetectable levels (method used not mentioned) in cultured pituitary cells (pri-
mary cultures of cells from the pituitary gland of adult female rats) [185], Messina
et al. report intracellular cGMP levels to be increased during MPA-induced neu-
roblastoma differentiation in LAN5 and SHEP cells (human neuroblastoma) [180].
Overall most negative effects of MPA on nucleotide levels (Tab. 2.1) were ameliorated
or fully reversed by supplementation with guanosine (Tab. 2.2). In a physiologic con-
text and for discussion of our data presented in the next sections, experiments using
1000µM guanosine supplementation are the most relevant. Despite supplementa-
tion with 1000µM guanosine levels of all guanosine nucleotides were significantly
decreased (p<0.001) as well as levels of uridine and cytosine nucleotides upregu-
lated with effects on the UEC (these findings will be discussed in later sections).
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2.6 HPLC-MS method development and preliminary
studies for method validation
In the context of a different study performed in our laboratory “A High-Throughput
Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay
for the Quantification of Mycophenolic Acid and its Major Metabolites Mycopheno-
lic Acid Glucuronide and Mycophenolic Acid Acyl Glucuronide in Human Plasma
and Urine” was developed by Klepacki et al. [186]. The assay met all predefined
acceptance criteria and the quantification of MPA was successfully cross-validated
with an HPLS-MS assay routinely used for clinical therapeutic drug monitoring in
our laboratory.
While this newly developed assay uses human ethylenediaminetetraacetic acid (EDTA)
plasma and urine as matrices an assay for the determination of intracellular and ex-
tracellular drug concentrations in cell extracts (MeOH extracts) and cell culture
media of LS180 cells was developed (Sec. 2.6.1) and it was attempted to validate
this assay in these media. The routinely used assay for clinical therapeutic drug
monitoring served as basis, but since this assay only measures MPA concentrations
with MMF as an internal standard, modification of the assay was necessary. During
assay development and validation problems with the stabilities of MPA metabolites
presented themselves. As these problems have not been described in the literature
before, they will be presented in Section 2.6.2.
2.6.1 HPLC-MS method development
An HPLC-MS assay was developed for MPA, MMF, MPAG, AcMPAG, DM-MPA,
and MPA-GS. It was not possible to capture morpholinoethanol along with the
other analytes due to low sensitivity and unsatisfying peak shape at higher con-
centrations (most likely due to problems with chromatography). DM-MPA-6G and
DM-MPA-4G were not included in the method due to a lack of commercial avala-
bility of reference material. AcMPA-GS was not included (although it was included
in Sec. 2.7.2 in the search for covalent modifications of proteins) due to very low
amounts present in body fluids of transplant patients (concentrations below detec-
tion limits, Sec. 1.1.5).
Measurements were performed on an API 4000 triple quadrupole (AB Sciex) or API
5000 triple quadrupole (AB Sciex). The instrument was operated in the positive mul-
tiple reaction monitoring (MRM) mode with electrospray ionization (ESI) source and
was equipped with an Agilent 1100 HPLC system (Agilent 1100 HPLC pump, Agi-
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lent 1100 inline extraction system, Agilent 1100 well plate autosampler, Agilent 1100
binary pump, and Agilent 1100 column thermostat). Analytes were extracted using
a ZORBAX Eclipse XDB-C8, 5µm (4.6mm x 5mm) column (Agilent Technologies)
and separated using a ZORBAX Eclipse XDB-C8, 3.5µm (4.6mm x 150mm) column
(Agilent Technologies). The solvents were 0.1% aqueous formic acid (FA, mobile
phase A) and methanol + 0.1% FA (mobile phase B). The gradient used for inline
extraction was: 0.0-0.5min 15% methanol at a flow rate of 3000µL/min, 0.5-0.6min
15%-98% methanol at a flow rate of 3000µL/min, 0.6-3.5min 98% methanol at a
flow rate of 100µL/min, 3.5-4.3min 98% methanol at a flow rate of 4000µL/min, 4.3-
4.8min 98%-15% methanol at a flow rate of 4000µL/min, 4.8-4.9min 15% methanol
at a flow rate of 3000µL/min for re-equilibration to starting conditions. The gradient
used for separation (at a constant flow rate of 1000µL/min) was: 0.0-0.5min 50%
methanol, 0.5-2.5min 50-82% methanol, 2.5-6.7min 82-98% methanol, 6.7-7.0min
98-50% methanol for re-equilibration to starting conditions. Nitrogen was used as
drying gas and collision gas. The mass spectrometry parameters were: ion transi-
tion MPA: m/z = 343.1 [M+Na]+ → 187.3 with 50msec dwell time, 66V decluster-
ing potential (DP), 25V collision energy (CE), and 16V collision cell exit potential
(CXP); ion transition MMF: m/z = 434.3 [M+H]+ → 195.3 with 50msec dwell
time, 61V DP, 47eV CE, 14V CXP; ion transition MPAG/AcMPAG: m/z = 519.0
[M+Na]+ → 343.0 with 50msec dwell time, 66V DP, 25eV CE, 16V CXP; ion tran-
sition DM-MPA: m/z = 307.2 [M+H]+ → 193.1 with 50msec dwell time, 56V DP,
31eV CE, 16V CXP, ion transition MPA-GS: m/z = 505.3 [M+Na]+ → 343.1 with
50msec dwell time, 81V DP, 35eV CE, 10V CXP; ion transition MPA-d3: m/z =
346.3 [M+Na]+ → 232.1 with 50msec dwell time, 66V DP, 25eV CE, 16V CXP; ion
transition MPAG-d3: m/z = 522.0 [M+Na]+ → 346.0 with 50msec dwell time, 66V
DP, 25eV CE, 16V CXP. MPA-d3 and MPAG-d3 were used as internal standards.
The source temperature was set to 450◦C with a capillary voltage of 5000V and
collissionally activated dissociation (CAD) set to 12. The column oven temperature
was set to 65±5◦C. The injection volume was 100µL. Total run time was 7.0min.
In Figure 2.31 a representative total ion chromatogram showing peaks of all analytes
included in the above described method is depicted. MeOH/H2O (1:1) was used as
matrix. MPAG and AcMPAG (pink) are only distinguishable by their retention
times (3.5min for MPAG and 4.3min for AcMPAG) as the glucuronide metabolites
are of the same mass and share the same ion transition. Small amounts of MPA
(blue) are detected at the retention times of the glucuronides due to in-source frag-
mentation of MPAG and AcMPAG in the electrospray interface after separation.
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Fig. 2.31: Representative total ion chromatogram of all analytes included in
the HPLC-MS method for quantification of MPA, MMF, and their metabo-
lites. The chromatogram was recorded under the conditions described above in
MeOH/H2O (1:1) as matrix.
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2.6.2 Preliminary studies prior to HPLC-MS method validation
Limits of detection
Limits of detection in MeOH/H2O (1:1) were found to be 250pM for MPA, 25pM
for MMF, MPAG, AcMPAG, as well as for DM-MPA, and 50pM for MPA-GS (API
4000 triple quadrupole mass spectrometer).
Possible pH- and matrix component-dependency of the stability of AcMPAG
and MPAG
Validation was started at a time when LS180 cell culture media were still supple-
mented with 10% FBS. During method validation in cell culture media as matrix
(media at neutral pH, extracted with 30% 0.2M ZnSO4/70% MeOH-solution at
ph=5.82 as the normal pH of this solution) remarkable effects were seen, starting
with calibration curves showing rapid degradation of AcMPAG. In publications it
is often recommended to acidify samples which are going to be subjected to mea-
surement of AcMPAG levels to a pH of 2 immediately [187] as AcMPAG and acyl
glucuronides in general are known to be instable at neutral pH and to be more stable
in acidic environments [187, 188].
For a quick scan of pH-dependent effects, cell culture media containing all analytes
at medium concentration ranges were extracted with two different MeOH/ZnSO4-
solutions acidified with FA to pH=4.47 (0.01% FA) and pH=3.75 (0.1% FA). Usage
of MPA-d3 and MPAG-d3 as internal standards revealed pH-dependent conversion
of MPAG-d3 to AcMPAG-d3, which only became obvious due to usage of the deuter-
ated forms of the analytes MPA and MPAG. Figure 2.32 shows chromatograms of
analytes recorded in the internal standard channel after extraction of 10.000µM cali-
brators with MeOH/ZnSO4-solutions of different pH values. Degradation of MPAG-
d3 (retention time ca. 3.5min) can be seen as well as formation of AcMPAG-d3 (re-
tention time ca. 4.2min) and even MPA-d3 (retention time ca. 3.5min) at lower pH
values. Since all analytes (undeuterated) were spiked into samples the respective
contributions to the occurring analyte formation/degradation as well as mechanisms
(intra- or intermolecular conversion) remain unknown.
For a more qualitative and quantitative approach starting conditions for experi-
ments were refined. Four buffers of different pH values were used. 10mM ammo-
nium acetate was used as matrix to clarify the above described interconversions
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Fig. 2.32: Ion chromatograms of calibrators (10.000µM) extracted with
MeOH/ZnSO4-solutions of different pH values for stability experiments for
MPA method development recorded in the internal standard channel. The
experiment was preliminary and due to the described stability problems no absolute
concentrations were calculated. The experiment was performed with an N=3 showing
similar results.
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which were initially thought to be only pH-dependent. The pH values of interest
were chosen to be pH=2, 5, 7, and 9 to cover the entire pH range of the GI tract
(Fig. 1.6). Knowledge of pH-dependent (and matrix component-dependent as de-
scribed below) drug/metabolite stability/conversion within the GI tract (especially
in terms of metabolites forming covalent adducts with proteins, Sec. 2.7.2) is not
only important in terms of extraction method and HPLC-MS method validation, but
is also inevitable when researching/discussing the reasons for GI toxicity of MPA.
The 10mM ammonium acetate buffers (slightly basic) were put to neutral or acidic
pH with HCl (pH=2, 5, and 7), or to a basic pH (pH=9) with ammonium hy-
droxide. Different sets of samples (MPAG alone, MPAG + MPA, MPAG + MMF;
0, 100, 1000, 10000µM) were prepared in buffers of distinct pH values and mea-
sured immediately or incubated for different time periods (30min, 2h, 5h, 24h) on
ice. MPAG alone was used to check on intramolecular conversion of MPAG to
AcMPAG, MPAG + MPA were used in case of intermolecular conversion of MPAG
to AcMPAG and the availability of free MPA as a prerequisite, MPAG + MMF
as a negative control in case of intermolecular conversion (MMF turned out to be
relatively stable over at least 24h even at 37◦C in cell culture medium in previously
conducted experiments, data not shown; MMF is also used as an internal standard
in the above mentioned clinical assay). No internal standard was used due to pos-
sible interference with analytes.
Surprisingly, no excessive conversion of MPAG to AcMPAG or MPA was seen in
any sample at any pH value. This led to the idea of other matrix components,
present in the used cell culture media but not in the used buffers, triggering analyte
degradation/conversion.
A vast amount of literature on the stability/instability and reactivity of drugs
and/or their glucuronide metabolites in the presence of albumin and/or FBS is
available [189–197]. While much of the literature deals with pH- and albumin-
dependent acyl migration and protein binding of glucuronides, hydrolysis of glu-
curonides in the presence of albumins is addressed as well [194]. Examining the
stability of glucuronides matrices such as buffers, human serum albumin (HSA)
solutions (eventually of different HSA percentages), and human plasma are often
routinely investigated [190–192]. Drug/metabolite conversion, degradation, binding
to matrix components, and even stereoselectivity of reactions are not unusual [193].
Thus, Akira et al. found the extent of hydrolysis of synthetic probenecid glucuronides
in plasma larger than that in buffer [194], and Mc Gurk et al. described mefenamic
acid 1-O-acyl glucuronide to be relatively stable at physiological pH values (more
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instable at basic pH values) [195].
Data discussed in this section gives hints for future experiments of MPA method
validation and necessary experiments preceeding MPA method validation including
extraction methods. Thus, the stabilizing effect of low pH values which is discussed
in the literature and recommended for sample handling, may be due to conversion
of MPAG to AcMPAG in the presence of albumin especially since the matrix used
in the above cited assays and studies is generally human plasma which provides a
certain amount of HSA.
2.7 Investigation of proteome alterations in LS180
cells after MPA treatment
Two kinds of experiments were conducted to identify MPA-induced changes in the
proteome of LS180 cells. Overall changes to the protein content of cells were iden-
tified successfully using Stable Isotopic Labeling by Amino Acids in Cell Culture
(SILAC) technology. Additionally an anti-MPA/AcMPAG antibody was used to
detect direct protein targets of MPA and certain MPA metabolites (this experiment
did not yield resonable results as discussed in Section 2.7.2).
As data analysis in this section inevitably involves database searches and usage of
the available online tools, it is remarked that ambiguities regarding the nomencla-
ture of genes and proteins are a major problem in the literature and databases [198]
(e.g. EC numbers not being assigned for many proteins). In this thesis, protein/gene
names used by the Uniprot database were chosen to identify proteins/genes as well
as Uniprot abbreviations. In cases of mistakable, intricate or not assigned abbrevi-
ations, the gene symbol was used as abbreviation for the encoded protein.
2.7.1 SILAC
For SILAC experiments two cell culture populations (i.e. treated and untreated
cells) were grown in cell culture media supplemented with light (normal) amino
acids (here L-lysine was used, but L-arginine or L-lysine and L-arginine in combina-
tion are routinely used as well) for one population and heavy (isotopic) amino acids
for the other [199, 200]. Cellular proteins were labeled with the chemically identical
light/heavy forms of the respective amino acids as cells proliferated and lysates of
treated/untreated (labeled/unlabeled) cell populations were processed and analyzed
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together eliminating errors due to unequal sampling. Isotopically different peptides
were distinguished by MS analysis and differential proteome expression was quanti-
fied.
After a successful initial screen for positive/negative correlations of protein expres-
sion levels and MPA concentrations by GelC-MS of lysates of MPA-treated LS180
cells (no SILAC labeling, N=1 only, Sec. 3.9) SILAC experiments were conducted
to identify and quantify proteome alterations in LS180 cells reliably. LS180 cells
were labeled with light and heavy lysine according to the manufacturer’s manual
of the used labeling kit (Invitrogen, SILAC Protein Identification and Quantifi-
cation Kits, Carlsbad, CA). Cells were treated with 0, 0.1, 5, 100, and 250µM
MPA for 72h (redosed every 24h, supplemented with 1000µM guanosine). After
extraction, lysis (Sec. 3.4), protein determination (Sec. 3.3), and in-solution tryptic
digestion (Sec. 3.9.2) were performed and labeling efficiency was checked to be suf-
ficient (>99%) for cell lysates grown in media containing heavy lysine (0.1, 5, 100,
and 250µM MPA, Sec. 3.9). For SILAC experiments MPA treated lysates (labeled
with heavy lysine, 20µg) were combined with equal amounts of control lysates (la-
beled with light lysine, 20µg). Samples were processed and analyzed by GelC-MS
as described in Section 3.9.1.
Initial data filtering
Analysis of MS data using the MaxQuant software package (version 1.2.2.5, Max
Planck Institute of Biochemistry, Martinsried, Germany; Sec. 3.9.2) conveyed a to-
tal of 2095 protein IDs. After removing protein ID hits without sufficient amounts
of data for statistical analysis the remaining 268 IDs were filtered for changes in
H/L ratios of >20% inbetween H/L=1 (ideal control value) versus H/L of 250µM
MPA-treated/-untreated cell lysates (threshold H/L=1.2 for upregulated proteins,
threshold H/L=0.8 for downregulated proteins). 75 proteins passed the threshold
criteria out of which 35 proteins showed statistically significant changes among H/L
ratios of treatments (no H/L-labeled set for controls was run since no H-labeled
controls were available (no additional control labeled with heavy lysine was pre-
pared) and H/L ratio of controls ideally equals 1; only treatments of different MPA
concentrations, i.e. 0.1, 5, 100, and 250µM, were compared among each other).
The 35 proteins are listed in Table 2.3 - Table 2.6 sorted by their percentagewise
increases/decreases in levels. Abbreviations of protein names and genes, Uniprot
accession numbers, Ensemble gene IDs, the number of unique peptides that served
to identify respective proteins, means ± standard deviations of SILAC H/L ratios,
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and Pearson product-moment correlation coefficients are given as well (for detailed
explanation please see tables). Pearson product-moment correlation coefficients only
served to illustrate linearity of H/L ratios and concentration changes, but were not
used as a threshold criterion for sorting of proteins since non-linearity of H/L ratios-
concentration relationship was not supposed to be a criterion for exclusion.
93
2
R
es
u
lt
s
a
n
d
D
is
cu
ss
io
n
Table 2.3: LS180 proteins of levels increased by >30% after MPA treatment identified by SILAC. Shown are protein numbers
(assigned for clarity), protein names, protein and gene (italic) abbreviations, Uniprot accession numbers and Ensemble gene IDs, numbers of
unique peptides identified, SILAC heavy/light (H/L) ratios for four MPA concentrations, Pearson product-moment correlation coefficients
r for the correlation/linear dependence of H/L ratios and MPA concentrations, and the increase in protein levels after 250µM MPA
treatment compared to a H/L ratio=1 as expected for controls (= calculation as % of controls). H/L ratios are given as means ± standard
deviations (N=3). Significance was determined for effects of increasing MPA concentrations using one-way ANOVA combined with Scheffe’s
post − hoc test with ∗/ ♯/ ◦: p<0.05; ∗∗/ ♯♯/ ◦◦: p<0.005; ∗ ∗ ∗/ ♯♯♯/ ◦ ◦ ◦: p<0.001 versus treatment with 0.1, 5, and 100µM MPA.
∗: significance versus treatment with 0.1µM MPA, ♯: significance versus treatment with 5µM MPA, ◦: significance versus treatment with
100µM MPA. Due to lack of H/L-labeled controls only treatments of different MPA concentrations were compared among each other.
Abbr. prot. Uniprot acc. no. Unique SILAC H/L ratio H/L 250µM MPA
# Protein name Abbr. gene Ensemble gene ID peptides 0.1µM MPA 5µM MPA 100µM MPA 250µM MPA r vs. H/L=1 [%]
1 Long-chain acyl-CoA ACSL5 Q9ULC5 18 0.83 ± 0.20 1.07 ± 0.08 1.44 ± 0.21 1.94 ± 0.15 0.977 193.6
synthetase 5 ACSL5 ENSG00000197142 ∗ ∗∗ ♯♯
2 UDP glucuronosyltrans- UGT1A1 P22309 7 1.12 ± 0.25 1.45 ± n.a. 1.55 ± 0.23 1.91 ± 0.29 0.917 191.0
ferase 1A1 UGT1A1 ENSG00000167165 ∗
3 Very long-chain specific VLCAD P49748 25 0.94 ± 0.14 1.02 ± 0.11 1.21 ± 0.20 1.83 ± 0.16 0.990 183.0
acyl-CoA dehydrogenase ACADVL ENSG00000072778 ∗∗ ♯♯ ◦
4 Annexin A1 ANXA1 P04083 14 1.17 ± 0.20 1.14 ± 0.11 1.68 ± 0.21 1.75 ± 0.17 0.891 174.6
ANXA1 ENSG00000135046 ∗ ♯
5 Peroxisomal acyl-CoA oxidase 1 AOX Q15067 15 0.88 ± 0.11 1.01 ± 0.09 1.28 ± 0.10 1.75 ± 0.08 0.992 174.5
ACOX1 ENSG00000161533 ∗ ∗ ∗ ∗ ♯♯ ◦◦
6 Fatty acid-binding protein 1 FABP1 Q6FGL7 4 0.84 ± 0.33 0.91 ± 0.05 1.88 ± 0.31 1.70 ± 0.21 0.771 169.9
FABP1 ENSG00000163586 ∗ ♯ ∗
7 Integrin β-4 ITGB4 P16144 46 1.07 ± 0.06 1.27 ± 0.02 1.34 ± 0.04 1.44 ± 0.11 0.836 143.5
ITGB4 ENSG00000132470 ∗ ∗∗
8 Guanine nucl.-binding protein GNG12 Q9UBI6 3 1.01 ± 0.12 1.17 ± 0.03 1.15 ± 0.11 1.35 ± 0.04 0.888 135.4
G(I)/G(S)/G(O) subunit γ-12 GNG12 ENSG00000172380 ∗
94
2
.7
In
v
estig
a
tio
n
o
f
p
ro
teo
m
e
a
ltera
tio
n
s
in
L
S
1
8
0
cells
a
fter
M
P
A
trea
tm
en
t
Table 2.4: LS180 proteins of levels increased by >20% but <30% after MPA treatment identified by SILAC. For explanation
of the depicted parameters please refer to Table 2.3.
Abbr. prot. Uniprot acc. no. Unique SILAC H/L ratio H/L 250µM MPA
# Protein name Abbr. gene Ensemble gene ID peptides 0.1µM MPA 5µM MPA 100µM MPA 250µM MPA r vs. H/L=1 [%]
9 Single-stranded DNA-binding MtSSB Q04837 7 0.97 ± 0.10 1.04 ± 0.11 1.02 ± 0.10 1.29 ± 0.07 0.926 128.8
protein 1, mitochondrial SSBP1 ENSG00000106028 ∗
10 Acetyl-CoA acyltrans- ACAA2 P42765 8 0.96 ± 0.14 0.89 ± 0.01 1.09 ± 0.11 1.28 ± 0.06 0.979 128.4
ferase ACAA2 ENSG00000167315 ∗ ♯
11 Dihydrolipoamide dehydrogenase DLD P09622 11 0.96 ± 0.04 1.04 ± 0.07 1.09 ± 0.10 1.27 ± 0.07 0.967 127.1
DLD ENSG00000091140 ∗∗
12 Trifunctional enzyme TFP P40939 21 0.87 ± 0.13 0.94 ± 0.10 1.04 ± 0.07 1.26 ± 0.04 0.988 126.4
subunit α HADHA ENSG00000084754 ∗∗ ∗
(Long-chain 3-hydroxyacyl-CoA (LCHAD)
dehydrogenase)
13 Electron-transfer- α-ETF P13804 12 0.90 ± 0.02 0.99 ± 0.08 1.09 ± 0.09 1.26 ± 0.04 0.974 125.5
flavoprotein ETFA ENSG00000140374 ∗ ∗∗ ♯
14 NAD(P)H dehydrogenase, NQO1 P15559 8 1.11 ± 0.04 1.09 ± 0.00 1.25 ± 0.01 1.25 ± 0.06 0.847 124.6
quinone 1 NQO1 ENSG00000181019 ∗ ♯ ∗ ♯
15 Heat shock 70kDa protein 9 HSPA9 P38646 25 0.98 ± 0.08 1.02 ± 0.05 1.03 ± 0.01 1.24 ± 0.07 0.956 124.5
(mortalin) HSPA9 ENSG00000113013 ∗∗ ♯ ◦
16 Delta(3,5)-Delta(2,4)-dienoyl- ECH1 Q13011 14 0.91 ± 0.05 0.88 ± 0.07 1.03 ± 0.06 1.22 ± 0.10 0.995 122.4
CoA isomerase, mitochondrial ECH1 ENSG00000104823 ∗ ♯
17 Glycerol-3-phosphate dehy- GPD2 P43304 22 0.91 ± 0.03 1.04 ± 0.05 1.02 ± 0.10 1.22 ± 0.13 0.886 122.3
drogenase 2, mitochondrial GPD2 ENSG00000115159 ∗
18 GTP:AMP phosphotransferase, AK3 Q9UIJ7 7 0.79 ± 0.13 0.86 ± 0.09 1.01 ± 0.07 1.21 ± 0.14 0.988 121.4
mitochondrial AK3 ENSG00000147853 ∗
(Adenylate kinase 3)
19 Elongation factor Tu/P43 EF-Tu P49411 18 0.98 ± 0.02 1.00 ± 0.02 0.99 ± 0.01 1.20 ± 0.09 0.918 120.4
TUFM ENSG00000178952 ∗∗ ♯ ◦ ◦
20 Succinyl-CoA ligase [ADP/GDP- SCS-α P53597 3 0.88 ± 0.14 1.06 ± 0.05 1.05 ± 0.07 1.20 ± 0.06 0.842 120.1
forming] subunit α SUCLG1 ENSG00000163541 ∗
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Table 2.5: LS180 proteins of levels decreased by >30% after MPA treatment identified by SILAC. Shown are protein numbers
(assigned for clarity), protein names, protein and gene (italic) abbreviations, Uniprot accession numbers and Ensemble gene IDs, numbers of
unique peptides identified, SILAC heavy/light (H/L) ratios for four MPA concentrations, Pearson product-moment correlation coefficients
r for the correlation/linear dependence of H/L ratios and MPA concentrations, and the increase in protein levels after 250µM MPA
treatment compared to a H/L ratio=1 as expected for controls (= calculation as % of controls). H/L ratios are given as means ± standard
deviations (N=3). Significance was determined for effects of increasing MPA concentrations using one-way ANOVA combined with Scheffe’s
post − hoc test with ∗/ ♯/ ◦: p<0.05; ∗∗/ ♯♯/ ◦◦: p<0.005; ∗ ∗ ∗/ ♯♯♯/ ◦ ◦ ◦: p<0.001 versus treatment with 0.1, 5, and 100µM MPA.
∗: significance versus treatment with 0.1µM MPA, ♯: significance versus treatment with 5µM MPA, ◦: significance versus treatment with
100µM MPA. Due to lack of H/L-labeled controls only treatments of different MPA concentrations were compared among each other.
Abbr. prot. Uniprot acc. no. Unique SILAC H/L ratio H/L 250µM MPA
# Protein name Abbr. gene Ensemble gene ID peptides 0.1µM MPA 5µM MPA 100µM MPA 250µM MPA r vs. H/L=1 [%]
21 Polymeric immunoglobulin receptor PIgR P01833 13 0.97 ± 0.04 0.78 ± 0.05 0.45 ± 0.05 0.35 ± 0.05 -0.888 34.8
PIGR ENSG00000162896 ∗ ∗ ∗ ∗ ♯♯ ∗ ∗ ∗ ♯♯♯
22 Regenerating islet-derived REG-4 Q9BYZ8 8 0.86 ± 0.06 0.93 ± 0.15 0.61 ± 0.12 0.48 ± 0.15 -0.950 47.7
protein 4 REG4 ENSG00000134193 ∗ ♯
23 Solute carrier family 12 SLC12A2 P55011 30 0.96 ± 0.05 0.99 ± 0.05 0.63 ± 0.07 0.48 ± 0.06 -0.952 48.0
member 2 SLC12A2 ENSG00000146828 ∗∗ ♯♯ ∗ ∗ ∗ ♯♯♯
24 Creatine kinase B-type B-CK P12277 16 0.93 ± 0.05 0.74 ± 0.06 0.59 ± 0.06 0.50 ± 0.05 -0.969 49.8
CKB ENSG00000166165 ∗ ∗∗ ∗ ∗ ∗ ♯
25 Cadherin-17 CDH17 Q12864 24 0.98 ± 0.04 0.96 ± 0.05 0.75 ± 0.02 0.63 ± 0.04 -0.969 62.7
CDH17 ENSG00000079112 ◦◦ ∗∗ ♯♯ ◦◦ ∗ ∗ ∗ ♯♯♯ ◦
26 Dihydropyrimidinase-like 2 DRP-2 Q16555 7 1.13 ± 0.13 0.97 ± 0.24 0.84 ± 0.05 0.63 ± 0.09 -0.946 63.4
variant DPYSL2 ENSG00000092964 ∗
27 Stromal cell-derived SDF2L1 Q9HCN8 3 1.08 ± 0.02 1.02 ± 0.28 0.83 ± 0.07 0.67 ± 0.06 -0.978 66.5
factor 2-like 1 SDF2L1 ENSG00000128228 ∗
28 Acetyl-CoA acetyltransferase ACAT2 Q9BWD1 8 1.04 ± 0.08 1.00 ± 0.05 0.95 ± 0.08 0.70 ± 0.03 -0.983 70.0
ACAT2 ENSG00000120437 ∗∗ ♯♯ ◦ 96
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Table 2.6: LS180 proteins of levels decreased by <30% but >20% after MPA treatment identified by SILAC. Shown are
protein numbers (assigned for clarity), protein names, protein and gene (italic) abbreviations, Uniprot accession numbers and Ensemble
gene IDs, numbers of unique peptides identified, SILAC heavy/light (H/L) ratios for four MPA concentrations, Pearson product-moment
correlation coefficients r for the correlation/linear dependence of H/L ratios and MPA concentrations, and the increase in protein levels
after 250µM MPA treatment compared to a H/L ratio=1 as expected for controls (= calculation as % of controls). H/L ratios are given
as means ± standard deviations (N=3). Significance was determined for effects of increasing MPA concentrations using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗/ ♯/ ◦: p<0.05; ∗∗/ ♯♯/ ◦◦: p<0.005; ∗∗∗/ ♯♯♯/ ◦◦◦: p<0.001 versus treatment with 0.1,
5, and 100µM MPA. ∗: significance versus treatment with 0.1µM MPA, ♯: significance versus treatment with 5µM MPA, ◦: significance
versus treatment with 100µM MPA. Due to lack of H/L-labeled controls only treatments of different MPA concentrations were compared
among each other.
Abbr. prot. Uniprot acc. no. Unique SILAC H/L ratio H/L 250µM MPA
# Protein name Abbr. gene Ensemble gene ID peptides 0.1µM MPA 5µM MPA 100µM MPA 250µM MPA r vs. H/L=1 [%]
29 Tubulin α-4A chain TUBA4A P68366 3 1.12 ± 0.09 0.97 ± 0.03 0.96 ± 0.10 0.74 ± 0.05 -0.926 74.0
TUBA4A ENSG00000127824 ∗∗
30 UDP-glucose:glycoprotein UGT1 Q9NYU2 33 0.93 ± 0.03 0.93 ± 0.03 0.89 ± 0.07 0.74 ± 0.08 -0.978 74.4
glucosyltransferase 1 UGGT1 ENSG00000136731 ∗
31 Tubulin α-1C chain TUBA1C Q9BQE3 2 1.13 ± 0.09 0.97 ± 0.01 0.96 ± 0.10 0.75 ± 0.05 -0.909 75.3
TUBA1C ENSG00000167553 ∗∗
32 Sodium/potassium-transport- ATP1B1 P05026 6 0.92 ± 0.06 1.02 ± 0.00 0.79 ± 0.04 0.77 ± 0.05 -0.824 77.1
ing ATPase subunit β-1 ATP1B1 ENSG00000143153 ♯♯ ∗ ♯♯
33 Tubulin β chain TUBB P07437 4 1.15 ± 0.11 1.05 ± 0.10 0.98 ± 0.11 0.77 ± 0.07 -0.969 77.1
TUBB ENSG00000196230 ∗
34 GTP-binding nuclear RAN P62826 8 1.08 ± 0.09 0.93 ± 0.01 0.92 ± 0.02 0.79 ± 0.03 -0.867 78.9
protein RAN RAN ENSG00000132341 ∗ ∗∗
35 Tubulin β-4A chain TUBB4A P04350 1 1.13 ± 0.11 1.05 ± 0.07 1.01 ± 0.09 0.79 ± 0.07 -0.966 79.2
TUBB4A ENSG00000104833 ∗97
2 Results and Discussion
Table 2.7: Description of proteins with changed levels as identified by SILAC.
Cell compartments, regulation of expression, and short descriptions of physiological func-
tions are given for proteins listed in Table 2.3 - Table 2.6.
Cell Regulation Physiological
# Protein compartment of expression function
1 ACSL5 Mitochondrion
outer membrane,
ER [201]
Upregulated by
glucose/carbohydrates and
insulin [202], regulated by
fatty acids and
insulin [203]
Conversion of free long-chain fatty
acids into fatty acyl-CoA esters, lipid
biosynthesis, fatty acid degradation,
ATP + long-chain fatty acid +
CoA ↔ AMP + diphosphate +
acyl-CoA [201]
2 UGT1A1 Microsome, ER
membrane [204]
PXR-mediated regulation,
upregulated by certain
endogenous and exogenous
lipophilic compounds [205]
Glucuronidation of bilirubin IX-α and
other small lipophilic molecules [204]
3 VLCAD Mitochondrion [206] Regulated in response to
changes in energy status
of cells [207]
Catalysis of the initial step of
β-oxidation of long-chain fatty acids
with a chain length of 14 to 20
carbons [206]
4 ANXA1 Cytosol [208] Induction by
glucocorticoids [208]
Promotion of membrane fusion,
involvement in exocytosis, regulation
of phospholipase A2 activity [209],
which is essential for biosynthesis of
mediators of inflammation as
prostaglandins and leukotrienes [210]
5 AOX Peroxisome [211] Regulated by peroxisome
proliferator-activated
receptor (PPAR) α [212]
Fatty acid β-oxidation (first enzyme
of pathway, desaturation of acyl-CoAs
to 2-trans-enoyl-CoAs) [213], highest
activity against medium-chain fatty
acyl-CoAs [211]
6 FABP1 Peroxisome [214] Regulated by transcription
factor pancreatic and
duodenal
homeobox 1 [215]
Binding of long-chain fatty acids and
other hydrophobic ligands, also able
to bind bile acids [214], uptake,
transport and metabolism of fatty
acids (assumed) [214]
7 ITGB4 Membrane [216] Upregulated in gastric
cancers [217], upregulated
by certain endogenous and
exogenous
compounds [217, 218]
Receptor for laminin [216], critical
structural role in the hemidesmosome
of epithelial cells [216] (cell-matrix
adhesion [219])
Continued on next page.
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2.7 Investigation of proteome alterations in LS180 cells after MPA treatment
Description of proteins with changed levels as identified by SILAC, continued
from previous page.
Cell Regulation Physiological
# Protein compartment of expression function
8 GNG12 Cell membrane,
cytoplasmatic
side [220]
Kinin-dependent
regulation [221]
Modulator/transducer in various
transmembrane signaling
systems [220], β + γ chains required
for GTPase activity, replacement of
GDP by GTP, and for
G protein-effector interaction [220]
9 MtSSB Mitochondrion,
Mitochondrion
nucleotide [222]
Nuclear respiratory
factor 2-regulated [223]
Mitochondrial biogenesis [224], evtl.
associated with mitochondrial DNA
replication [222], subunit of a
single-stranded DNA-binding complex
involved in the maintenance of
genome stability [224]
10 ACAA2 Cytoplasm [225] Induction by certain
endogenous [226] and
exogenous substances [227]
Involvement in lipid metabolism [225]
11 DLD Mitochondrial
matrix [228]
Regulated as part of the
pyruvate dehydrogenase
complex [229]
Component of the pyruvate
dehydrogenase complex,
α-ketoglutarate dehydrogenase
complex (conversion of α-keto acids
to acyl-CoA and CO2), and the
branched-chain α-keto acid
dehydrogenase complex [228], part of
the mitochondrial glycine cleavage
system [228]
12 TFP Mitochondrion [230] NAD+- and
CoA-dependent [231]
Includes two domains: Long-chain
enoyl-CoA hydratase (EC 4.2.1.17),
Long-chain 3-hydroxyacyl-CoA
dehydrogenase (EC 1.1.1.211) [230],
lipid metabolism, fatty acid
β-oxidation [230]
13 α-ETF Mitochondrial
matrix [232]
Dependent on
developmental, nutritional
(e.g. starvation), and
hormonal factors [233]
Specific electron acceptor for several
dehydrogenases, transfer of electrons
to the main mitochondrial respiratory
chain via ETF-ubiquinone
oxidoreductase (ETF
dehydrogenase) [232]
14 NQO1 Cytoplasm [234] Upregulated by oxidative
stress, antioxidants, heavy
metals, ionizing radiation,
and hypoxia [235]
Reduction of quinones to
hydroquinones, involved in
detoxification and biosynthetic
processes [234]
Continued on next page.
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2 Results and Discussion
Description of proteins with changed levels as identified by SILAC, continued
from previous page.
Cell Regulation Physiological
# Protein compartment of expression function
15 HSPA9 Mitochondrion
(primarily), ER,
plasma membrane,
cytoplasmic
vesicles [236]
Upregulated in many
human tumors [237],
associated with p53
inactivation [238]
Role in cell proliferation, stress
response, maintenance of
mitochondria [236], chaperone (assists
in protein folding) [237]
16 ECH1 Peroxisomes
and/or
mitochondria [239]
Upregulated in gastric
carcinomas, upregulation
associated with tumor
metastasis [240]
Isomerization of
3-trans,5-cis-dienoyl-CoA to
2-trans,4-trans-dienoyl-CoA, lipid
metabolism, fatty acid
β-oxidation [241]
17 GPD2 Inner
mitochondrial
membrane [242]
Upregulated by
insulin [243], regulated by
dietary effects and certain
exogenous
substances [243], protein
kinase C might be
involved in
regulation [243],
upregulated in cancer
cells [244]
Conversion of glycerol-3-phosphate to
dihydroxyacetone phosphate,
constituent of the glycerol phosphate
shuttle, which reoxidizes NADH
formed during glycolysis [242]
18 AK3 Mitochondrion
matrix [245]
Developmentally
regulated [246]
NTP + AMP ↔ NDP + ADP [245]
19 EF-Tu Mitochondrion [247] Expression altered in
gastric cancers [248]
Promotion of GTP-dependent binding
of aminoacyl-transfer RNA to the
A-site of ribosomes during protein
biosynthesis, protein
biosynthesis [247]
20 SCS-α Mitochondrion [249] Activity allosterically
regulated by GDP
concentration [250],
regulation of expression
unclear
Catalyzes the ATP- or
GTP-dependent ligation of succinate
and CoA to form succinyl-CoA
(nature of the β subunit determines
the nucleotide specificity, i.e. GTP +
succinate + CoA ↔ GDP +
phosphate + succinyl-CoA or ATP +
succinate + CoA ↔ ADP +
phosphate + succinyl-CoA [249]
21 PIgR Cell membrane,
secreted [251]
Upregulated in response
to viral or bacterial
infection linking innate
and adaptive immunity,
abnormal expression in
cancers [252]
Receptor binds polymeric
immunoglobulin A and
immunoglobulin M at the basolateral
surface of epithelial cells, the complex
is then transported across the cell to
be secreted at the apical surface [251],
immune defence of the intestinal
mucosa [253]
Continued on next page.
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2.7 Investigation of proteome alterations in LS180 cells after MPA treatment
Description of proteins with changed levels as identified by SILAC, continued
from previous page.
Cell Regulation Physiological
# Protein compartment of expression function
22 REG-4 Secreted, cell
membrane [254]
Upregulated by mucosal
injury and in tumors [254]
Lectin display, mannose-binding, evtl.
involved in inflammatory and
metaplastic responses of the GI
epithelium [254]
23 SLC12A2 Membrane [255] Unclear Sodium and chloride transport and
reabsorption, regulation of ionic
balance and cell volume [256]
24 B-CK Cytoplasm [257] Tissue-specific, probably
linked to cell
proliferation [258]
Reversible catalysis of the transfer of
phosphate between ATP and various
phosphogens (e.g. creatine phosphate:
ATP + creatine ↔ ADP +
phosphocreatine, energy homeostasis),
central role in energy transduction in
tissues with large, fluctuating energy
demands [257, 259]
25 CDH17 Cell
membrane [260]
Upregulated in
cancers [261]
Cell adhesion/connection of cells,
evtl. involved in morphological
organization of the intestine [260],
glycoprotein [262]
26 DPYSL2 Cytoplasm [263] Possibly altered in
Alzheimer’s
disease [264, 265]
Remodeling of the cytoskeleton, cell
migration [263], promotion of
microtubule assembly [266]
27 SDF2L1 ER
lumen [267, 268]
Stess-inducible [269],
ubiquitously expressed in
various cancer cell
lines [270]
Unknown [268]
28 ACAT2 Cytoplasm [271] Upregulated by saturated
fatty acids [272] and
cholesterol [273]
Involvement in lipid metabolism [274]
29 TUBA4A Cytoplasm →
cytoskeleton,
microtubules [275]
Regulation of tubulin
expression mostly
unexplored, multiple
overlapping
mechanisms [275]
Tubulin is the major constituent of
microtubules, binds two molecules of
GTP [276]
30 UGT1 ER lumen [277] Induction by certain drugs
and chemical compounds
via PXR or aryl
hydrocarbon receptor [278]
Quality control for protein
folding/recognition of glycoproteins
with minor folding defects [277], drug
and xenobiotic metabolism [278]
Continued on next page.
101
2 Results and Discussion
Description of proteins with changed levels as identified by SILAC, continued
from previous page.
Cell Regulation Physiological
# Protein compartment of expression function
31 TUBA1C Cytoplasm →
cytoskeleton,
microtubules [276]
Regulation of tubulin
expression mostly
unexplored, multiple
overlapping
mechanisms [275]
Tubulin is the major constituent of
microtubules, binds two molecules of
GTP [276]
32 ATP1B1 Membrane [279] Upregulated by
prostaglandin E(1),
eventually mediated
through cAMP and Ca2+
pathways [280]
β subunit: regulation of number of
sodium pumps transported to the
plasma membrane, non-catalytic
component of the active enzyme
(enzyme: hydrolysis of ATP coupled
with the exchange of Na+ and K+
ions across the plasma
membrane) [279]
33 TUBB Cytoplasm →
cytoskeleton,
microtubules [281]
Regulation of tubulin
expression mostly
unexplored, multiple
overlapping
mechanisms [275]
Tubulin is the major constituent of
microtubules, binds two molecules of
GTP [281]
34 RAN Nucleus,
cytoplasm,
melanosome [282]
Overexpressed in many
cancers [283], feedback
regulation of RAN gene
expression by RAN
protein [284]
GTP-binding, translocation of RNA
and proteins through the nuclear pore
complex, control of DNA synthesis
(chromatin condensation [282]) and
cell cycle progression, could be a key
signaling molecule regulating
microtubule polymerization during
mitosis [285]
35 TUBB4A Cytoplasm →
cytoskeleton,
microtubules [286]
Regulation of tubulin
expression mostly
unexplored, multiple
overlapping
mechanisms [275]
Tubulin is the major constituent of
microtubules, binds two molecules of
GTP [281]
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2.7 Investigation of proteome alterations in LS180 cells after MPA treatment
Data analysis by DAVID, Pathway Palette, and Panther databases (protein
networks and functional analysis)
The 35 differentially expressed and significantly affected proteins identified in MPA-
treated LS180 cells were subjected to analysis through the Database for Annota-
tion, Visualization, and Integrated Discovery (DAVID), version 6.7, available online
at [287], analysis through Pathway Palette available online at [288], and Protein
Analysis Through Evolutionary Relationships (PANTHER), version 7.2, available
online at [289].
Databases as well as DAVID and PANTHER software require a gene or protein list
to be uploaded. Although gene products, i.e. proteins, were identified in this exper-
iment by SILAC and GelC-MS, gene lists were analyzed in certain cases. Data anal-
ysis therefore is non-redundant in the sense that proteins encoded by the same gene
are presented in a single record (e.g. alternative splicing isoforms, fragments, poly-
morphisms, sequence conflicts). Databases which were used to identify proteins and
analyze affected proteins, e.g. UniProtKB/Swiss-Prot and UniProtKB/TrEMBL,
are based on this concept as well [290], therefore the terms “protein” and “gene”
are used interchangeably in the following section. In all analyses, DAVID, Pathway
Palette, and Panther, UniProt accession numbers (Tab. 2.3 - Tab. 2.6) served as
identifiers for affected proteins.
For easier reference, differentially expressed proteins discussed in this section are al-
ways listed with the number under which they are listed in Table 2.3 - Table 2.6 and
described in Table 2.7, e.g. peroxisomal acyl-coenzyme A (CoA) oxidase 1 (AOX, 5).
DAVID analysis DAVID facilitates functional annotation and systematic analysis
of a given list of genes [291–293]. The gene list was analyzed using (1) DAVID’s
Functional Annotation Tool (comprehending (A) Functional Annotation Clustering,
(B) Functional Annotation Chart, and (C) Functional Anntotation Table), as well
as (2) DAVID’s Gene Functional Classification tool. Employing all DAVID tools
settings were customized (for detailed description and explanation please see Sec-
tion 3.9.2).
In addition, the 35 identified genes/proteins were subjected to a Pathway En-
richment Analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database and DAVID’s Functional Annotation Chart tool (tool 1B, settings cus-
tomized as described in Section 3.9.2). KEGG pathway maps of pathways enriched
in affected proteins in LS180 cells listed in Table 2.9 are shown in the appendix
(Fig. 4.25 - Fig. 4.31). Differentially expressed proteins are marked with red circles.
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2 Results and Discussion
Results for DAVID analyses of affected proteins in LS180 cells are described and
shown in tables and figures on the following pages. The output of all DAVID tools
is discussed together. To further validate the LS180 model, our data were com-
pared to the currently available proteomics data on MPA toxicity employing rat
models [175, 176, 294] and human cell culture models using cells of non-cancerous
origin [295, 296]. These two data sets were individually subjected to DAVID analysis
(Tool 1A and Pathway Enrichment Analysis using tool 1B). Comparison of LS180
data with these two data sets is included in the general discussion as well. To avoid
confusion it should be mentioned that proteins listed in the named publications were
assigned the wrong identifiers occasionally (rat instead of human, human instead of
rat, Sulfolobus solfataricus/Pseudomonas aeruginosa/Saccharomyces cerevisiae in-
stead of rat). Identifiers representing the correct species were reassigned prior to
DAVID analysis (proteins with their correct identifiers are listed in Table 4.1 and
Table 4.2 in the appendix).
The following data sets from different model types were compared:
• LS180 cell model versus rat model
For comparison of the LS180 cell model (human colon cancer) with a common rat
model (Wistar rats) proteins/genes from the three available publications on this
topic (kidney tissue of MMF-treated rats [175], liver and colon tissue of MMF-
treated rats [176], analysis of gene expression (complementary DNA (cDNA) mi-
croarray analysis) in liver and gut of MMF-treated rats [294]) were pooled. Gene
IDs were converted to protein IDs (Uniprot accession numbers) using DAVID’s Gene
ID Conversion tool. Protein/Gene targets were subjected to Functional Annotation
Clustering (Tool 1A) and Pathway Enrichment Analysis (Tool 1B). Results are
shown in Table 4.3.
• LS180 cell model versus human cells of non-cancerous origin
To compare results from LS180 cell with other human data, Pathway Enrichment
Analysis was performed using protein targets listed in the available publications deal-
ing with human models, i.e. the human embryonic kidney cell line HEK-293 [295],
and the T-lymphoblast cell line CCRF-CEM [296].
Two additional publications concerning MPA-induced proteome changes are avail-
able. Ghiggeri et al. analyzed protein changes in human urine after MPA and
everolimus treatment of patients [297], Petrova et al. published data from a murine
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model of renal fibrosis [298]. These two publications were not taken into account
comparing the LS180 cell model to already published data due to the everolimus-
containing regimen of patients and unsuitable type of model (mouse, cystic fibrosis),
respectively.
DAVID anlayses results in tables and figures: Results of all DAVID anal-
yses are shown in Table 2.8 - Table 2.11 and Figure 2.33 on the following pages,
results are discussed starting on page 111.
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2 Results and Discussion
Table 2.8: Functional Annotation Clustering of 35 significantly affected
genes/proteins after MPA treatment of LS180 cells by DAVID (Tool 1A).
Functional Annotation Clustering was performed using customized options as described
in Section 2.7.1. 4 annotation clusters were found (# 1-4), a representative annotation
term was assigned to characterize grouping terms as comprehensively as possible (for
specification of all terms contributing to an annotation cluster/gene functional group see
footnotes), enrichment scores are given ranking biological significance of gene groups
based on overall EASE scores (for explanation see Section 3.9.2) of all enriched annota-
tion terms, the number of genes/proteins in each cluster is given (Count) as well as the
gene/protein itself including the number under which it is listed in Table 2.3 - Table 2.6
and described in Table 2.7. 51 terms were not clustered.
Representative Enr. Proteins encoded
# annotation term score Count by analyzed genes
1 Guanyl nucleotide-binding 1 4.99 8 RAN(34), EF-Tu(19), AK3(18),
SCS-α(20), TUBA1C(31),
TUBA4A(29), TUBB4A(35),
TUBB(33)
2 Lipid catabolic process 2 3.49 4 VLCAD(3), AOX(5)
ECH1(16), TFP(12)
3 Protein polymerization 3 3.15 4 TUBA1C(31), TUBA4A(29),
TUBB4A(35), TUBB(30)
4 Mitochondrial membrane 4 2.74 6 ACSL5(1), VLCAD(3),
GDP-M(17), TFP(12),
ACAA2(10), SCS-α(20)
1 GTP-binding, guanyl ribonucleotide-binding, guanyl nucleotide-binding
2 Fatty acid β-oxidation, fatty acid catabolic process, fatty acid oxidation, lipid oxidation, lipid modification, cellular lipid catabolic
process, organic acid catabolic process, carboxylic acid catabolic process, lipid catabolic process
3 Tubulin/FtsZ, 2-layer sandwich domain; tubulin, conserved site; tubulin/FtsZ, GTPase domain, tubulin, PIRSF002306:tubulin,
protein polymerization, microtubule-based movement, pathogenic Escherichia coli infection, cellular protein complex assembly,
gap junction, microtubule, cellular macromolecular complex assembly, cellular macromolecular complex subunit organization
4 Mitochondrial inner membrane, organelle inner membrane, mitochondrial membrane, mitochondrial envelope
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Table 2.9: Pathway Enrichment Analysis of 35 significantly affected
genes/proteins after MPA treatment of LS180 cells (Tool 1B and KEGG).
The KEGG database and DAVID’s Functional Annotation Chart tool were used and cus-
tomized as described in Section 2.7.1. 7 terms were found (# 1-7). The number of
genes/proteins in each cluster is given (Count), the gene/protein itself including the
number under which it is listed in Table 2.3 - Table 2.6 and described in Table 2.7, as
well as a p-value describing the significance of enrichment of affected proteins in the
respective term. 22 genes from the list were not in the output.
Proteins encoded
# Term Count by analyzed genes p-value
1 Fatty acid metabolism 7 ACAT2(28), ACSL5(1), 7.1E-7
VLCAD(3), AOX(5),
TFP(12), ACAA2(10)
2 Valine, leucine, and 4 ACAT2(28), DLD(11), 9.5E-4
isoleucine degradation TFP(12), ACAA2(10)
3 Pathogenic Escherichia 4 TUBA1C(31), TUBA4A(29), 2.0E-3
coli infection TUBB4A(35), TUBB(33)
4 Gap junction 4 TUBA1C(31), TUBA4A(29), 7.1E-3
TUBB4A(35), TUBB(33)
5 Propanoate metabolism 3 ACAT2(28), TFP(12), 8.9E-3
SCS-α(20)
6 Fatty acid elongation 2 TFP(12), ACAA2(10) 3.6E-2
in mitochondria
7 PPAR signaling pathway 3 ACSL5(1), AOX(5), 3.8E-2
FABP1(6)
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Table 2.10: Functional Annotation Chart focusing main terms involved in the
biochemistry of 35 significantly affected genes/proteins after MPA treatment
of LS180 cells by DAVID (Tool 1B). The Functional Annotation Chart tool’s op-
tions were customized as described in Section 2.7.1. 17 terms (# 1-17) were found to
accumulate in the descriptions of analyzed genes/proteins (only terms comprising 10 or
more genes/proteins were allowed). The number of genes/proteins comprising the term
is given (Count). The percentage of proteins out of all 35 affected genes/proteins, and
p-values are listed. Due to an overlap of terms, 2 genes from the list were not in the
output.
# Term Count [%] p-value
1 Phosphoprotein 24 68.6 3.9E-4
2 Acetylation 22 62.9 1.1E-10
3 Mitochondrion 1 16 45.7 1.1E-8
4 Nucleotide-binding 1 16 45.7 4.0E-5
5 Purine nucleotide-binding 15 42.9 3.2E-5
6 Mitochondrion 1 13 37.1 9.0E-9
7 Intracellular organelle lumen 13 37.1 7.7E-4
8 Organelle lumen 13 37.1 9.5E-4
9 Membrane-enclosed lumen 13 37.1 1.1E-3
10 Mitochondrial part 12 34.3 1.1E-7
11 Intracellular non-membrane-bound organelle 12 34.3 4.5E-2
12 Non-membrane-bound organelle 12 34.3 4.5E-2
13 Transit peptide 11 31.4 6.0E-9
14 Nucleotide-binding 1 11 31.4 4.8E-4
15 Purine ribonucleotide-binding 11 31.4 6.3E-3
16 Ribonucleotide-binding 11 31.4 6.3E-3
17 Transit peptide: mitochondrion 10 28.6 8.8E-8
1 Terms are listed repeatedly since each categories/databases defined by the settings for annotation (Sec. 2.7.1) is
generally searched separately. Due to this overlap the extract of 17 terms accumulating in the descriptions of
analyzed genes/proteins retrenches to 15 terms.
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Table 2.11: Functional Annotation Classification of 35 significantly affected
genes/proteins after MPA treatment of LS180 cells by DAVID (Tool 2). Func-
tional Annotation Classification was performed using customized options as described in
Section 2.7.1. 4 annotation clusters were found (# 1-4). A representative annotation
term was assigned to characterize grouping terms as comprehensively as possible (for a
condensed specification of terms contributing to a representative annotation term please
see footnotes or Figure 2.33). Enrichment scores are given ranking biological significance
of gene groups based on overall EASE scores (for explanation, please see Section 3.9.2)
of all enriched annotation terms. The number of genes/proteins in each cluster is given
(Count) as well as the gene/protein itself including the number under which it is listed
in Table 2.3 - Table 2.6 and described in Table 2.7. 20 genes from the list were not in
the output.
Enr. Proteins encoded
# Rep. ann. term score Count by analyzed genes
1 Mitochondrial matrix 1 4.76 5 MtSSB(9), HSPA9(15),
α-ETF(13), VLCAD(3),
EF-Tu(19)
2 Lipid catabolic process 2 3.51 4 AOX(5), ECH1(16),
TFP(12), VLCAD(3)
3 Tubulin/cytoskeleton 3 2.86 4 TUBB(33), TUBA4A(29),
TUBA1C(31), TUBB4A(35)
4 Transmembrane protein 4 0.41 3 SLC12A2(23), Cadherin-17(25),
PIgR(21)
1 Phosphoprotein, disease mutation, purine nucleoside-binding, adenyl nucleotide-binding, acetylation, mitochondrial nu-
cleotide, purine nucleotide-binding, mitochondrial matrix, transit peptide: mitochondrion
2 α tubulin, β tubulin, acetylation, cytosol, tubulin, phosphoprotein, protein complex assembly, GTP-binding, gap junction,
microtubule, cytoskeleton
3 Peroxisome, biosynthesis of unsaturated fatty acids, flavoprotein, purine nucleotide-binding, adenyl nucleotide-binding, purine
nucleoside-binding, mitochondrial nucleoid, mitochondrial matrix, phosphoprotein, generation of precurser metabolites and
energy, transit peptide: mitochondrion, disease mutation, acetylation, lipid catabolic process
4 Transport, signal peptide, phosphoprotein, glycoprotein, cell membrane, transmembrane
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Fig. 2.33: 2D heat map (genes-to-terms 2D view) of genes and their major
annotated terms in correlation to gene groups/annotation clusters 1-4. Green
represents a positive correlation of gene and annotation term, black represents an un-
known relationship; a group’s related annotations are shown by unicolored areas (green
block, right side/bottom), while scattered areas (green-black block, left side/top) depict
functional differences; for further details please see [299]. Annotation terms were con-
densed and resorted for easier reference (by default annotation terms are ordered based
on their enrichment scores associated with the groups).
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Discussion of DAVID anlayses results Functional Annotation Clustering (clus-
tered or non-redundant chart report of annotation terms for all selected annotation
categories [300]) of 35 significantly affected genes/proteins after MPA treatment of
LS180 cells by DAVID yielded 4 annotation clusters (gene functional groups) listed
in Table 2.8. Involvement of binding of guanosine nucleotides was attributed to the
function of 8 proteins out of the 35 affected proteins in LS180 cells (Group #1:
“Guanyl nucleotide-binding”). Data presented in Section 2.5.2 already suggested
impairment of cell metabolism involving guanosine nucleotides, which is confirmed
here. Commonly throughout the literature described effects of MPA are attributed
to guanosine nucleotide depletion as well [148, 167, 169, 301], e.g. changes in protein
glycosylation especially studied in respect of modifications of adhesion molecules [169,
301]. An effect of MPA and AcMPAG on tubulin polymerization (even in the
presence of exogenous GTP) has been described before by Feichtiger et al. [302].
As tubulin subunits constitute 50% of the proteins listed in group #1 (“Guanyl
nucleotide-binding”) and 100% of the proteins of group #3 (“Protein polymeriza-
tion”), an effect on tubulin can be seen in LS180 cells as well. In contradiction
to our findings Feichtiger et al. reported induction of tubulin polymerization while
the cellular amount of all 4 tubulin subunits was decreased to 74.0-79.2% of control
values in LS180 cells treated with 250µM MPA (Tab. 2.6). Morath et al. on the
other hand found several cytoskeletal proteins (vinculin, actin, and tubulin) to be
downregulated in human fibroblasts suggesting that MPA induces cytoskeletal dys-
function [303].
Expression of 4 proteins was significantly altered (increased, as described in Table 2.3
and Table 2.4) and attributed to the term “Lipid catabolic process” (Group #2
in Table 2.8). Literature on MPA’s effect on lipid and fatty acid metabolism is
scarce [304]. Clinical studies show association of MMF and hyperlipidemia but
without direct evidence [304]. No significant changes occured in serum cholesterol
or triglyceride levels of rabbits on high-cholesterol diets with or without MMF [304].
Comparing our data to proteomics data gained from MMF-treated rats, 4 pro-
teins involved in fatty acid metabolism were affected in rats (#6 in Table 4.4),
but Functional Annotation Clustering of rat model data only yielded clusters of
proteins involved in carbohydrate or nucleotide processes (results for Functional
Annotation Clustering for pooled rat model data is shown in Table 4.3, appendix).
Sufficient data on MPA’s effect on glucose metabolism is lacking [304]. No effects
of MMF on glucose metabolism were observed in clinical trials and effects of MMF
on insulin secretion and insulin gene expression seem to differ inbetween species
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in vitro (MMF inhibits insulin secretion in rat islets [305] versus no effect on in-
sulin secretion or insulin gene expression in human islets [306]). Although multiple
other reasons might be involved (e.g. cancerous nature of LS180 cells, differences in
methods used, changes not reaching statistical significance due to a small N) this
pattern is traced comparing our LS180 cell data to data from rat models. As in
Table 4.3 (appendix) the term “Carbohydrate catabolic process” shows up as the
most enriched term, it is not among enriched terms in Table 2.8 listing Functional
Annotation Clusters from LS180 cell modifications. Comparison of Pathway En-
richment Analyses of 35 MPA-affected proteins in LS180 cells and 73 MPA-affected
proteins/genes in rats using the KEGG database and DAVID’s Functional Anntoa-
tion Chart tool (Tab. 2.9 versus Tab. 4.4) shows the same species-dependent pat-
tern. For LS180 cells several of the listed terms are linked to lipid metabolism (e.g.
#1: Fatty acid metabolism, #5: Propanoate metabolism, #6: Fatty acid elon-
gation in mitochondria, #7: Peroxisome proliferator-activated receptor (PPAR)
signaling pathway; KEGG pathway maps of LS180 cell model data are shown in
the appendix in Figure 4.25 - Figure 4.31). Several enriched terms linked to lipid
metabolism were yielded as well when analysing rat proteome data (#4: Propanoate
metabolism, #6: Fatty acid metabolism, #11: Butanoate metabolism). On the
other hand alterations in the expression of proteins more or less closely involved
in glucose and protein metabolism/amino acid degradation are mainly affected in
rats under MMF treatment (i.e. #1: Glycolysis/gluconeogenesis, #2: Pyruvate
metabolism, #3: Arginine and proline metabolism, #7: Tryptophan metabolism,
#8: Phenylalanine metabolism, #10: Fructose and mannose metabolism), while
only two pathways concerning amino acid degradation in LS180 cells seem signifi-
cantly affected (i.e. #2: Valine, leucine, and isoleucine degradation, #5: Propanoate
metabolism). Metabolomics data supporting this pattern are presented in Sec-
tion 2.8. Metabolomics data shows very little to no alterations in glucose metabolism
in MPA-treated LS180 cells (Sec. 2.8.1 and Sec. 2.8.2), but significant effects on lipids
and fatty acids occur (Sec. 2.8.3).
Results of DAVID analysis of modified proteins in human non-cancer cells were
not as substantial as results gained from rat models as only 22 modified proteins
found in two different cell types were included in the data set. Functional An-
notation Clustering yielded four annotation terms (Tab. 4.5, appendix), Pathway
Enrichment Analysis did not yield any significantly enriched pathways. Comparing
the LS180 cell model to human non-cancer cell culture models there were no evi-
dent overlaps in annotation term clusters. As mentioned above the expression of
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actin and other cytoskeletal proteins has been found to be decreased in MPA-treated
human fibroblasts [303]. As discussed in Section 2.3.2 MPA’s potential to induce
apoptosis is strongly cell type-dependent and no significant apoptosis was seen in
LS180 cells. As proteins listed under the term “Regulation of apoptosis” were found
in HEK-293 and CCRF-CEM cells these two cell types might be more predisposed
to impairment of mechanisms of apoptosis. No significant effects on either carbohy-
drate or lipid metabolism of MPA on cells of non-cancerous origin were revealed by
DAVID analysis of this data set.
Use of DAVID’s Functional Annotation Chart tool (linear or redundant chart re-
port of annotation terms for all selected annotation categories [300]) revealed the
15 most affected biochemical features the differentially expressed proteins are as-
sociated with in the used databases (Tab. 2.10, default settings were used). The
listed features/terms give a rough overview of protein classes, protein functions,
and protein locations that are affected in LS180 cells by MPA, but classification
of proteins/genes is strongly database-dependent as databases are searched sepa-
rately by this tool (which leads to terms being listed repeatedly in Table 2.10).
Proteins/genes listed under a specific term are not specified as this tool was just
used to gain a brief overview in terms of affected protein classes and actions. To
mention the most significantly affected protein groups (groups sorted according to
protein counts, see p-values) proteins contributing to the term “Acetylation” (#2 in
Table 2.10) were mostly proteins involved in fatty acid and lipid metabolism such
as very long-chain specific acyl-CoA dehydrogenase (VLCAD, 3) and AOX(5) and
protein polymerization (tubulins). The term “Mitochondrion” (#3 and 6 in Ta-
ble 2.10) again includes fatty acid and lipid metabolizing proteins as well as other
mitochondrial proteins (e.g. elongation factor Tu/P43 (EF-Tu, 19), mitochondrial
GTP:AMP phosphotransferase (AK3, 18), see Table 2.7 for cellular location of pro-
teins). Transport proteins also seem to be affected as the terms “Transit peptide”
(#13 in Table 2.10) and “Transit peptide: mitochondrion” (#17) are enriched as
well (i.e. EF-Tu and electron-transfer-flavoprotein (α-ETF, 13)). Effects on pro-
teins involved in transport processes can also be seen in Figure 4.23 (appendix),
which will be discussed later (Sec. 2.7.1). Overall Table 2.10 hints towards MPA-
induced effects on acetylation, mitochondrial processes and function, and transport
processes in LS180 cells. Acetylation is a post-translational modification occurring
typically on the ǫ-amino group of lysine residues and influencing protein function
crucially [307]. Lots of mitochondrial proteins are subject to this modification so
that acetylation is closely linked to mitochondrial function [308] which may be one
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of the reasons for the significant accumulation of proteins involving these functions.
DAVID’s Functional Annotation Table tool (table report for all selected annotation
categories [300]) was used to gain an overview of genes/proteins, their functions,
linkage to disease, etc. Since most important characteristica (compartment, regula-
tion, function) of each protein are listed in Table 2.7 already, the output of DAVID’s
Functional Annotation Table tool is not shown.
DAVID’s Functional Classification tool (classification of highly related genes into
functionally related groups [300], e.g. physiologic functions, cell compartment) re-
vealed four major groups of proteins identified to be affected by MPA treatment
(Tab. 2.11). The four annotation clusters are shown in Figure 2.33 as 2D heat
maps to give an overview of correlations of genes/proteins and annotation terms
contributing to clusters. Overall the same terms are listed as discussed before show-
ing effects of MPA on mitochondrial, lipid catabolic, cytoskeletal, and transport
processes/functions.
Pathway Palette analysis Pathway Palette is an internet-based application for
peptide-, protein-, and pathway-oriented analysis of MS data [309]. It is freely ac-
cessible under [288] and enables the user to easily transition from peptides/proteins
to biological pathways and networks.
Seven pathways (Pathway Enrichment Analysis) were found to contain a statistically
significant number of differentially expressed proteins (Tab. 2.9). The 13 proteins of
significantly enriched KEGG functional categories (EASE score < 0.05) were sub-
jected to Pathway Palette analysis, i.e. acetyl-CoA acetyltransferase (ACAT2, 28),
long-chain acyl-CoA synthetase 5 (ACSL5, 1), VLCAD(3), AOX(5), trifunctional
enzyme subunit α (TFP, 12), acetyl-CoA acyltransferase (ACAA2, 10), dihydro-
lipoamide dehydrogenase (DLD, 11), tubulin α-1C chain (TUBA1C, 31), tubulin
α-4A chain (TUBA4A, 29), tubulin β-4A chain (TUBB4A, 35), tubulin β chain
(TUBB, 33), succinyl-CoA ligase [ADP/GDP-forming] subunit α (SCS-α, 20), and
fatty acid-binding protein 1 (FABP1, 6) (Sec. 2.7.1).
Pathway Palette generates a protein-protein interaction network based on the Bio-
GRID Interaction Database and divides interaction types of the BioGrid ontology
into major subtypes [310], i.e. low-throughput techniques, HTP/complex detection,
HTP/pairwise (no interactions of HTP/pairwise subtype in figure), and genetic in-
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teractions, of which the first three options are selected by default.
Selected proteins/genes were analyzed twice using the BioGrid database (Fig. 2.34,
default settings used) and the Human Protein Reference Database (HPRD) which is
available as an option in Pathway Palette as well (Fig. 2.35; HPRD, i.e.
HPRD(+mouse):in-vivo and HPRD(+mouse):in-vitro). Proteins constituting groups
#1, 2, 5, 6, and 7 assigned by Pathway Enrichment Analysis through KEGG are
labeled with red stars. Proteins of groups #3 and 4, which are entirely made up
by tubulin chains, are labeled with green stars for a better overview. For further
explanation and clarification of data processing please see figure legends.
A summary and description of additional proteins that are potentially affected as
well and numbers of their interactions with differentially expressed proteins identi-
fied by SILAC is given in Table 2.12 and Table 2.13 for proteins identified using the
BioGRID and HPRD databases, respectively. Only proteins/genes with ≥3 interac-
tions are listed. Eventually affected proteins identified by Pathway Palette are linked
to functions/annotation terms that were found to accumulate in DAVID charts as
well (i.e. regulation of cell cycle, signaling processes, transcription, tight junctions,
cytoskeletal properties, and transport). As this analysis only reveals potentially
affected genes, elucidation of actual differences in levels of protein expression by
western blot was required. Tight junction protein ZO-1 (ZO-1) and 14-3-3 protein θ
(14-3-3 θ) (#6 and #9 in Table 2.12 and Table 2.13) were chosen as representative
proteins to be quantified by western blot analysis due to their simultaneous identifi-
cation by both of the databases used, ubiquitin (UBC, #1 in Table 2.12) was chosen
as well due to its number of interactions assigned by BioGRID. No differences in
expression levels were seen after western blotting of proteins as shown and discussed
later in this section.
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Fig. 2.34: Network of proteins of enriched pathways and first-order shared
neighbors constructed using Pathway Palette and the BioGRID database. First-
order shared neighbors were assigned based on interaction data in the BioGRID database
using Pathway Palette. To reduce the network’s compexity, interactions between the in-
terconnecting proteins are not shown. 18 protein pairs linked through first-order shared
neighbors, but no direct interactions between the proteins of affected pathways were
found. Star-shaped nodes represent the proteins found in significantly affected pathways
annotated by Pathway Enrichment Analysis using DAVID and KEGG with a color scheme
corresponding to their pathway as classified in Table 2.9: proteins of groups #1, 2, 5,
6, and 7, red; proteins of groups #3 and 4, green. First-order interconnection proteins
are depicted as circles, with their color indicating the number of interactions to pro-
teins of groups #1-7: >3 interactions, pink; 3 interactions, blue; 2 interactions, yellow.
The edge color indicates the source interaction database: BioGRID: Low-Troughput,
blue; BioGRID: HTP/Complex, green; no interactions resulted from searching BioGRID:
HTP/Pairwise. Proteins are indicated by their gene names. Proteins with ≥3 interac-
tions are listed in Table 2.12 with their full name, abbreviation, gene name, accession
number, and short description of their physiological function.
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Fig. 2.35: Network of proteins of enriched pathways and first-order shared
neighbors constructed using Pathway Palette and the HPRD database. First-
order shared neighbors were assigned based on interaction data in the HPRD (+mouse)
database using Pathway Palette. To reduce the network’s compexity, interactions be-
tween the interconnecting proteins are not shown. 58 protein pairs linked through
first-order shared neighbors and 3 direct interactions between the proteins of affected
pathways were found. Star-shaped nodes represent the proteins found in significantly
affected pathways annotated by Pathway Enrichment Analysis using DAVID and KEGG
with a color scheme corresponding to their pathway as classified in Table 2.9: proteins
of groups #1, 2, 5, 6, and 7, red; proteins of groups #3 and 4, green. First-order
interconnection proteins are depicted as circles, with their color indicating the num-
ber of interactions to proteins of groups #1-7: >3 interactions, pink; 3 interactions,
blue; 2 interactions, yellow. The edge color indicates the source interaction database:
HPRD (+mouse): in-vitro, blue; HPRD (+mouse): in-vivo, green; no interactions re-
sulted from searching BioGRID: HTP/Pairwise. Proteins are indicated by their gene
names. Proteins with ≥3 interactions are listed in Table 2.13 with their full name, ab-
breviation, gene name, accession number, and short description of their physiological
function.
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Table 2.12: Description of additional proteins identified by Pathway Palette analysis using the BioGRID database. Shown
are protein numbers (assigned for clarity), protein names, protein and gene (italic) abbreviations, Uniprot accession numbers, the number
of interactions identified by Pathway Palette as shown in Figure 2.34, and a short descriptions of physiological functions.
Abbr. prot. Acc. No. of Physiological
# Protein Abbr. gene number interactions function
1 Polyubiquitin-C, cleaved into Ubiquitin xxUBCxx
UBC
P0CG48 9 Multiple functions, e.g. DNA repair, cell cycle regulation, degradation and signaling
processes, activation of the transcription factor NF-κB, and activation of
kinases [311]
2 NAD+-dependent protein deacetylase
sirtuin-7
xSIRT7x
SIRT7
Q9NRC8 4 Regulation of acetylation, cell survival, apoptosis, gene transcription, autophagy,
DNA repair, stress response, genome stability [312]; positive regulation of
transcription on exit from mitosis [313]
3 Myc-proto-oncogene protein xxMYCxx
MYC
P1106 3 Regulation of gene transcription, seems to activate the transcription of
growth-related genes [314]
4 β-arrestin 1 xARRB1x
ARRB1
P49407 3 Regulation of agonist-mediated G protein-coupled receptor signaling, negative
regulation of NF-κB transcription factor activity [315]
5 β-arrestin 2 xxARRB2xx
ARRB2
P32121 3 Regulation of agonist-mediated G protein-coupled receptor signaling, negative
regulation of NF-κB transcription factor activity [316]
6 Tight junction protein ZO-1 xxZO-1xx
TJP1
Q07157 3 Tight junction assembly, specific properties of tight junctions, stabilizing junctions,
regulation of cell migration [317]
7 Small ubiquitin-related modifier 1 xSUMO-1x
SUMO1
P63165 3 Post-translational modification of proteins, which plays a crucial role in nuclear
transport, DNA replication/repair, mitosis, and signal transduction [318]
8 Small ubiquitin-related modifier 2 xSUMO-2x
SUMO2
P61956 3 Post-translational modification of proteins, which plays a crucial role in nuclear
transport, DNA replication/repair, mitosis, and signal transduction [319]
9 14-3-3 protein θ x14-3-3 θx
YWHAQ
P27348 3 Regulation of signaling pathways, negatively regulates the kinase activity of
3-phosphoinositide-dependent protein kinase-1 [320]
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Table 2.13: Description of additional proteins identified by Pathway Palette analysis using the HPRD database. Shown are
protein numbers (assigned for clarity), protein names, protein and gene (italic) abbreviations, Uniprot accession numbers, the number
of interactions identified by Pathway Palette as shown in Figure 2.35, and a short descriptions of physiological functions. *: previously
identified and listed in Table 2.12.
Abbr. prot. Acc. No. of Physiological
# Protein Abbr. gene number interactions function
10 Actin, cytoplasmatic 1 xxACTBxx
ACTB
P60709 5 Involvement in various types of cell motility [321]
11 α-actinin-4 xxACTN4xx
ACTN4
O43707 4 F-actin cross-linking protein, anchoring actin to various intracellular structures [322]
12 Keratin type II, cytoskeletal 1 xxCK-1xx
KRT1
P04264 4 May regulate the activity of kinases such as protein kinase C via binding to integrin
β-1 and the receptor of activated protein kinase C [323]
13 Keratin type II, cytoskeletal 8 xxCK-8xx
KRT8
P05787 4 Linkage of the contractile apparatus dystrophin at the costameres of striated
muscle [324]
6* Tight junction protein ZO-1 xxZO-1xx
TJP1
Q07157 3 Tight junction assembly, specific properties of tight junctions, stabilizing junctions,
regulation of cell migration [317]
9* 14-3-3 protein θ x14-3-3 θx
YWHAQ
P27348 3 Regulation of signaling pathways, negatively regulates the kinase activity of
3-phosphoinositide-dependent protein kinase-1 [320]
14 Plectin xxPCNxx
PLEC
Q15149 3 Interlinks intermediate filaments with microtubules and microfilaments and anchors
intermediate filaments to desmosomes or hemidesmosomes [325]
15 Annexin A6 xxANXA6xx
ANXA6
P08133 3 May regulate the release of Ca2+ from intracellular stores [326]
16 Spectrin α chain, non-erythrocytic 1 xSPTAN1x
SPTAN1
Q13813 3 Involvement in calcium-dependent movement of the cytoskeleton at the
membrane [327]
17 Keratin type I, cytoskeletal 10 xxCK-10xx
KRT10
P13645 3 Composition of the cytoskeleton of epithelial cells [328, 329]
18 Vimentin xxVIMxx
VIM
P08670 3 Stabilization of cytoskeleton [330]
19 Filamin-A xxFLN-Axx
FLNA
P21333 3 Linkage of actin filaments, scaffold function for a wide range of cytoplasmic
signaling proteins [331]119
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PANTHER analysis PANTHER is a database of gene products organized by
biological functions and pathways using protein family and subfamily classifica-
tion [332, 333]. It uses gene ontology (GO) terms for classification by molecular
function, biological process, and cellular component. It was used to group the
35 affected genes/proteins identified by SILAC in respect of molecular functions
and biological processes (Fig. 2.36). Additionally gene/protein hits were uploaded
with their fold change numerical value (not possible in DAVID), sorted according
to increases/decreases in affected gene/protein groups (lipid metabolism, carbohy-
drate metabolism, developmental processes, transport processes, protein class), and
changes were depicted graphically (Fig. 4.20 - Fig. 4.24, appendix).
Fig. 2.36: PANTHER charts of gene ontology (GO) terms for (A) Molecular
functions and (B) Biological processes of differentially expressed proteins in
LS180 cells after MPA treatment. GO terms are given with number of comprised
genes and percentage of gene hits versus total number of genes.
Pie charts generated using PANTHER show results closely related to results gained
through DAVID as terms such as “Structural molecule activity”, “Transport”, “Cell
cycle”, “Developmental process”, and “Generation of precursor metabolites and en-
ergy” constitute the most enriched groups besides groups of lesser specificity (e.g.
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“Catalytic activity”, “Binding”, “Metabolic process”, “Cellular process”).
PANTHER charts of differentially expressed proteins linked to lipid metabolism,
carbohydrate metabolism, developmental processes, and transport processes as well
as proteins grouped into protein classes are shown in the appendix in Figure 4.20 -
Figure 4.24, respectively. Fold changes of proteins of distinctive groups show specific
patterns in increases/decreases according to their groups and GO terms. Proteins
of lipid and carbohydrate metabolism seem to be constantly upregulated (Fig. 4.20
and Fig. 4.21), while most affected proteins linked to developmental and transport
processes in LS180 cells after MPA treatment were downregulated (Fig. 4.22 and
Fig. 4.23). Levels of tubulins are decreased, while levels of dehydrogenases and
oxidoreductase are increased (Fig. 4.24).
Confirmation of MS results by immunoblot analysis
To verify SILAC GelC-MS results western blot analysis was carried out for five rep-
resentative proteins. Due to the semiquantitative nature of densitometry analysis
proteins with relatively high changes in expression values after 250µM MPA treat-
ment compared to SILAC H/L ratio=1 (control) were chosen to be analyzed. Other
factors for the selection of proteins were their biological function in relation to MPA
GI toxicity and antibody availability. ACSL5 and annexin A1 (ANXA1, 4) were
chosen among the proteins with increased levels after MPA treatment, SLC12A2 so-
lute carrier family 12 member 2 (SLC12A2, 23), polymeric immunoglobulin receptor
(PIgR, 21) and regenerating islet-derived protein 4 (REG-4, 22) as representatives
of proteins with decreased levels.
SILAC results could only partly be confirmed by immunoblot analysis. Western
blots of the five proteins are shown in Figure 2.38, the corresponding graph in Fig-
ure 2.39. To elucidate the discrepancy between MS results and western blot results,
amino acid sequences of the chosen proteins are listed in the appendix. Immunogen
sequences against which the respective antibodies were raised and unique peptides
that served for protein identification by Mascot are marked (appendix, page 283
to 287).
Two western blots for ACSL5 were conducted with two different antibodies (an-
tibody 1: Sigma WH0051703M1, antibody 2: Abcam ab104892), of which each one
was raised against a different immunogen. Details concerning the antibodies, e.g.
immunogen sequence, are listed in the appendix (page 283).
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For the increase in ACSL5 determined by SILAC ratios, a trend was observed in ex-
pression leves determined by western blotting using antibody 1. Since western blot
analysis is less sensitive than MS analysis and standard deviations are a lot higher,
these results seem reasonable. The second western blot for ACSL5 using antibody 2
yielded a surprising result as drastic decreases in protein can be seen for 100µM
and 250µM MPA (66.4 ± 8.3% of controls and 8.7 ± 1.2% of controls). In this
experiment only unmodified peptides were identified by MS analysis, not peptides
that were covalently modified by MPA, MPA metabolites, and/or “natural” co- or
post-translational modifications such as phosphorylation and glycosylation. Only
unmodified peptides and standard variable modifications, i.e. methionine oxidation
“Oxidation (M)”, N-α-acetylation “Acetyl (Protein N-term)”, and cyclization of N-
terminal glutamine residues to pyroglutamic acid “Gln → pyro-Glu”, were allowed
for protein quantification using MaxQuant (Sec. 3.9.2). The about 2-fold increase
in ACSL5 in SILAC experiments relates to these unmodified peptides. The drastic
decrease seen in western blot using the second anti-ACSL5 antibody is most likely
due to a modification of the antibody binding site (marked in blue in the ACSL5
amino acid sequence in the appendix, page 283). One aspect arguing strongly for
this modification is the antibody binding site not being part of a unique peptide
that served for protein identification. This modification would be induced by high
MPA concentrations and can either be a covalently bound MPA molecule, an MPA
metabolite (Sec. 2.7.2) or a “natural” modification. Since MPA is known to influ-
ence glycosylation of proteins (Sec. 1.1.4) and UTP and GTP levels were found to
be affected by MPA even under 1000µM guanosine supplementation, glycosylation
of the antibody binding site through MPA treatment is likely.
Nucleotides are intermediates in the glycosylation process of proteins and lipids [42,
334]. While glucose, galactose, and other amines are transferred to proteins via
UDP intermediates, fucose and mannose are transferred via GDP (Fig. 2.37).
Although publications often only refer to MPA-induced inhibition of glycosylation
of proteins (especially in context of adhesion molecules facilitating leukocyte attach-
ment to endothelial cells) through depletion of guanosine nucleotides [42, 43, 46],
augmentation of glycosylation in LS180 cells due to UTP increases could occur as
well.
The results for ANXA1 western blots are consistent with the SILAC results. The
immunogen sequence of the used anti-ANXA1 antibody (Cell Signaling, #3299) is
unpublished. The peptide comprehends the amino acid (aa) 207 (in human, aa 206
in rabbit; tyrosine) which is marked in red in the protein sequence on page 284.
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Fig. 2.37: Requirement of UTP and GTP for glycoprotein synthesis. Changes
in UTP and/or GTP levels influence glycoprotein synthesis as sugar nucleotides and
dolichol phosphate transfer N-acetylglucosamine and mannose to e.g. asparagine residues
of proteins; Asn: asparagine, Dol: dolichol, Glc: glucose, GDP: guanosine diphosphate,
GTP: guanosine triphosphate, Man: mannose, NAc: N-acetylglucosamine, P: phosphate,
UDP: uridine diphosphate, UTP: uridine triphosphate. Adapted from [42].
As can be seen in the marked sequence two peptides in close proximity to aa 207
were identified as unique peptides. These two peptides are likely to be part of
the immunogen as well, which would argue for a widely/fully preserved (no co- or
post-translational modifications) immunogen sequence in ANXA1. This is further
supported by the about 2-fold increase of protein amount in densitometry analysis
of western blots.
The significant decreases in protein levels for SLC12A2, PIgR, and REG-4 seen in
SILAC results were not detected in western blot analyses. Multiple bands of different
molecular weights suggest post-translational modifications of SLC12A2 (Fig. 2.38)
such as glycosylation, which can account for big differences in protein size [125].
SLC12A2 is also predicted to have several N-linked glycosylation sites [335, 336].
Only a trend could be seen in decreases of protein content for bands at 170kDa and
150kDa for SLC12A2. The immunogen sequence comprises two of the 28 unique
peptides identifying SLC12A2 and is therefore relatively unlikely to be modified,
but modification of the uncovered immunogen sequence part cannot be ruled out
completely (appendix, page 285).
The immunogen sequence of the anti-PIgR antibody (Abcam, ab91269) is a peptide
from the C-terminal region of the protein (page 286). Without further informa-
tion available no conclusions can be drawn from distribution of unique peptides and
location of the immunogen sequence. Post-translational modifications on unique
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peptides could account for the decrease in PIgR determined by GelC-MS.
As recombinant human full length REG-4 protein served as antigen for the anti-
REG-4 antibody used (Abcam, ab89917) and unique peptides are distributed rel-
atively evenly over the full length of the protein, the reason for the discrepancy
between MS and immunoblot results is unclear.
Not all SILAC results were confirmed by immunoblot analysis. SILAC results seem
to be more resonable than the immunoblot results due to reasons discussed above
(especially visible in differences in western blots of ACSL5 where band intensities
were dependent on the antibody/immunogen sequence of the antibody), MPA’s
known ability to strongly influence protein glycosylation, results from DAVID and
PANTHER analyses, and results from the comparison of human cancer and rat
models. Additionally SLC12A2 (#60 in Table 4, appendix) and PIgR (#70 in Ta-
ble 4, appendix) were found to be covalently modified by MPA treatment in rats
before [294].
It should be noted that distinctive patterns in PANTHER charts (Fig. 4.20 - Fig. 4.24,
appendix). i.e. distinctive increases/decreases of all proteins attributed to a cer-
tain protein group, argue for upregulation/downregulation of specific protein groups
necessary for specific cellular functions. Either protein levels themselves might be
up- or downregulated or changes could be due to downregulated/upregulated post-
translational modifications of the respective proteins or adduct formation of the
protein/unique peptides of the protein with MPA and/or MPA metabolites (ex-
cept for the above mentioned exclusions for which only unmodified unique peptides
served for protein identification and quantification). Increases/decreases in post-
translational modifications would have to occur for proteins of a specific protein
group consistently, i.e. increase of modifications for all proteins of a certain group
or decrease of modifications for all proteins of a certain group, to explain patterns
in charts. Adduct formation of proteins with MPA and/or MPA metabolites could
only be a reason for decreases in measured protein levels (modified unique peptides
do not get picked up mass spectrometrically which results in less protein quanti-
fied). Adduct formation of proteins with MPA and/or MPA metabolites is unlikely
to cause patterns as seen in PANTHER charts since adduct formation is unlikely to
hit only proteins of a certain class.
Immunoblot analysis of additional potentially affected proteins identified by
Pathway Palette analysis
Out of the 19 proteins listed in Table 2.12 and Table 2.13 three proteins were ana-
lyzed by western blot analysis. Ubiquitin was chosen since 9 interactions with dif-
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Fig. 2.38: Western blots for confirmation of results of SILAC experiments.
Bands are shown with their respective β-actin bands (N=3). Relative intensities nor-
malized to β-actin are shown in Figure 2.39 including their statistical analysis in the figure
legend below the figure. M: molecular weight, ∗: difference between actual and predicted
band size probably due to post-translational modifications, post-translational cleavage,
splice variants, relative charge or multimerization [125], ∗∗: due to cutting/stripping of
the membrane the same β-actin band served for the normalization of multiple proteins.
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Fig. 2.39: Western blot expression levels of representative proteins identified
by SILAC and GelC-MS in LS180 cells after treatment MPA and 1000µM
guanosine for 72h. Values are given as means of % of controls of relative intensities
normalized to β-actin as determined by densitometry analysis (N=3). Western blots with
their respective β-actin bands are shown in Figure 2.38. Significance was determined
using one-way ANOVA combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗:
p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
ferentially expressed proteins were found using Pathway Palette (BioGrid database
only, Figure 2.34 and Table 2.12; number of interactions using the HPRD database<2,
Figure 2.35 and Table 2.13. ZO-1 and 14-3-3 θ were assigned 3 interactions each
by both of the databases. Physiological functions of all three proteins may play a
significant role in MPA GI toxicity as partly already demonstrated by previously
discussed data, e.g. ubiquitin (cell cycle regulation) and ZO-1 (tight junction as-
sembly, Tab. 2.12).
No statistically significant changes were found after immunoblot analysis. Consider-
ing that western blot analysis is relatively unreliable quantifying changes in levels of
proteins related to MPA toxicity as already seen and discussed above, MS analysis of
proteins hinted that Pathway Palette results could potentially yield different results
and valuable indications of the mechanisms of MPA toxicity.
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Fig. 2.40: Western blots of additional potentially affected proteins as identified
by Pathway Palette analysis. Bands are shown with their respective β-actin bands
(N=3). Relative intensities normalized to β-actin are shown in Figure 2.39 including
their statistical analysis in figure legend. M: molecular weight, ∗: difference between
actual and predicted band size probably due to post-translational modifications, post-
translational cleavage, splice variants, relative charge or multimerization [125], ∗∗: due
to cutting/stripping of the membrane the same actin band served for the normalization
of multiple proteins.
Fig. 2.41: Western blot expression levels of representative proteins identified by
Pathway Palette in LS180 cells after treatment with increasing concentrations
of MPA and 1000µM guanosine for 72h. Values are given as means of % of controls
of relative intensities normalized to β-actin (N=3). Western blots with their respective
β-actin bands are shown in Figure 2.40. No statistically significant differences were
found using one-way ANOVA combined with Scheffe’s post − hoc test.
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Overall this SILAC experiment shows that our LS180 cell culture model yields re-
sults relatively close to results of the often employed rat models with exemptions
concerning MPA-induced changes in carbohydrate metabolism. As multiple pro-
teins were identified to be affected by MPA that are known to be upregulated in
cancers (Tab. 2.7, column “Regulation of expression”) the LS180 cell model might
even make protein targets that are usually low abundance proteins more accessible.
On the other hand excessive changes in these proteins might be attributable to the
cancerous origin of LS180 cells and of lesser value in non-cancerous tissues. Other-
wise results shown in other sections of this thesis were confirmed such as impairment
of nucleotide-related processes and lipid metabolism (Sec. 2.8.3). The often inves-
tigated and discussed effects of MPA on protein glycosylation were seen to play an
important role in LS180 cells and especially proteome analysis of this cell line as
well.
2.7.2 Identification of protein targets using an
anti-MPA/AcMPAG antibody
Following experiments performed by Asif et al. [175] and Shipkova et al. [176] an
anti-MPA antibody (kind gift of Fisher Scientific) exhibiting cross-reactivity with
AcMPAG as described in the literature [108, 175, 176, 337] was used to identify
protein targets of MPA and certain MPA metabolites in LS180 cells directly.
Antibody binding to MPA and MPA metabolites
Nomenclature As labeling of functional groups in the MPA molecule is inconsis-
tent in the literature, it was decided to stick to the labeling routine which is com-
menly cited as the IUPAC name for MPA (Fig. 2.42). The hydroxy position of the
benzofuran structure which in the literature is often termed the 7-O-position (which
is technically correct when starting labeling of the benzofuran at the oxo function
as the highest functional group following IUPAC convention) is referred to as the
4-hydroxy position in the following. This way the labeling of functional groups of
metabolites, i.e. DM-MPA, DM-MPA-6G, and DM-MPA-4G stays consistent with
the published literature, except for MPAG which is often termed 7-O-glucuronide
of MPA (also termed β-D-glucuronide).
Anti-MPA/AcMPAG antibody As the antibody, usually used in Enzyme Multi-
plied Immunoassays and Cloned Enzyme Donor Immunoassays to determine trans-
plant patients’ MPA trough plasma concentrations, does not exhibit notable cross-
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reactivity with MPAG, antibody binding is thought to occur at the 4-hydroxy-
position of MPA and AcMPAG [108, 337] (Fig. 2.42). As of today only MPA and
AcMPAG binding of the used antibody is considered in the literature [108, 187, 337,
338] although other minor MPA metabolites (DM-MPA and glucuronides, AcMPA-
GS) might be captured by this antibody as well, as explained and illustrated in the
next section.
Fig. 2.42: Commonly used atom numbering scheme for MPA. The scheme is
shown to avoid confusion about nomenclature of MPA metabolites. The 4-hydroxy
position is considered the anti-MPA/AcMPAG antibody binding site. Nucleophilic groups
of proteins can bind to MPA via the carboxylic acid function (Fig. 2.43).
Protein binding by MPA and MPA metabolites
As commonly known for carboxylic drugs [339] MPA can bind to proteins through its
carboxylic acid function [340, 341] (nucleophilic dispacement mechanism, explained
below using the example of acyl glucuronides). Especially for HSA protein binding
of MPA has been extensively studied [340, 341]. HSA is the most abundant plasma
protein which commonly accounts for most of the occurring drug binding of any
given drug in plasma [342], but binding to other proteins of MPA is likely as well.
In addition acyl glucuronide conjugates of carboxylic acid drugs are known to be
highly reactive intermediates [339]. Two hypothetical mechanisms have been pos-
tulated to explain irreversible protein binding of acyl glucuronides [107]. The first
option is direct nucleophilic displacement of glucuronic acid by cysteine thiol or ty-
rosine residues of proteins [343] (Fig. 2.43), a second way is imine formation between
the aldehyde group of an open-chain glucuronic acid and a nucleophile, i.e. lysine
or the N-terminus of a protein (Schiff base mechanism) [107, 344] (Fig. 2.44).
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Fig. 2.43: Irreversible binding of carboxylic acids to proteins by a nucleophilic
displacement mechanism. The postulated reaction yields an acylated protein and D-
glucuronic acid as products. Mr: relative molecular mass. Adapted from [107], modified.
Fig. 2.44: Irreversible binding of acyl glucuronides to proteins by an imine
mechanism. The postulated reaction yields an acylated protein with D-glucuronic acid
as part of the adduct. Mr: relative molecular mass. Adapted from [107], modified.
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Although protein adducts formed by MPA and AcMPAG are probably the most
important protein modifications to focus on when elucidating the mechanisms of
MPA GI toxicity due to relatively high doses of MPA in the gut lumen (Sec. 2.1.1)
and known potential of toxicity of acyl glucuronides [66, 175, 176, 302], the possibility
of protein binding of other MPA metabolites needs to be taken into account as
well. Structural similarity of glucosides and glucuronides argue for protein adduct
formation of glucosides via nucleophilic displacement and imine mechanism as well.
Table 2.14 summarizes possible covalent protein modifications by MPA and MPA
metabolites. Modifications by DM-MPA-4G and DM-MPA-6G were not taken into
account and not incorporated in the search due to two transformation steps necessary
to yield these metabolites (Fig. 1.3), their low concentrations in transplant patients
(Sec. 1.1.5), and unclear clinical significance (Sec. 1.1.5). Furthermore DM-MPA-4G
lacks the ability to bind the used anti-MPA/AcMPAG antibody.
Table 2.14: Covalent protein modifications by MPA and MPA metabolites.
Modifications are sorted by metabolites given with their relative molecular masses (Mr)
and molecular formulas. Dependent on the mechanism of adduct formation, nucleophilic
displacement (ND) versus imine mechanism (IM), relative molecular masses and molec-
ular formulas of additions to the proteins or losses differ for the respective metabolites.
Each metabolite’s/adduct’s ability to bind the anti-MPA/AcMPAG antibody is indicated.
Molecular Mr Molecular Molecular AB
Mr formula Mecha- addi- formula Mr formula bind-
# Compound met. met. nism tion 1 addition 1 loss 2 loss 3 ing
1 MPA 320.34 C17H20O6 ND 302.32 C17H18O5 17.10, 1.01 OH, H ✓
2 AcMPAG 496.46 C23H28O12 ND 302.32 C17H18O5 193.13, 1.01 C6H9O7, H ✓
3 AcMPAG 496.46 C23H28O12 IM 478.44 C23H26O11 16.00, 2*1.01 O, 2H ✓
4 DM-MPA 4 306.31 C16H18O6 ND 288.29 C16H16O5 17.10,1.01 OH, H ✓
5 AcMPA-GS 482.48 C23H30O11 ND 302.32 C17H18O5 179.15, 1.01 C6H11O6, H ✓
6 AcMPA-GS 482.48 C23H30O11 IM 464.46 C23H28O10 16.00,2*1.01 O, 2H ✓
7 MPAG 496.46 C23H28O12 ND 478.44 C23H26O11 17.10, 1.01 OH, H ✕
8 MPAG 496.46 C23H28O12 IM 478.44 C23H26O11 16.00, 2*1.01 O, 2H ✕
9 MPA-GS 482.48 C23H30O11 ND 464.46 C23H28O10 17.10, 1.01 OH, H ✕
10 MPA-GS 482.48 C23H30O11 IM 464.46 C23H28O10 16.00, 2*1.01 O, 2H ✕
1 includes -H/-2H (-1.01/-2*1.01) released by the protein (Fig. 2.43/Fig. 2.44)
2 the first number gives the loss of the metabolite, the second number the loss of the protein
3 the first formula gives the loss of the metabolite, the second formula the loss of the protein
4 DM-MPA-4G and DM-MPA-6G were not incorporated in the search due to two transformation steps necessary to yield these metabolites
(Fig. 1.3), their low concentrations in transplant patients, and unclear clinical significance (Sec. 1.1.5). Furthermore DM-MPA-4G lacks
the ability to bind the used anti-MPA/AcMPAG antibody.
131
2 Results and Discussion
Table 2.15: Covalent protein adducts potentially identifiable by the IP ex-
periment. Four different protein adducts may be identified in this experiment due to
structural overlaps in modifications, i.e. molecular formulas and relative molecular masses
(Mr) of additions, as specified in Table 2.14. Metabolites are sorted by mechanism of
adduct formation, nucleophilic displacement (ND) versus imine mechanism (IM), relative
molecular masses and molecular formulas of additions to the proteins.
Modi- Mr Molecular
Adduct fication Mecha- addi- formula
# # Metabolite nism tion 1 addition 1
1 1/2/5 MPA/AcMPAG/AcMPA-GS ND 302.32 C17H18O5
2 3 AcMPAG IM 478.44 C23H26O11
3 4 DM-MPA ND 288.29 C16H16O5
4 6 AcMPA-GS IM 464.46 C23H28O10
1 includes -H/-2H (-1.01/-2*1.01) released by the protein (Fig. 2.43/Fig. 2.44)
Surveying western blots for identification of protein targets using an
anti-MPA/AcMPAG antibody
UGT2B7 inhibition and cell culture conditions AcMPAG toxicity being con-
sidered a major issue in MPA GI toxicity brought up the idea of inhibition of
UGT2B7 to decrease AcMPAG formation. In the literature the antifungal drug
fluconazole is described to inhibit UGT2B7 relatively selective at concentrations of
10-1000µM [345]. Inbibition of other UGT isoforms tested was only 0-15% and flu-
conazole concentrations as high as 2500µM still only provided inhibition of ≤ 14%
for the UGT isoforms that are involved in MPA GI metabolism but do not generate
AcMPAG (i.e. UGT1A7/8/9/10).
Examining in vitro-in vivo extrapolation of drug interaction effects of fluconazole
on the drug zidovudine glucuronidation kinetics showed strong dependency on the
presence or absence of exogenous bovine serum albumin (BSA) potentially caused
by drug-protein interactions of fluconazole and albumin [345]. BSA is a major
constituent of FBS which is typically added to cell culture media in amounts of
10% (Sec. 3.1). Considering the above mentioned excessive binding of MPA to HSA
(up to 90% of MPA is known to be bound to HSA) [340, 341] and that withdrawl of
FBS (Sec. 2.3.1 and Sec. 2.3.2) had no significant effect on MPA’s cytotoxic poten-
tial on LS180 cells, different conditions were tested to optimize results, e.g. sufficient
amount of free MPA in LS180 cell cultures to form sufficient amounts of metabolites
and ensure the use of effective fluconazole concentrations.
To further validate the model, to test the efficiency of the inhibitor fluconazole,
as well as to survey the anti-MPA/AcMPAG antibody’s properties, western blots
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of lysates of LS180 cells treated with MPA for 72h (1000µM guanosine, with and
without FBS) were conducted. Figure 2.45 shows western blot results for cells
treated with ascending MPA concentrations in the presence of 10% FBS. Samples
for controls and for 250µM MPA treatment in serum-free media were run as well.
In addition, effects of 0.5mM and 5mM fluconazole in the presence and absence of
10% FBS while incubating with 250µM MPA were assessed.
Fig. 2.45: Western blot of LS180 cell lysates after 72h of MPA and/or flucona-
zole treatment and incubation with an anti-MPA/AcMPAG antibody. Western
blots of experiments run serum-free are shown in Figure 2.46 and Figure 4.37.
Strong bands in the control experiment conducted with 10% FBS compared to con-
trols of experiments without FBS suggests cross-reactivity of the anti-MPA/AcMPAG
antibody with FBS components. Increased band intensities of 250µM MPA samples
generated without FBS compared to those with FBS additionally argue for cap-
ture of MPA by albumin (band at about 70kDa) and other proteins contained in
FBS. Control samples incubated without FBS show light bands at certain molec-
ular weights, suggesting cross-reactivity of the antibody with intracellular proteins
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as well.
Treatment with 0.5mM and 5mM fluconazole in presence and absence of FBS showed
decreases in band sizes for 5mM fluconazole compared to 0mM and 0.5mM flucona-
zole samples (250µM MPA) without FBS (e.g. band at about 25kDa). Reason for
this decrease could be the desired competitive inhibition of UGT2B7, therefore low-
ered intracellular AcMPAG levels resulting in less AcMPAG protein adducts as de-
tected by the anti-MPA/AcMPAG antibody. Another explanation could be however
binding of fluconazole to proteins (serum protein binding of fluconazole is known to
be 14% [346, 347]) that are also prone to MPA and/or MPA metabolite binding.
Based on the above listed findings the experiment was repeated without addition
of FBS to the culture medium. Figure 2.46 (below) and Figure 4.37 (appendix)
show the same western blot of LS180 cell lysates after 72h of MPA treatment and
incubation with the anti-MPA/AcMPAG antibody (different film exposure times).
In Figure 4.37 especially differences in bands resulting from proteins of high and low
molecular weights can be identified, whereas Figure 2.46 facilitates differences in
protein binding of MPA/MPA metabolites of proteins of medium molecular weight
range. In this experiment 2.5mM fluconazole was applied additionally to 0.5mM and
5mM, with 5mM fluconazole still yielding the most promising results for decreasing
responses to MPA treatment of LS180 cells.
The western blots showed that the most promising option for immunoprecipitation
(IP) experiments described in the next paragraph was denial of FBS in LS180 cell
culture media for experiments using the anti-MPA/AcMPAG antibody. For ex-
periments described in the following sections the use of FBS was waived as done
before already for better comparability of results and to avoid diminishing the free
MPA/MPA metabolite fraction as described above.
As the use of 5mM fluconazole for UGT2B7 inhibition seemed most reasonable, the
cytotoxic potential of fluconazole on LS180 cells was evaluated. LS180 cells were
treated with concentrations of fluconazole (0, 10, 25, 50, 100, 250, 500, 1000, 2500,
and 5000µM, no FBS, 1000µM guanosine) for 72h (redosed every 24h). Under the
chosen conditions fluconazole exhibited significant cytotoxic potential (Fig. 4.38; as
fluconazole is not described in the literature to act as an antiproliferative, cytotoxic
effects are most likely to account for decreases in LS180 cell number). No significant
change in LDH activities was found, but a trend towards an increase for higher
fluconazole concentrations reflecting increased necrosis of LS180 cells could be seen.
No proteomics experiments were conducted using fluconazole due to difficulties with
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Fig. 2.46: Western blot of LS180 cell lysates after 72h of MPA and/or flucona-
zole treatment in FBS-free media and incubation with an anti-MPA/AcMPAG
antibody. A film developed after a longer exposure time is shown in Figure 4.37 to
facilitate visualization of proteins at low and high molecular weights. A western blot of
the same experiment run with FBS is shown in Figure 2.45.
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the initial experiment (MPA treatment only) and performance of the antibody/IP as
described below. However as 63.8±5.6% of cells still survived, drug concentrations
of 5mM fluconazole should be considered as a potential UGT2B7 inhibitor in future
proteomics experiments involving LS180 cells.
IP of covalently modified proteins and analysis The same LS180 cell lysates
(1000µM guanosine, no FBS, 72h treatment, redosed every 24h) that had served
before for e.g. the assessment of cAMP/cGMP levels of LS180 cells under MPA
treatment and the Thermo Scientific Pierce Classic IP Kit were used for antigen IP.
For an IP a sample is incubated with a specific antibody (here anti-MPA/AcMPAG)
to form an immune complex which is then linked to a solid substrate (here Protein
A/G Plus Agarose, kit component). This way the complex can be isolated and con-
centrated for further analysis.
The IP was conducted according to the protocol provided by the manufacturer of the
IP kit (Sec. 3.9.2). Sample preparation by in-solution tryptic digestion and analysis
by HPLC-MS is described in Section 3.9.2. Database searches for covalent modifi-
cations of proteins by MPA and MPA metabolites were performed as described in
Section 3.9.2.
No covalent protein adducts as listed in Table 2.15 were found. As the IP was
conducted with the maximal amount of sample possible (1mg of total protein), in-
solution tryptic digestion was performed with the entire amount of sample yielded
after the IP step (150µL), protein concentrations of samples were undetectably low
(samples were assayed before the in-solution digestion step as described in Sec-
tion 3.3), and protocols were strictly followed, it is likely that the IP part of this
experiment did not yield satisfactory results. Western blots shown in Figure 2.45
and Figure 2.46/4.37 were produced using the antibody shortly after delivery by the
manufacturer and show the antibody’s potency for the detection of MPA and MPA
metabolites. The actual experiment was conducted over 12 months later after stor-
age of the antibody at 4◦C. Aliquots of the antibody that were stored at -20◦C were
lost due to a freezer failure. Remanufacturing of the antibody was not considered
due to an 8 month period for delivery of the original antibody.
Unfortunately, no covalently modified proteins were found in LS180 cells which
would have elucidated results from SILAC and other experiments. Decreases and
increases in protein levels measured by SILAC and GelC-MS which eventually are
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partly due to covalent modifications by MPA and MPA metabolites could have
been clarified by knowledge of covalent modifications of proteins by MPA and MPA
metabolites or at least been further elucidated.
It should be mentioned that the possibility of MPAG forming adducts with proteins
needs to be considered as well. Although MPAG is described as non-toxic through-
out the literature and has never been considered to form covalent protein adducts
it exhibits a carboxy function as MPA does, which is known for protein binding
(nucleophilic displacement). Additionally adduct formation via the glucuronic acid
moiety and the imine mechanism should be possible as well. Taking these options
into account, MPAG’s toxic potential in terms of covalent modifications of proteins,
eventually compromising protein function or antigen formation eventually triggering
immune reactions, is unlikely to be inferior to the potential of MPA or AcMPAG.
2.8 Metabolome analysis in LS180 cells after MPA
treatment
NMR spectroscopy is a reliable, non-invasive technique to determine changes in con-
centrations of certain small organic molecules (metabolites) in biological samples.
Additionally the use of labeled precursors and consecutive 13C isotopomer analysis
provides a quantitative approach for the assessment of metabolic pathways.
LS180 cells were incubated with 0, 0.1, 5 and 100µM MPA and 1000µM guanosine
for 72h (redosed every 24h). No FBS was used to avoid MPA/MPA metabolite-
serum component interactions (Sec. 2.7.2). For the last 5h of the 72h incubation
time cell cultures were treated with media containing 5mM [1-13C]glucose, instead of
25mM (4500mg/L) unlabeled glucose as in the routinely used medium. For these 5h
cells were redosed with DMSO for controls or MPA in respective concentrations and
1000µM guanosine (no FBS) and subsequently extracted with PCA as described in
Section 3.4.
The samples for metabolome analysis were prepared prior to proteomics experiments
(where cells were also incubated with 250µM MPA) so that 100µM MPA instead of
250µM MPA was used as the highest tested drug concentration. 100µM MPA were
chosen due to findings in earlier conducted experiments, i.e. proliferation assays with
and without guanosine supplementation (Sec. 2.4), measurements of nucleotide lev-
els with and without guanosine supplementation (Sec. 2.5), which had indicated that
137
2 Results and Discussion
100µM MPA was more than sufficient to induce significant changes in LS180 cells.
It turned out that 250µM MPA treatment would have been beneficial as metabolic
changes in LS180 cells just started to occur at concentrations around 100µM MPA.
31P NMR measurements were not conducted since HPLC-MS analyses carried out
prior to NMR studies had provided significant and expansive results already (Sec. 2.5).
Furthermore, the magnetic field intensity used (600MHz) was incapable to resolve
specific mono-, di-, and trinucleotides as it had been established already through
HPLC-MS analyses.
Extracellular metabolite and glucose concentrations from cell culture media were
not measured. Due to contamination of the solvent used for sample preparation
the necessary magnetic field homogenity for measurements could not be established
(most likely due to paramagnetic ions in the solvent used for sample preparation).
2.8.1 Quantitative 1H NMR spectroscopy of hydrophilic cell
extracts
In Figure 2.47 simulated 1H NMR spectra of MPA and its main metabolite MPAG
are shown. Spectra were simulated, instead of recorded, using the nmrdb.org NMR
simulator (http://www.nmrdb.org/simulator) which is operating based on an algo-
rithm by Castillo et al. [348]. Spectra were simulated to rule out interference of drug
signals with metabolite signals and compromise of signal integration and quantifi-
cation. No signals attributable to MPA or MPAG were found in 1H NMR spectra
of cell extracts (Fig. 2.48).
For analysis of LS180 cell extracts, metabolically interesting and highly abundant
compounds from 1H NMR spectra (Fig. 2.48) were integrated and quantified after
confirmation of signal assignment by 2D NMR (Sec. 2.8.4, Fig. 2.58, Fig. 4.34, and
Fig. 4.34). In Table 2.16 absolute values of metabolites are given in µmol/g cell wet
weight and as % of controls. 13C enrichments in lactate and alanine are given as
well.
Integration of the glucose-1α signal (5.24ppm; glucose-1β at 4.655) did not seem
reasonable due to low signal/noise (S/N) ratios. As the water signal at 4.72ppm
potentially overlaps with the glucose-1α resonance, suppression of the water signal,
as it was used recording the 1H NMR spectra of LS180 cell extracts, also affects the
signals in close proximity, such as the glucose-1α peak. Due to very small amounts
of unmetabolized intracellular glucose, no reliable integration and calculation of
glucose concentration was possible from 1H NMR spectra of LS180 cell extracts.
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Fig. 2.47: Simulated 1H NMR spectra of MPA and MPAG. ppm regions 1.0-
6.0 are shown. 1H NMR spectra were simulated using the nmrdb.org NMR simulator
(http://www.nmrdb.org/simulator) which is operating based on an algorithm by Castillo
et al. [348]
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Fig. 2.48: Representative 1H NMR spectra of LS180 cell extracts. ppm regions
1.7-4.2 are shown. Cells were incubated with 0, 0.1, 5, and 100µM MPA and 1000µM
guanosine for 72h (redosed every 24h). For the last 5h cells were incubated with 5mM
[1-13C]glucose. Compounds were identified by comparison with 1H-13C HSQC spectra
of cell extracts of same experimental conditions using published databases [349, 350].
Amino acid abbreviations are based on IUPAC nomenclature. Ac: acetate, BCAA:
branched chain amino acids, Cho: choline, Cr: creatine, Glc: glucose, Glx: glutamate
and glutamine, GSH: reduced glutathione, GSSG: oxidized glutathione, Hypo Tau: hy-
potaurine, Ins: myo-inositol, PC: phosphocholine, PCr: phoshocreatine, Suc: succinate,
Tau: taurine.
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Table 2.16: Metabolite concentrations in LS180 cells after 72h of MPA treat-
ment. Values were calculated from 1H NMR spectra of cell extracts and are given in
µmol/g cell wet weight and as % of controls (bold) with standard deviations (N=6).
Percentaged 13C enrichments (italic) and ratios PCr/Cr (italic) are given. For the last
5h of incubation time LS180 cells were incubated with 5mM [1-13C]glucose. No statis-
tically significant changes were found using one-way ANOVA combined with Scheffe’s
post − hoc test versus controls. Changes are depicted in graphs in Figure 2.49 - Fig-
ure 2.51.
control 0.1 µM MPA 5 µM MPA 100 µM MPA
[12C]Lac 6.71 ± 2.25 6.20 ± 1.27 7.05 ± 1.75 10.78 ± 0.92
100.0 ± 33.5 92.4 ± 19.0 105.1 ± 26.1 160.8 ± 13.8
[13C]Lac 0.76 ± 0.17 0.65 ± 0.04 0.76 ± 0.11 0.84 ± 0.27
100.0 ± 22.4 85.9 ± 5.1 99.6 ± 15.1 110.8 ± 35.9
Lac total 7.46 ± 2.29 6.89 ± 1.42 7.80 ± 1.74 11.61 ± 1.01
100.0 ± 30.6 92.3 ± 19.0 104.5 ± 23.3 155.5 ± 13.5
% 13C enrichment 10.79 ± 3.60 9.75 ± 2.29 10.06 ± 2.87 7.02 ± 1.64
100.0 ± 33.4 90.4 ± 21.2 93.3 ± 26.6 65.1 ± 15.2
[12C]Ala 5.60 ± 1.90 5.48 ± 1.31 6.18 ± 1.56 9.03 ± 0.44
100.0 ± 33.9 97.9 ± 23.5 110.4 ± 27.9 161.2 ± 7.8
[13C]Ala 1.08 ± 0.31 1.02 ± 0.41 1.08 ± 0.23 1.30 ± 0.48
100.0 ± 28.8 93.9 ± 37.5 99.8 ± 21.6 120.0 ± 44.4
Ala total 6.68 ± 1.84 6.50 ± 1.12 7.26 ± 1.39 10.22 ± 0.73
100.0 ± 27.6 97.2 ± 16.7 108.7 ± 20.7 152.8 ± 10.9
% 13C enrichment 17.05 ± 6.79 16.16 ± 7.45 15.55 ± 5.82 11.30 ± 4.15
100.0 ± 39.8 94.8 ± 43.7 91.2 ± 34.1 66.3 ± 24.4
Glu C4 8.98 ± 1.81 9.41 ± 1.93 9.93 ± 0.36 13.19 ± 4.97
100.0 ± 20.2 104.8 ± 21.5 110.5 ± 4.0 146.9 ± 55.3
Gln C4 6.40 ± 1.35 6.34 ± 1.46 7.37 ± 0.74 10.34 ± 3.98
100.0 ± 21.1 99.1 ± 22.8 115.2 ± 11.6 161.5 ± 62.1
GSH/GSSG Glu C4 4.32 ± 1.00 4.10 ± 1.27 4.05 ± 0.55 4.84 ± 2.20
100.0 ± 23.1 95.0 ± 29.4 93.9 ± 12.8 112.0 ± 50.8
Glx C2 1 18.23 ± 4.75 16.77 ± 4.49 17.53 ± 2.33 22.35 ± 9.08
100.0 ± 26.0 92.0 ± 24.6 96.2 ± 12.8 122.6 ± 49.8
Cr (CH2) 1.80 ± 0.38 1.64 ± 0.46 1.74 ± 0.41 1.38 ± 0.23
100.0 ± 21.2 90.9 ± 25.6 96.4 ± 22.6 76.4 ± 12.8
PCr (CH2) 2.73 ± 0.90 2.29 ± 0.54 2.10 ± 0.41 2.50 ± 0.22
100.0 ± 32.9 84.1 ± 19.9 77.1 ± 14.9 91.6 ± 7.9
PCr/Cr (CH2) 1.52 ± 0.40 1.44 ± 0.27 1.34 ± 0.07 1.49 ± 0.26
100.0 ± 26.0 94.5 ± 17.9 87.7 ± 4.5 97.8 ± 16.8
BCAA 1.20 ± 0.30 1.12 ± 0.21 1.25 ± 0.18 1.77 ± 0.68
100.0 ± 24.8 93.9 ± 17.5 103.7 ± 15.2 147.5 ± 56.3
Acetate 0.70 ± 0.24 0.68 ± 0.15 0.67 ± 0.11 0.99 ± 0.35
100.0 ± 33.8 97.9 ± 22.0 95.8 ± 15.7 141.2 ± 50.6
Succinate 0.27 ± 0.08 0.23 ± 0.11 0.27 ± 0.01 0.45 ± 0.19
100.0 ± 28.0 84.6 ± 39.3 101.1 ± 4.4 166.6 ± 72.2
Choline 1.8 ± 0.59 1.73 ± 0.37 1.70 ± 0.41 2.28 ± 1.09
100.0 ± 32.7 96.0 ± 20.5 94.1 ± 22.8 126.1 ± 60.3
Taurine 3.52 ± 0.61 3.62 ± 0.70 4.04 ± 0.85 4.39 ± 1.68
100.0 ± 17.4 102.7 ± 20.0 114.7 ± 24.0 124.6 ± 47.6
Hypotaurine 1.47 ± 0.57 1.07 ± 0.29 1.24 ± 0.13 1.67 ± 0.79
100.0 ± 38.5 72.2 ± 19.4 84.4 ± 8.8 113.4 ± 53.9
myo-Inositol 18.98 ± 4.13 18.46 ± 3.45 18.3 ± 2.88 19.69 ± 7.62
100.0 ± 21.8 97.2 ± 18.2 95.0 ± 15.2 103.7 ± 40.2
1 Glx C2 accounts for Glu C2, Gln C2, and GSH/GSSG Glu C2
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Fig. 2.49: Amounts of lactate and alanine and 13C enrichments calculated from
1H NMR spectra of LS180 cell extracts. Cells were incubated with 0, 0.1, 5, and
100µM MPA and 1000µM guanosine for 72h (redosed every 24h). For the last 5h cells
were incubated with 5mM [1-13C]glucose (N=6). No statistically significant changes
were found using one-way ANOVA combined with Scheffe’s post − hoc test. Absolute
values of changes are given in Table 2.16.
Fig. 2.50: Amounts of glutamate, glutamine, creatine, and phosphocreatine
and PCr/Cr ratio calculated from 1H NMR spectra of LS180 cell extracts.
Cells were incubated with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h
(redosed every 24h). For the last 5h cells were incubated with 5mM [1-13C]glucose
(N=6). No statistically significant changes were found using one-way ANOVA combined
with Scheffe’s post − hoc test. Absolute values of changes are given in Table 2.16.
None of the changes measured in metabolite concentrations from 1H NMR spectra
of LS180 cell extracts reached statistical significance, but clear trends towards ele-
vated lactate, alanine, glutamate, glutamine, branched chain amino acid, acetate,
and succinate concentrations as well as decreases in creatine and phosphocreatine
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Fig. 2.51: Amounts of remaining metabolites from 1H NMR spectra of LS180
cell extracts. Cells were incubated with 0, 0.1, 5, and 100µM MPA and 1000µM
guanosine for 72h (redosed every 24h). For the last 5h cells were incubated with 5mM
[1-13C]glucose. No statistically significant changes were found using one-way ANOVA
combined with Scheffe’s post − hoc test. Absolute values of changes are given in Ta-
ble 2.16.
for 100µM MPA-treated samples was observed.
Remarkable are the elevated 12C lactate and 12C alanine levels while levels of 13C lac-
tate and 13C alanine stay relatively constant. Percentaged 13C enrichments of both
metabolites therefore drops to about 65% of control values (not significant). These
findings will be discussed in the context of results from 13C NMR measurements in
the next section.
2.8.2 Quantitative 13C NMR spectroscopy of cell extracts
Incubation of cell cultures with labeled glucose results in formation of isotopomers
of TCA cycle intermediates and therefore diversly 13C-marked sets of the same
metabolite [102, 351]. 13C patterns of metabolites are dependent on a cell’s uti-
lization of the two enzymatic routes of pyruvate turnover, pyruvate dehydrogenase
(PDH, EC 1.2.4.1) and pyruvate carboxylase (PC, EC 6.4.1.1), and enables identifi-
cation of drug dependent alterations in PDH and PC fluxes additionally to metabolic
changes. 13C labeling patterns in glutamate and glutamine obtained through 13C
NMR spectroscopy allowed for the determination of potential changes in metabolic
fluxes in LS180 cells. The metabolic distribution of the 13C label of [1-13C]glucose via
glycolysis, pyruvate metabolism, and the TCA cycle resulting in labeled metabolites
of glutamate, glutamine, lactate, and alanine among others (signals were assigned
to the 13C NMR spectra of LS180 cell extracts as shown in Figure 2.52) is depicted
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in the appendix (Fig. 4.32). In Table 2.17 isotopomers of α-ketoglutarate (precursor
of glutamate and glutamine) and oxaloacetate (precursor of aspartate) derived from
[1-13C]glucose via the initial metabolites pyruvate and oxaloacetate in the 1st and
2nd TCA cycle turn are listed.
Table 2.17: Isotopomers derived in 1st and 2nd turn of the TCA cycle from
[1-13C]glucose metabolized via PDH and PC, respectively. The columns “Ini-
tial metabolite”, pyruvate (Pyr) or oxaloacetate (OAA), and “Formed isotopomers”,
α-ketoglutarate (α-KG) or oxaloacetate, list positions of 13C labels within metabo-
lites or the utilization/formation of unlabeled metabolites. Isotopomer formation from
[1-13C]glucose is graphically depicted in Figure 4.32 in the appendix.
Enzyme Turn Initial metabolite Formed isotopomers
Pyr OAA α-KG OAA
PDH 1 [3] [12C] [4] [2], [3]
2 [12C] [2] [3] [2], [3]
[12C] [3] [2] [1], [4]
[3] [2] [3,4] [1,2], [3,4]
[3] [3] [2,4] [1,3], [2,4]
PC 1 [3] [2], [3] [2], [3]
2 [12C] [1] [12C] [1], [2], [3], [4]
[12C] [2] [3]
[12C] [3] [2] [2], [3]
[12C] [4] [1] [1], [4]
[3] [1] [4] [12C]
[3] [2] [3,4] [2], [3]
[3] [3] [2,4] [1,3], [2,4]
[3] [4] [1,4] [2], [3]
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Fig. 2.52: Representative 13C NMR spectrum of an LS180 cell extract. The ppm
region 14-66 is shown. Cells were incubated with 0, 0.1, 5, and 100µMMPA and 1000µM
guanosine for 72h (redosed every 24h). For the last 5h cells were incubated with 5mM
[1-13C]glucose. Compounds were identified by comparison with 1H-13C HSQC spectra
of cell extracts of same experimental conditions using published databases [349, 350].
Amino acid abbreviations are based on IUPAC nomenclature; GSH: reduced glutathione.
Levels of relevant isotopomers quantified from 13C NMR spectra of LS180 cell ex-
tracts are given in Table 2.18, changes are depicted graphically in Figure 2.53 and
Figure 2.54. Mono and double labels of metabolites dependent on the number of
TCA cycle turns were quantified separately to determine TCA cycle ratios (please
see below and Section 3.6.3). To avoid confusion please note that values in Ta-
ble 2.16 listing concentrations of total metabolites calculated from 1H NMR spectra
are given in µmol/g cell wet weight while concentrations of metabolites labeled in
certain carbon positions calculated from 13C NMR spectra are given in nmol/g cell
wet weight in Table 2.18.
None of the changes listed in Table 2.18 for labeling patterns in glutamate or glu-
tamine reached statistical significance. Overall a strong concentration-dependent
trend towards increased concentrations of glutamate and glutamine, mono- as well
as doubly-labeled, can be seen. From the amounts of mono and double labels in
compounds conclusions can be drawn about TCA cycle progression in general and
under the respective treatment conditions. Mono labels can be seen in glutamate
and glutamine (C2 and C4, emerging via PC and PDH after the 1st turn, respec-
tively) and double labels in glutamate C4 (emerging via PC and PDH; please see
Figure 4.32 and Table 2.17) but not in integratable amounts in glutamine C4 (syn-
thesized from Glu) or glutamine C4 in GSH (synthesized from glutamate), which
confirms 5h to be an appropriate incubation time for treatment of LS180 cells with
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[1-13C]glucose to generate integratable spectra without allowing cells to metabolize
[1-13C]glucose too extensively.
Table 2.18: Isotopomer concentrations in LS180 cells after 72h of MPA treat-
ment. Values were calculated from 13C NMR spectra of cell extracts and are given in
nmol/g cell wet weight and in % of controls (bold) with standard deviations. For the
last 5 hours of the incubation time LS180 cells were incubated with 5 mM [1-13C]glucose
(N=3). No statistically significant changes were found using one-way ANOVA combined
with Scheffe’s post − hoc test. Changes are depicted in graphs in Figure 2.53 - Fig-
ure 2.54.
control 0.1 µM MPA 5 µM MPA 100 µM MPA
Glu C4 mono 574.1 ± 86.9 693.7 ± 322.9 714.3 ± 305.0 1186.4 ± 406.6
100.0 ± 15.1 120.8 ± 56.3 124.4 ± 53.1 206.7 ± 70.8
Glu C4 double 38.2 ± 0.8 58.0 ± 25.8 60.5 ± 31.1 107.9 ± 40.7
100.0 ± 2.2 152.0 ± 67.6 158.5 ± 81.4 282.6 ± 106.5
Glu C4 total 612.2 ± 87.0 751.7 ± 347.2 774.8 ± 336.1 1294.3 ± 447.2
100.0 ± 14.2 122.8 ± 56.7 126.6 ± 54.9 211.4 ± 73.0
Gln C4 total 1 133.3 ± 40.4 168.8 ± 92.9 184.4 ± 106.0 300.7 ± 104.3
100.0 ± 30.3 126.6 ± 69.7 138.3 ± 79.5 225.6 ± 78.3
Glu C2 mono 1646.0 ± 320.9 2076.6 ± 1035.2 2181.7 ± 1049.4 3431.2 ± 1098.9
100.0 ± 19.5 126.2 ± 62.9 132.5 ± 63.8 208.5 ± 66.8
Glu C2 double 158.3 ± 40.0 177.8 ± 99.9 192.9 ± 79.8 304.0 ± 122.4
100.0 ± 25.2 112.3 ± 63.1 121.8 ± 50.4 192.0 ± 77.3
Glu C2 total 1804.4 ± 360.2 2254.4 ± 1128.0 2374.6 ± 1127.5 3735.2 ± 1221.2
100.0 ± 20.0 124.9 ± 62.5 131.6 ± 62.5 207.0 ± 67.7
Gln C2 mono 153.7 ± 25.2 182.9 ± 107.4 193.8 ± 102.5 344.3 ± 132.6
100.0 ± 16.4 119.0 ± 69.8 126.1 ± 66.7 224.0 ± 86.3
Gln C2 double 262.3 ± 56.6 299.4 ± 153.2 326.2 ± 168.2 491.8 ± 167.0
100.0 ± 21.6 114.2 ± 58.4 124.4 ± 64.1 187.5 ± 63.7
Gln C2 total 416.0 ± 80.3 482.3 ± 260.0 520.0 ± 270.5 836.1 ± 299.6
100.0 ± 19.4 115.9 ± 62.5 125.0 ± 65.0 201.0 ± 72.0
Glx C3 mono 251.1 ± 64.0 344.2 ± 175.0 353.6 ± 176.3 548.5 ± 176.7
100.0 ± 25.5 137.1 ± 69.7 140.8 ± 70.2 218.4 ± 70.4
Glx C3 double 26.1 ± 8.1 30.8 ± 15.9 32.4 ± 15.4 62.3 ± 17.1
100.0 ± 31.2 117.9 ± 60.7 123.9 ± 58.8 238.6 ± 65.6
Glx C3 total 277.2 ± 71.9 375.0 ± 190.9 386.0 ± 190.7 610.8 ± 193.8
100.0 ± 25.9 135.3 ± 68.9 139.2 ± 68.8 220.4 ± 69.9
GSH Glu C4 total 1 195.3 ± 41.0 245.1 ± 118.1 251.7 ± 117.8 409.3 ± 175.8
100.0 ± 21.0 125.4 ± 60.5 128.8 ± 60.3 209.5 ± 90.0
1 due to a low S/N ratio peaks arising from double labels were not integratable, total amounts of metabolites basically relate
to mono-labeled metabolites
Utilization of oxidative versus anaplerotic glucose metabolism and TCA cycle
ratios
To quantify relative contributions of the oxidative (via PDH) versus the anaplerotic
(via PC) pathway (Fig. 4.32) the ratios of [4-C13]/[2-C13]Glx (glutamate and glu-
tamine) as described by Zwingmann et al. were used [102]. No difference in metabolic
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Fig. 2.53: Amounts of C4-labeled glutamate, glutamine, and glutamate in GSH
calculated from 13C NMR spectra of LS180 cell extracts. Cells were incubated
with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h (redosed every 24h).
For the last 5h cells were incubated with 5mM [1-13C]glucose (N=3). Absolute values
of changes are given in Table 2.18. No statistically significant changes were found using
one-way ANOVA combined with Scheffe’s post − hoc test.
Fig. 2.54: Amounts of C2-labeled glutamate, glutamine, and glutamate in GSH
calculated from 13C NMR spectra of LS180 cell extracts. Cells were incubated
with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h (redosed every 24h).
For the last 5h cells were incubated with 5mM [1-13C]glucose (N=3). Absolute values
of changes are given in Table 2.18. No statistically significant changes were found using
one-way ANOVA combined with Scheffe’s post − hoc test.
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fluxes through PC versus PDH (in oxidative to anaplerotic glucose metabolism) was
found in LS180 cells treated with increasing concentrations with MPA for 72h. In
the first two rows of Table 2.19 ratios of PDH and PC fluxes calculated as % of
controls are given.
After the first TCA cycle turn [4-13C]Glx is generated through PDH activity, the
second turn leads to a doubly-labeled [3,4-13C]Glx (and [2,4-13C]Glx) [102]. Ra-
tios of double to mono labels arising from the C4 position in Glx give the number
of turns that [2-13C]acetyl-CoA formed from [1-13C]glucose has passed through the
TCA cycle (Fig. 4.32). Ratios of double to mono labels in the C4 position of glu-
tamate were used to assess the increase in TCA cycle progression in MPA-treated
LS180 cells. The third line of Table 2.19 shows ratios calculated as % of controls.
Changes in TCA cycle progression were not statistically significant, but a trend to-
wards an increase of TCA cycle speed was obvious. This finding is coherent with the
assumed increase in mitochondrial metabolism in LS180 cells under MPA treatment
as discussed in the next paragraph.
Table 2.19: Changes in metabolic fluxes and number of TCA cycle turns in
MPA-treated LS180 cells. Values were calculated from metabolite concentrations
from 13C NMR spectra of cell extracts and are given in % of controls with standard
deviations (N=3). For the last 5h of the incubation time LS180 cells were incubated
with 5mM [1-13C]glucose. No statistically significant changes were found after one-way
ANOVA combined with Scheffe’s post − hoc test.
control 0.1 µM MPA 5 µM MPA 100 µM MPA
PDH/PC (Glu C4/C2) 100.0 ± 7.9 99.5 ± 7.0 96.7 ± 5.1 101.2 ± 3.5
PDH/PC (Gln C4/C2) 100.0 ± 14.3 110.9 ± 6.1 109.7 ± 7.7 114.0 ± 2.6
TCA cycle ratio 100.0 ± 16.1 126.6 ± 17.7 120.8 ± 16.3 134.5 ± 9.0
Overall no statistically significant changes in metabolite or isotopomer concentra-
tions were found in LS180 cells treated with MPA concentrations up to 100µM. Since
trends can be seen up to 100µM MPA, treatment with 250µM MPA as used in other
experiments would most likely have elucidated metabolomic changes in LS180 cells
further. On the other hand our other data, especially those gained from proteomics
experiments (Sec. 2.7), did not point towards significant changes in carbohydrate
metabolism in MPA-treated LS180 cells either.
It needs to be kept in mind that for this experiment LS180 cells recieved an extra
dose of MPA due to the exchange of cell culture media containing [12C]glucose for
[1-13C]glucose-containing media 5h prior to the end of the 72h incubation time.
Several observations point towards abnormalities in cell metabolism that could be
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related to the cancerous nature of LS180 cells (as seen and discussed in previous
sections) or even their colonic origin. Therefore a brief outline of the metabolism of
cancer and intestinal cells is given below.
In malignant cells metabolic deviations occur, e.g. glycolytic and oxidative path-
ways, ATP-generating mechanisms, and growth rate are affected [119]. With cancer
state progression these deviations increase, i.e. the degree of alteration correlates
with the grade and progression of malignancy (LS180 are grade II tumor cells).
While cancer cells usually are known to exhibit enhanced glycolysis rates, mito-
chondrial metabolism, and ATP generation through oxidative phosphorylation is
suppressed in comparison to normal cells (Warburg effect) [352]. For a long time
glycolytic tumor cells were thought to basically transform the majority of pyruvate
generated by glycolysis into lactate [353]. In this case only a small portion of the
residual pyruvate would be metabolized through the TCA cycle and high glycolysis
rates can cause glutamine to be the main carbon source for respiration instead of
glucose in cancer cells. On the other hand cancer cells might be able to adapt their
metabolism dependent on microenvironments and cellular needs and reversibly shift
inbetween oxidative phosphorylation, i.e. increased TCA cycle activity, and glycol-
ysis for ATP generation (Crabtree effect) [352].
Rapidly dividing cells as they constitute the linings of the intestine are known to
preferentially utilize certain amino acids, especially glutamine and arginine, besides
glucose [354]. In the intestine homeostasis of precursor utilization is regulated by
food intake and protein turnover. In addition gut barrier function in inflamma-
tion and intestinal stress responses were found to be closely related to glutamine
metabolism [354, 355].
The trend towards increased TCA cycle progression with higher doses of MPA in
LS180 cells with trends towards increases in 13C-labeled lactate and alanine but
decreased [13C]enrichments in lactate and alanine (due to increases in [12C]lactate
and [12C]alanine) might be due to the above described Crabtree effect in cancer
cells. As lactate and alanine can be built from pyruvate generated from glutamine
via the TCA cycle elevated lactate and alanine concentrations with relatively low
[13C]enrichments could be a relict of the metabolic pecularity of intestinal cells
and/or the Crabtree effect.
In addition to these metabolic abnormalities is tumoral PDH known to differ from
normal PDH. Tumoral PDH can give rise to the compound acetoin by non-oxidative
decarboxylation of pyruvate and cancer cells can utilize an alternative metabolic
pathway circumventing the TCA cycle [119]. Acetoin signals are present in 1H-13C
heteronuclear single quantum coherence (HSQC) spectra of LS180 cell extracts
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(Sec. 2.8.4). This confirms that the cancerous nature of this cell culture model
needs to be kept in mind.
2.8.3 Quantitative 1H NMR spectroscopy of lipid extracts
From 1H NMR spectra of lipid extracts of MPA-treated LS180 cells the amounts of
certain lipids, fatty acids, and carbon positions were determined. Absolute quantifi-
cation of lipids was not carried out due to different chain lengths of fatty acids and
overlap of signals (Sec. 3.6.3). Lipids were quantified as % of controls.
Representative examples of spectra for each condition are shown in Figure 2.55.
Table 2.20 summarizes amounts of compounds under the different MPA concentra-
tions used, changes are depicted graphically with statistically significant changes in
Figure 2.56 and Figure 2.57.
Table 2.20: Changes in concentrations of lipids/lipid compounds in LS180 cells
after 72h of MPA treatment. Cells were incubated with 0, 0.1, 5, and 100µM
MPA and 1000µM guanosine for 72h (redosed every 24h). For the last 5h cells were
incubated with 5mM [1-13C]glucose. Values were calculated from 1H NMR spectra of
lipid extracts and are given in % of controls with standard deviations (N=6). Significance
was determined using one-way ANOVA combined with Scheffe’s post − hoc test with ∗:
p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
control 0.1 µM MPA 5 µM MPA 100 µM MPA
Chol C18 100.0 ± 9.0 100.9 ± 14.0 105.0 ± 7.8 110.6 ± 11.4
Chol C19 100.0 ± 11.5 93.7 ± 7.5 102.5 ± 7.5 120.4 ± 8.2 ∗
Fα 100.0 ± 11.7 99.4 ± 13.1 109.0 ± 7.6 128.5 ± 4.7 ∗∗
Fβ 1 100.0 ± 12.5 100.1 ± 8.9 112.3 ± 10.7 125.1 ± 13.0 ∗
F (CH2)x+Fω-1 1 100.0 ± 9.4 99.9 ± 12.5 110.0 ± 8.9 126.2 ± 16.5 ∗
PtdCho α 100.0 ± 17.1 107.9 ± 17.8 111.4 ± 10.3 134.0 ± 20.1 ∗
PtdCho β 100.0 ± 27.9 93.6 ± 22.4 96.6 ± 8.7 127.3 ± 24.6 ∗∗
N+(CH3)3 100.0 ± 9.3 103.8 ± 14.5 108.1 ± 8.9 121.3 ± 15.7
DAG β 100.0 ± 27.9 95.4 ± 8.3 93.2 ± 16.4 104.7 ± 29.0
TAG β 100.0 ± 19.3 109.7 ± 19.5 109.6 ± 31.3 158.9 ± 19.0
F∆-1 (MUFA) 1 100.0 ± 11.8 97.6 ± 10.7 104.6 ± 8.2 118.3 ± 13.3
F∆-CH2-∆ (PUFA) 100.0 ± 9.7 101.0 ± 12.9 105.3 ± 9.1 116.7 ± 4.4
TDB (MUFA + PUFA) 1 100.0 ± 10.2 99.3 ± 11.0 107.5 ± 8.2 119.6 ± 13.3
1 values were corrected for overlap with cholesterol signals according to number of protons of respective cholesterol signals using
cholesterol C18 values as correction factors, for details please see Section 3.6.3
Significant increases were measured in fatty acids (for Fα, Fβ, Fγ, and F(CH2)x +
Fω-1 (overlap of signals)) as well as cholesterol (Chol C19), and phosphatidylcholine
(PtdCho; increases in PtdCho α and PtdCho β). Results for PtdCho were relatively
consistent (PtdCho α and PtdCho β significantly increased versus trends towards
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Fig. 2.55: 1H NMR spectra of LS180 lipid extracts. ppm regions 0.4-5.8 are shown.
Cells were incubated with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h
(redosed every 24h). For the last 5h cells were incubated with 5mM [1-13C]glucose.
Compounds were identified by comparison with 1H-13C HSQC spectra of cell extracts
of same experimental conditions using published databases [349, 350]. Amino acid
abbreviations are based on IUPAC nomenclature, Chol: cholesterol/cholesterol ester, F:
fatty acid, Fα/β: carbon atom in α/β-position to carbonyl carbon atom, F∆: carbon
atom at a double bond, Fω: terminal carbon atom, MUFA: monounsaturated fatty acids,
PE: phosphatidylethanolamine, plas: plasmalogen, PtdCho: phosphatidylcholine, PUFA:
polyunsaturated fatty acids, SPH: sphingomyeline, TDB: total number of double bonds
(MUFA and PUFA).
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Fig. 2.56: Changes in concentrations of cholesterol and certain fatty acid signals
calculated from 1H NMR spectra of LS180 lipid extracts. Cells were incubated
with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h (redosed every 24h).
For the last 5h cells were incubated with 5mM [1-13C]glucose (N=6). Chol: choles-
terol/cholesterol ester, F: fatty acid, Fα/β: carbon atom in α/β-position to carbonyl
carbon atom, F∆: carbon atom at a double bond, Fω: terminal carbon atom. Signifi-
cance was determined using one-way ANOVA combined with Scheffe’s post − hoc test
with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
1 values were corrected for overlap with cholesterol signals according to number of protons of respective cholesterol signals
using cholesterol C18 values as correction factors, for details please see Section 3.6.3
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Fig. 2.57: Changes in concentrations of phosphatidylcholine, trimethyl ammo-
nium compounds, acyl glycerols, and mono- and polyunsaturated fatty acids
calculated from 1H NMR spectra of LS180 cell extracts. Cells were incubated
with 0, 0.1, 5, and 100µM MPA and 1000µM guanosine for 72h (redosed every 24h).
For the last 5h cells were incubated with 5mM [1-13C]glucose (N=6). DAG: diacyl
glycerols, MUFA: monounsaturated fatty acids, N+(CH3)3: trimethyl ammonium com-
pounds/choline headgroup, PtdCho: phosphatidylcholine, PUFA: polyunsaturated fatty
acids, TAG: triacyl glycerols, TBD: total number of double bonds. Significance was
determined using one-way ANOVA combined with Scheffe’s post − hoc test with ∗:
p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
1 values were corrected for overlap with cholesterol signals according to number of protons of respective cholesterol signals
using cholesterol C18 values as correction factors, for details please see Section 3.6.3
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increases in levels of the choline headgroup) as results for cholesterol (Chol C19
significantly increased versus trends towards increases in Chol C18) were as well.
Increases in concentrations of fatty acids on the other hand were confirmed by sig-
nificant increases for all quantified positions within a fatty acid. Compositions of
fatty acids (number of double bonds) do not seem to change since the increase in
F(CH2)x + Fω-1 is likely to be due to enhanced Fω-1 synthesis.
After metabolism of glucose to acetyl-CoA, entry of acetyl-CoA into the TCA cycle,
further metabolism, and export of citrate into the cytosol, citrate is converted into
fatty acids via resynthesis of acetyl-CoA. Mono- (MUFA) and polyunsaturated fatty
acids (PUFA) with double bonds in certain positions are synthesized by selective
dehydration at the cytosolic membrane of the ER [356]. Via glycerin aldehyde-3-
phosphate derived from glycolysis glycerol emerges as the backbone for diacyl glyc-
erols, triacyl glycerols, and phospholipids. Phospholipids are a main constituent of
biomembranes and are often esters of divers amino alcohols. PtdCho is the most
prominent membrane phospholipid. PtdCho is an important constituent of the GI
tract (e.g. intestinal cell membranes) and crucial for maintenance of GI barrier
function [357]. Intracellular PtdCho is secreted by epithelial cells and passaged
across tight junctions into the apical mucus layer [358]. PtdCho contributes in large
parts to the colonic mucus layer establishing a hydrophobic surface [357]. In the
plasma membrane of enterocytes it modulates the mucosal signaling state as cellu-
lar membrane and lipid composition are regulatory parameters of signaling pathways
of inflammation [357]. Interestingly, decreased levels of luminal PtdCho in colonic
mucus have been linked repeatedly to ulcerative colitis, an IBD similar to Crohn’s
disease [357, 359] (not found in Crohn’s disease patients [359, 360]). The finding of
upregulated intracellular PtdCho in MPA-treated LS180 cells is contradictory to the
above described mechanisms of impaired barrier function, but suggests disturbances
of lipid levels strongly linked to mucosal defense. The upregulation of certain mem-
brane components/lipids could also be a secondary effect of MPA toxicity in LS180
cells. Compromised proliferation patterns (Sec. 2.4.1) could trigger upregulation of
main compounds constituting membranes and mucus barriers as important lines of
epithelial defense. Another interesting aspect is that PtdCho is synthesized from
choline via the Kennedy-pathway involving cytidine nucleotides [361]. Phospho-
choline and CTP form CDP-choline and PPi, consecutively CDP-choline and diacyl
glycerol (or alkyl-acylglycerol) are converted to PtdCho (with CMP as byprod-
uct). Elevated levels of cytidine nucleotides observed in previous experiments under
the here used experimental conditions (72h incubation time, 1000µM guanosine;
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Sec. 2.5.2, Tab. 2.2) might contribute to or precondition for PtdCho biosynthesis.
Cholesterol is a fundamental part of cellular function and cell membranes [362].
Involvement in the cell signaling of growth factors and modulation of immune re-
sponses (after conversions into hormones, e.g. androgens) makes it especially inter-
esting in terms of MPA GI toxicity. With increases in PtdCho and cholesterol levels
homeostasis of two major membrane constituents is affected in LS180 cells treated
with MPA. The importance of membrane integrity in epithelial defense of the GI
tract is explained in terms of Crohn’s disease in the introduction (Sec. 1.2.3) and
further discussed in Section 2.59 in context of the development of a coculture model
of LS180 cells and murine macrophages.
Results from NMR experiments confirmed results from proteomics studies as in
both analyses certain lipid compounds/proteins and pathways involved in lipid
metabolism were significantly affected. Most proteins listed in Section 2.7 and
which were assigned functions in lipid metabolism, i.e. “Fatty acid metabolism”
and “Fatty acid elongation in mitochondria” in Table 2.9 and “Lipid catabolic pro-
cesses” in Table 2.8 and Table 2.11 were significantly upregulated in LS180 cells
under MPA treatment (with the exemption of ACAT2, which was downregulated),
which is consistent with increases but no decreases in certain lipophilic compounds.
The term “Mitochondrial membrane” in Table 2.8 lists almost exclusively proteins
that were found to be increased in their levels (with the exemption of SCS-α, which
was downregulated). This coincidence might hint at already above discussed imbal-
ances in membrane composition.
2.8.4 1H-13C HSQC NMR spectroscopy of hydrophilic and
lipophilic cell extracts
Several 1H-13C HSQC NMR spectra were recorded to assign signals from 1D NMR
experiments and metabolic changes as a result of MPA treatment. As an example
the 1H-13C HSQC spectrum of ppm regions 0.0-3.0 (t1) and 10-40 (t2) of an LS180
control cell extract (hydrophilic extract) is shown in Figure 2.58. ppm regions 2.9-
5.0 (t1) and 33-80 (t2) and 4.0-6.5 (t1) and 80-110 (t2) of the same sample are shown
in Figure 4.33 and Figure 4.34 in the appendix.
Significant overlaps of signals could be observed (e.g. for the lactate C3 signal) as
well as metabolites linked to the previously discussed metabolic abnormalities of
cancer cells (acetoin). Quantification of metabolites as well as the choices of peaks
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for quantification are described based on the recorded 1H-13C HSQC spectra in Sec-
tion 3.6.3.
As for hydrophilic cell extracts several 1H-13C HSQC spectra of lipophilic cell ex-
tracts were recorded to revise integrated signals and metabolic changes as a result
of MPA treatment. Representative spectra of a lipophilic extract are shown in Fig-
ure 4.35 and Figure 4.36 in the appendix and their use for quantification is discussed
in Section 3.6.3.
Fig. 2.58: 1H-13C HSQC spectrum of ppm regions 0.0-3.0 (t1) and 10-40 (t2) of
LS180 cell extracts. Compounds were identified using published databases [349, 350]
and were compared to 1H and 13C NMR spectra of cell extracts of same experimen-
tal conditions (controls). Amino acid abbreviations are based on IUPAC nomenclature;
Ac: Acetate, GSH: reduced glutathione, GSSG: oxidized glutathione, Suc: succinate.
ppm regions 2.9-5.0 (t1)/33-80 (t2) and 4.0-6.5 (t1)/80-110 (t2) of the same 1H-
13C HSQC spectrum are shown in Figure 4.33 and Figure 4.34 (appendix).
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2.9 In vitro gut inflammation model
To integrate the potential implications of inflammation and immunologic factors
into the previously conducted research using LS180 cells an in vitro gut inflam-
mation model was developed. On the basis of a previously described model, a
coculture systems of the intestinal cell line Caco-2 and the murine macrophage cell
line RAW 264.7 [363], a modified coculture system using LS180 instead of Caco-2
cells was designed. Coculture systems based on RAW 264.7 cells are often used in
the literature to study induction of inflammation in conjunction with various cell
types [363–365].
Considering that side effects of MPA show patterns similar to IBD (Sec. 1.2.3) and
that in already existing coculture models of inflammation, factors such as integrity
of the epithelial barrier, secretion of cytokines by macrophages, and changes in the
epithelium are taken into account, it was decided to examine these factors more
thoroughly using the coculture system of LS180 and RAW 264.7 cells. While vali-
dating the in-vitro coculture system of LS180 and RAW 264.7 cells, limitations of
the model were noted. This included that LS180 cells did not form a confluent mono-
layer (Sec. 2.9.1). In addition, MPA and AcMPAG failed to induce cytokine release
from RAW 264.7 cells as it was seen with LPS as a positive control (Sec. 2.9.2).
In the planned in-vitro coculture system LS180 cells were supposed to be seeded
at the apical side of transwell inserts and RAW 264.7 cells at the basolateral side
(Fig. 2.59). Stimulation of RAW 264.7 cells with LPS as positive control (0.1µg/mL
and 5µg/mL), MPA (5µM and 100µM), and AcMPAG (5µM) for a duration of
4h was supposed to lead to cytokine release by RAW 264.7 cells. Cytokines were
supposed to increase mRNA expression of certain proteins in LS180 cells. Monitor-
ing of the following parameters was chosen to measure the potential to induce an
inflammatory response to the test compounds because of their established use in
existing models of inflammation and their role in the pathogenesis of inflammation
and Crohn’s disease:
• LPS as inflammatory stimulus
LPS is a cell wall component of gram-negative bacteria [366] and stimulates cells
through TLR4 to release cytokines critical for the activation of immune responses [367].
LPS is often used as an inflammatory stimulus in vitro to induce e.g. the release of
proinflammatory cytokines from macrophages [363, 366].
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• Release of cytokines from RAW 264.7 cells
Dysregulation of TNF-α secreted by macrophages induces destruction of the epithe-
lium [84] and is linked to IBD pathogenesis (Sec. 1.2.3, Fig. 1.8) [368]. Additionally
TNF-α and IL-1β have the potential to activate signaling pathways linked to the
regulation of adhesion molecule expression for the recruitment of leukocytes [369].
Other proinflammatory cytokines such as IL-6 and INF-γ secreted by macrophages
are often monitored in models of inflammation [370] and play a distinctive role in
IBD development and progression [371].
• Cell monolayer integration of LS180 cells
Transepithelial electrical resistance (TEER) measurements are commonly used to
determine damage of cell monolayers in cell culture systems and the possibility of
uncontrolled paracellular diffusion of substances [363]. TEER values are dependent
on the integrity of tight junctions inbetween epithelial cells. As findings from previ-
ous studies, such as differential expression of structural proteins (Sec. 2.7.1, effects
on gap junctions, decreases in cadherin-17 after MPA treatment) and imbalances in
proliferation, strongly point towards impairment of barrier function of the epithe-
lium (Sec. 2.4.1) TEER measurements seemed to be useful in the assessment of this
aspect of MPA GI toxicity.
• mRNA expression of marker proteins in LS180 cells
After epithelial injury IL-8 is secreted by epithelial cells to recruit neutrophils from
the blood stream into inflammed tissues (Sec. 1.2.3, Fig. 1.8) [84, 372]. As IL-8
release is a keyfactor in the epithelial immune response and manifests in the devel-
opment and progression of Crohn’s disease as depicted in Figure 1.8, IL-8 mRNA
expression in LS180 cells was chosen as a marker for the effect of proinflammatory
cytokines released by RAW 264.7 cells. As a second marker serotonin transporter
(SERT, also 5-hydroxytryptamine transporter) was chosen. SERT excretes sero-
tonin (5-hydroxytryptamine), which is essential for many functions involved in the
health of the GI tract [373, 374]. Inflammation, infection, and certain symptoms
of IBD are known to be related to altered serotonergic signaling. These symptoms
are evoked by imbalances in gut motor activity and altered secretion [374] causing
diarrhea [375]. Cell growth e.g. of epithelial microvilli can be affected as well [376].
SERT mRNA expression therefore seemed to be a comprehensive measure of GI
conditions including multiple aspects potentially causing MPA adverse events in the
GI tract.
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Fig. 2.59: In vitro gut inflammation model. AcMPAG: mycophenolic acid acyl
glucuronide, IL: interleukin, INF-γ: interferon-γ, LPS: lipopolysaccharide, mRNA: mes-
senger ribonucleic acid, SERT: serotonin transporter, TEER: transepithelial electrical
resistance, TNF-α: tumor necrosis factor-α.
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2.9.1 Evaluation of cell monolayer integration
As discussed initially LS180 cells are a suitable model for e.g. induction studies,
but not preferable when studying drug transport due to poor monolayer integration
(Sec. 2.2) [113, 377]. TEER measurements of LS180 cells seeded onto culture inserts
(Millipore Hanging Cell Culture Inserts, PIHT30R48, 0.4µM) was evaluated before
coculturing of LS180 and RAW 264.7 cells and drug treatment.
Usually integration of cell monolayers to confluency is accompanied by a rapid rise
in TEER values [377]. For Caco-2 cells which are described to have physiologically
valuable properties in terms of tight junctions, transport properties and integra-
tion [113, 377] TEER values often exceed 1000Ωcm2 [377, 378].
TEER values for LS180 cells were close to 1Ωcm2 (0.97Ωcm2 - 1.06Ωcm2). Cul-
tures were maintained over several days until cells started to grow from patches
into clumps. At this time there were still remarkable spaces inbetween islets and no
rise in TEER measureable. Despite seeding of cells at different densities to allow
for establishment of a monolayer from different starting points, no satisfying results
were gained.
Cell growth, function, migration, and attachment is dependent on the nature of the
surface on which cells are plated [379]. In vitro these characteristics can be improved
by coating surfaces with components of the extracellular matrix, e.g. proteins such as
collagen, fibronectin, or laminin. It was tried to facilitate cell adhesion and growth
of LS180 cells into a monolayer by coating cell culture inserts with two different
matrix proteins, i.e. rat tail collagen and human fibronectin (Sec. 3.10.1), but no
improvement of monolayer formation was seen when TEER values were measured.
These findings, which are also widely reported in the literature (TEER values close
to 0Ωcm2 for LS180 cells on uncoated inserts, no literature available for LS180 cells
grown on coated inserts) [113, 377], suggested again that LS180 cells are not suit-
able for in vitro studies requiring a confluent monolayer. Measurements of TEER
therefore had to be waived in our coculture experiments.
2.9.2 Cytokine release from RAW 264.7 cells
Western blot analysis of cell culture media of RAW 264.7 cells treated with LPS,
MPA, and AcMPAG showed only significant changes in levels of secreted proteins
for the positive control LPS (Fig. 2.60 and Fig. 2.61). While the response to LPS in
a concentration as low as 0.1µg/mL was relatively excessive for TNF-α, INF-γ, and
IL-1β and while IL-6 was secreted in measurable amounts as a response to 5µg/mL
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LPS, no response occured to MPA or AcMPAG as inflammatory stimuli. The induc-
tion of cytokine release through LPS shows the validity of this part of the cell culture
model, but suggests that neither MPA nor AcMPAG possess inflammatory potential
in the here applied concentrations. It needs to be taken into account that the innate
immune response which was mimicked by macrophages activated by LPS reacts to
structural motives expressed in proteins of bacteria, viruses, and fungi which are
commonly called pathogen-associated molecular patterns (PAMPs) [367]. PAMPs
from LPS are known to stimulate TLR4 and other particular TLRs expressed by
cells of the innate immune system [367]. Since this respective pathway is needed/was
chosen as a comparison when conducting experiments with macrophages and LPS
as a positive control a strong response to LPS can be expected. Although no sta-
tistically significant differences occured for MPA and AcMPAG versus controls, a
trend was found towards an increase in cytokine levels in boxplot diagrams of TNF-α
(band at 48kDa) and INF-γ measured in cell culture media of RAW 264.7 cells after
treatment with MPA and AcMPAG for 4h despite missing PAMPs in the tested
compounds (Fig. 2.62).
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Fig. 2.60: Western blots of inflammatory markers of cell culture media of
RAW 264.7 cells after treatment with LPS, MPA, and AcMAG for 4h. Bands
are shown with their respective β-actin bands (N=3). Relative intensities as determined
by densitometry analysis normalized based on β-actin are shown in Figure 2.61 including
their statistical analysis in figure legend. M: molecular weight, ∗: based on the informa-
tion provided in the vendor’s product sheet, the vendor is unsure about the identity of
the extra bands; difference between actual and predicted band size probably due to post-
translational modifications, post-translational cleavage, splice variants, relative charge
or multimerization [125], ∗∗: due to cutting/stripping of the membrane the same actin
band served for the normalization of multiple proteins, ∗ ∗ ∗: 23-25kDa O-glycosylated,
28-30kDa both O- and N-glycosylated.
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Fig. 2.61: Levels of inflammatory markers of cell culture media of RAW 264.7
cells after treatment with LPS, MPA, and AcMAG for 4h. Values are given
as means of % of controls with standard deviations of relative intensities normalized
based on β-actin (N=3). Western blots with their respective β-actin bands are shown in
Figure 2.60. Significance was determined by one-way ANOVA combined with Scheffe’s
post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
Fig. 2.62: Boxplot diagrams of levels of TNF-α (band at 48kDa) and INF-γ
measured in cell culture media of RAW 264.7 cells after treatment with LPS,
MPA, and AcMPAG for 4h. Values are depicted as relative intensities with stan-
dard deviations (densitometry units normalized based on β-actin (N=3). Western blots
with their respective β-actin bands are shown in Figure 2.60 and a bar graph including
statistically significant changes is shown in Figure 2.61.
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2.9.3 mRNA levels of IL-8 and SERT in LS180 cells
Aim of these experiments was the analysis of the inflammatory potential of MPA
and AcMPAG in contrast to a positive control of known inflammatory potential
and changes to the epithelium (LS180 cells) induced by a immune response to MPA
and AcMPAG. As no significant release into the culture medium for either of the
measured cytokines by MPA or AcMPAG could be observed, no further experiments
in this direction were conducted.
2.9.4 Evaluation of the LS180-RAW 264.7 coculture model
As discussed above this coculture models seems potent to measure responses of the
second cell type (LS180 or Caco-2 cells) to compounds of inflammatory potential.
If only changes in mRNA levels or other intracellular changes of the second cell
type are supposed to be evaluated, LS180 cells might be a useful choice. Lack of
monolayer integrity in untreated LS180 cells is a limitation. The use of Caco-2 cells
should be considered when persuing experiments requireing a cell monolayer over
LS180 cells.
In this experiment the inflammatory potential of MPA and AcMPAG in comparison
to LPS was tested. Modification of the coculture system, i.e. cocultivation of LS180
and RAW 264.7 cells in the same culture dish instead of hanging inserts for LS180
cells, would be an interesting approach to assess potential inflammatory responses
to the modifications of proteins caused by MPA and MPA metabolites. Althought
most, but not all, proteins that were affected in their expression levels as identified
by SILAC and GelC-MS (Sec. 2.7.1) or that were covalently modified as described
in the literature (Sec. 2.7.2) are intracellular proteins, an effect on RAW 264.7 cells
can not fully be ruled out. The same modifications as found in the proteome of
LS180 cells might as well occur in RAW 264.7 cells, so that a coculture or even a
monoculture of RAW 264.7 cells could be used to measure inflammatory markers
and inflammatory potential of intracellular protein modifications caused by MPA
and MPA metabolites.
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2.10 Summary discussion, conclusions, and
perspectives
With the validation of the LS180 cell culture model in respect of its applicability
in studies concerning MPA’s GI toxicity a stable, predictable, and easy-to-handle
cell culture model became available. Due to the stable expression of common drug-
metabolizing enzymes over several passages, its fast proliferation rate, and its re-
silience (cell viability is not compromised by the withdrawl of FBS over several days),
this cell culture model has the potential to be a valuable tool in the clarification
of pharmakon-induced mechanisms of toxicity in general and MPA-induced GI side
effects in particular.
In the scope of this thesis the model was systematically validated and improved in
terms of physiological aspects, that are often ignored in studies dealing with MPA
side effects (reversal of certain MPA-induced effects by supplementation with exoge-
nous guanosine). Possible toxicity of the MMF ester moiety morpholinoethanol or
drug-drug interactions of this moiety with MPA are usually not taken into account
either. Our initial experiments compared morpholinoethanol and morpholinoethanol
in combination with MPA to MPA alone, MMF, and controls. As no effects of mor-
pholinoethanol or drug-drug interactions in LS180 cells were seen in these initial
experiments the toxicity of this compound was not further researched.
As no cytotoxic effects of MPA on LS180 cells were found LS180 cells provided a
solid basis for consecutive in-depth studies. This is especially beneficial for experi-
ments requiring higher amounts of sample material such as NMR-based studies.
MPA’s antiproliferative properties are often claimed to be reversible by supplemen-
tation with guanine/guanosine. This work systematically looked at LS180 cell pro-
liferation profiles over different periods of time while cells were supplemented with
different guanosine concentrations. We found imbalances and significantly decreased
cell proliferation after 3 days and especially after 5 days, a time span that generally
does not get monitored although renewal of the GI epithelium takes up to 5 days.
Intracellular guanosine nucleotide depletion was not reversible and only marginally
improved by guanosine supplementation, although it is often claimed to be reversible,
especially for the GI epithelium due to nucleotide supply through food. These results
show that MPA’s antiproliferative properties have most likely been underestimated.
Direct impairment of the intestinal epithelium by MPA and an immune reaction to
the luminal content could probably be the most obvious trigger of Crown’s disease-
like patterns prominent in MPA therapy.
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The HPLC-MS assay for MPA, MMF, and metabolites that was developed and con-
secutive identification of pH-dependency of matrix effects compromising metabolite
stabilities, that have not been described before, provide a basis and important clues
in terms of sample extraction and preparation in case of matrices containing pro-
teins such as albumin. This observation could become relevant especially in terms
of clinical samples and clinical trials analyzing blood and urine from transplant pa-
tients, make further analysis of these effect indispensible and might finally provide
a reliable method for determination of metabolite concentrations in matrices that
are especially clinically relevant.
Very valuable information was gained from proteomics experiments based on SILAC
and GelC-MS. The observation that especially proteins involved in lipid metabolism
and structural proteins are affected in LS180 cells is consistent with other human
data. A comprehensive portfolio of online analysis tool was used for analysis of
our data and data published within the last years by other work groups and re-
vealed important inconsistencies comparing data from our human cancer cell line
with data gained by the use of rat models. The use of these or similar analysis
tools and the use of databases is inevitable dealing with results from proteomic
research due to the often times immense data load and complexity of data. The
present data was pooled and subjected to a comprehensive analysis to compare dif-
ferent types of models that are used throughout the literature to clarify mechanisms
of MPA toxicity, an approach that has not been conducted before, but was useful
in terms of e.g. validation of models and comparision and pooling of data in general.
Metabolome analysis revealed a changed lipid metabolism, but a widely unaffected
carbohydrate metabolism. Especially membrane- and therefore barrier-constituting
lipids were significantly upregulated again hinting towards defects of the epithelial
barrier. These results are compatible with results from HPLC-MS and SILAC exper-
iments. This shows that the combination of molecular biology methods, HPLC-MS,
metabolomics and proteomics approaches which are frequently used in our labora-
tory are able to generate a unique framework of mechanisms of action/toxicity, to
gain comprehensive insights into complex biochemical problems, and even to vali-
date models and evaluate previously collected data.
It needs to be kept in mind that LS180 cells are cancer cells, which can be re-
flected in results. On the other hand our model based on human cancer cells might
in certain respects provide more reliable results than results are gained by the use
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of e.g. rat model as it is consistently seen in the outcome of our proteomics studies.
For the elucidation of direct inflammatory processes linked to MPA another unique
cell culture model was created. As LS180 cells performed strongly in our previ-
ous studies and as they provided certain benefits over Caco-2 cells, a commonly-
used model based on Caco-2 and RAW 264.7 cells was modified. Neither MPA
nor AcMPAG did show direct inflammatory responses, whereas LPS triggered an
extensive response. Slight modifications to our LS180-based model such as direct
cocultivation of both cell lines in one cell culture dish could be used for further stud-
ies which would include assessment of the inflammatory potential of MPA-/MPA
metabolite-induced changes to LS180 cells such as covalently modified proteins.
Relying on the results gained from experiments using the LS180 cell culture model
MPA’s GI toxicity could result, as stated in the introduction, from impairment of
epithelial proliferation, consecutive loss of the GI barrier, and penetration of the
mucosa by luminal bacteria and proteins.
In Figure 2.63 the proposed molecular mechanisms of MPA’s toxicity are summa-
rized in context of the used methods.
167
2 Results and Discussion
Fig. 2.63: Proposed molecular mechanisms of MPA’s GI toxicity elucidated us-
ing the LS180 cell culture model and various methods. The listed MPA-dependent
effects were determined using the LS180 cell culture model except for “Covalent mod-
ification of proteins by MPA and MPA metabolites”. This experiment did not yield
analyzable results, but covalent modifications of proteins have been described in the
literature before. The LS180-RAW 264.7 cell coculture model as it was used by us did
not show immune reactions to MPA or MPA metabolites. A modified coculture model
as discussed in later sections could provide information about immune reactions to modi-
fied proteins and/or intra- and extracellular parameters. FBS: fetal bovine serum, GeLC:
gel-based liquid chromatography, HPLC: high performance liquid chromatography, MPA:
mycophenolic acid, MS: mass spectrometry, NMR: nuclear magnetic resonance, SILAC:
stable isotopic labeling by amino acids in cell culture.
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3.1 Cell cultures and incubation conditions
LS180 cells were purchased from the American Type Culture Collection (ATCC,
Manassas, VA; no. CL-187). This cell line was derived from a human type II colon
tumor. LS180 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)-
high glucose (Sigma, St. Louis, MO; DMEM 2964) and supplemented with antibi-
otics (100U/ml penicillin and 100µg/mL streptomycin, Sigma). For certain experi-
ments (as specified in text) LS180 cells were supplemented with 10% FBS (FetalPlex
Animal Serum Complex; Gemini Bio-Products, West Sacramento, CA). Cells were
subcultivated every 3-4 days (split ratio 1:3) using an EDTA solution (1L ESPG solu-
tion: 9g NaCl, 0.2g EDTA, 1g glucose, 20mL 1M KPi pH 7.6 (about 2.1g H2KPO4
and 14.7g HK2PO4 for 100mL) dissolved in 1L H2O, filtered sterile) to minimize
clumping.
RAW 264.7 cells were purchased from ATCC (no. TIB-71) and cultivated in DMEM-
high glucose (Sigma, DMEM 2964). The medium was supplemented with antibiotics
and with 10% FBS for general culturing and proliferation assays. Conducting ex-
periments for the inflammation model no FBS was used.
CCD-18Co cells were purchased from ATCC (no. CRL-1459) and cultivated in Ea-
gle’s Minimum Essential Medium (EMEM; Corning cellgro; no. 10-010-Cl, with 2mM
L-glutamine) and supplemented with antibiotics, 10% FBS, and 1% non-essential
amino acids (Cellgro).
All cell types were cultured at 37◦C in a humidified atmosphere with 5% CO2.
LS180 cells were grown and subcultivated in 75cm2 and 225cm2 flasks (DB Falcon).
For NMR experiments LS180 cells were grown on 150x15mm tissue culture dishes
(Nunc), for HPLC-MS and all other experiments on standard 100x20mm tissue cul-
ture dishes (DB Falcon). RAW 264.7 and CCD-18Co cells were grown on standard
100x20mm tissue culture dishes.
169
3 Materials and Methods
All solutions/media that consisted of partly unsterile components/supplements (ESPG
solution, media supplemented with guanosine, media containing labeled glucose or
amino acids) were filtered sterile using filter units of 0.2µm pore size (Nalgene).
3.1.1 Experimental conditions and drug treatment
For experiments all cells were plated in relation to incubation times. According to
each cell type’s doubling time (Sec. 3.2.1) cell densities were calculated to reach al-
most 100% confluency for controls at harvesting time, e.g. LS180 cells were seeded
to 75, 50, 35, or 25% confluency for 12, 24, 48, or 72h incubations, respectively
(doubling time of 51.1±2.7h).
MPA, MMF, and all MPAmetabolites were purchased from Toronto Research Chem-
icals (North York, Ontario, Canada). Morpholinoethanol was purchased from Sigma
Aldrich (purity 99%).
Drugs were spiked into cell culture media from concentrated stocks in DMSO/MeOH.
The final DMSO/MeOH concentration in culture media was 0.05% unless otherwise
specified.
3.2 Cell proliferation, cell viability, and other assays
3.2.1 Doubling time
Doubling time of all cell types was assessed by cell counts using a Nexelon Bioscience
Cellometer TM Auto T4 and the Cellometer Auto T4 software (N=3). Prior to
counting cells were stained with Trypan blue. Vital cells exclude this dye whereas
dead cells with compromised membrane integrity are penetrated and selectively take
on a blue color [380]. Using the Cellometer Auto T4 software cell numbers were
automatically corrected for dead cells. Doubling time of LS180 cells was determined
to be 51.1±2.7h, doubling time of RAW 264.7 cells was 15.4±0.2h, and doubling
time of CCD-18Co cells was 23.4±2.4h.
3.2.2 CyQUANT NF Cell Proliferation Assays
Cellular DNA content is highly regulated and closely corresponds to cell numbers
and therefore can be used to quantify cell populations [381]. The CyQUANT NF
Cell Proliferation Assay (Invitrogen) can be used to determine cellular DNA content
by fluorescent dye binding. It is more sensitive than the conventional MTT assay
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which is often used for proliferation studies.
96-well plates were prepared for incubation (Sec. 3.1.1), incubated with test com-
pounds (single dose or redosed every 24h), and the CyQUANT NF Cell Proliferation
Assay was performed following the manufacturer’s instructions. It was incubated
with 1X dye binding solution for 50-60min due to the large cell size of LS180 cells,
and fluorescence intensities were measured using a fluorescence microplate reader
(Thermo Scientific, Fluoroskan Ascent FL) at 485nm excitation and 530nm emis-
sion in combination with Ascent software (version 2.6).
3.2.3 LDH assays
During apoptosis and necrosis cell damage and lysis occur [382]. The soluble enzyme
LDH is released from the cytosol into the cell culture medium. LDH activity mea-
surement can be used to indicate cell death and therefore cytotoxicity-independent
of mechanism.
Cayman’s LDH Cytotoxicity Assay (Cayman Chemical Company, Ann Arbor, Michi-
gan) was performed following the manufacturer’s instructions. 96-well plates were
prepared for incubation (Sec. 3.1.1) and incubated with test compounds (single dose
or redosed every 24h), and the LDH assay was performed following the manufac-
turer’s instructions. The assay depends on a coupled two-step reaction. LDH from
the culture media oxidizes lactate to pyruvate and reduces NAD+ to NADH + H+.
The provided NADH + H+ serves to catalyze the reduction of the tetrazolium salt
2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride by diaphorase. The
amount of the product formazan, which absorbs at 490-520nm, is proportional to
the LDH concentrations in the culture media.
3.2.4 Caspase-3 western blots
In the process of apoptosis caspase-3 is cleaved into two activated fragments [144].
To test for induction of apoptosis in LS180 cells western blots for caspase-3 and
cleaved caspase-3 were conducted (Sec. 3.5.1). Samples were extracted for western
blots as described in Section 3.4.
3.2.5 cAMP/cGMP assays
cAMP and cGMP are second messengers and regulate a variety of cellular pro-
cesses [161]. Cyclic AMP/GMP XP Assays (Cell Signaling Technology) were per-
formed according to the manufacturer’s manual. 50µL cell lysate containing 175µg
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protein were used per well. cAMP/cGMP levels in samples compete with fixed
amounts of horseradish peroxidase (HRP)-linked cAMP/cGMP for binding to a
anti-cAMP/cGMP XP rabbit monoclonal antibody immobilized onto a 96-well plate.
After washing the finally added HRP substate 3,3’,5,5’-tetramethylbenzidine devel-
ops color and the absorbance at 450nm is inversely proportional to the quantity of
cAMP/cGMP in the sample.
3.3 Protein determination
The bicinchoninic acid (BCA) protein assay uses the reduction of Cu2+ to Cu+ by
protein in alkaline environment with the extend of reduction being proportional to
protein content [383]. The Cu+ generated forms a purple-colored chelate complex
with BCA. This complex strongly absorbs at 562nm. For determination of protein
content BCA assays were used (Pierce Biotechnology). As described in the manu-
facturer’s instructions 25µL of BSA standard or sample were used per microplate
well as well as 200µL working solution. It was incubated at 37◦C for 30min and
absorbance was read at 560nM.
3.4 Extraction methods
PCA extraction for HPLC-MS and NMR measurements
Lysis with 12% PCA inactivates enzymes through irreversible denaturation of the
structure of proteins and therefore stops cell metabolism.
For NMR experiments 5 150x15mm dishes were used per incubation condition and an
N=6 was prepared. For HPLC-MS experiments 1 dish was used per incubation con-
dition and an N=4 was prepared. After incubation cell culture media were removed
from cells (6mL per dish/30mL per condition were collected for NMR analysis). Cells
were washed 3 times with 5mL 0.9% NaCl and as much as possible of the remaining
solution was removed. Cells were frozen in liquid nitrogen and extracted with 3mL
12% PCA. Extracts were sonicated for 10min on ice and centrifuged (20min, 1450g,
4◦C). For NMR measurements pellets (proteins, lipids) were weighted for normal-
ization of metabolite concentrations to cell wet weight (weight of empty tubes had
been determined before) and temporarily stored at -80◦C. Supernatants (cell ex-
tracts) were neutralized with KOH and centrifuged again. Supernatants and cell
culture media (for NMR measurements) were frozen in liquid nitrogen and lyophyl-
ized.
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For NMR measurements protein-lipid pellets were resuspended in 5mL H2O and pH
values were adjusted to pH 7 with HCl and NaOH and lyophilized.
Extraction for western blots
Prior to extraction for western blot cells were washed 3 times with ice-cold phosphate-
buffered saline (PBS, Sigma). Cells were extracted with Cell Lysis Buffer (Cell
Signaling, no. 9803) according to the manufacturer’s instructions. 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF, Sigma) was used instead of phenyl-
methanesulfonylfluoride as protease inhibitor. Extracted cells were kept on ice for
10min, repeatedly vortexed, and centrifuged at 13.000g for 10min. The supernatants
were subjected to protein determination (Sec. 3.3) and prepared for western blots at
a concentration of 100µg/15µL in 1x Laemmli sample buffer (Bio-Rad) and stored
in aliquots at -20◦C.
Extraction for cAMP/cGMP assays
The same lysates that were used for western blot analyses were used for cAMP/cGMP
assays. The extraction is described in Section 3.4.
Extraction for QPCR
For RNA extraction the RNeasy Mini Kit (Qiagen, Chatworth, CA, no. 74104) was
used according to the manufacturer’s instructions. All steps were performed on ice
using nuclease-free materials. Cells (ca. 106) were washed with PBS, removed from
the plate, and pelleted. The pellet was resuspended in 200µL RLN buffer (contain-
ing 1U/µL RNAse inhibitor and 1mM DTT) to lyse the plasma membrane (but
leave the nuclear membranes intact) and the liquid preparation was placed in an
Eppendorf tube. Samples were centrifuged at 1000g at 4◦C to precipitate nuclei and
cell debris. The supernatants were added to a second tube containing 600µL RLT
buffer (provided) with 1% β-mercaptoethanol (ca. 800µL sample). 430µL ethanol
(200 proof) were added. 700µL sample were added to the provided spin columns and
centrifuged at 1000g, the liquid was discharged, the rest of the sample was added
and the centrifugation repeated, the liquid was discharged. The column was washed
twice with 700µL of RW1 buffer (provided). Using a new tube the column was
washed twice with RPE buffer (provided). After discharge of the liquid the remain-
ing ethanol was evaporated from the tube. To elute the sample from the column
two washing steps with nuclease-free water (100µL + 50µL) were performed and the
column discharged. Quantification and evaluation of purity was done spectrophoto-
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metrically (OD260x1.6 = RNA in µg/µL, for RNA purity OD260/OD280 >1.8) using
5µL of sample/nuclease-free water in 195µL milliQ water. Isolated RNA was stored
at -80◦C until analysis.
Extraction for SILAC
For SILAC experiments LS180 cells were extracted as described for western blots
(Sec. 3.4), but cells were washed 5 times with PBS (pelleted using a centrifuge
at 130g and resuspended) after removal from the cell culture dishes with ESPG
solution.
3.5 Molecular biology methods
3.5.1 Western blot analysis
To validate the LS180 cell culture model (stability of metabolizing enzymes over
passages, apoptotic potential of MPA by analysis of caspase-3 levels), and to vali-
date and further investigate SILAC results, western blot analysis was carried out.
Same samples were used for western blots of caspase-3 and Na+-K+-ATPase, valida-
tion/further investigation of proteomics results, as well as for cAMP/cGMP ELISA
assays. Protein lysis and preparation is described in Section 3.4. Samples were
aliquoted prior to storage at -80◦C limiting the number of freeze-thaw cycles to one.
Lysates at 100µg/15µL in 1x Laemmli Sample Buffer were boiled for 10min and
100µg protein (15µL) were loaded per well onto 26-well TCR-gels (Bio-Rad, Cri-
terion Tris-HCl precast gel, no. 345-0034). 5µL Precision Plus Protein Dual Color
Standard (Bio-Rad) and 2µL Biotinylated Protein Ladder (Cell Signaling) were used
per gel. Proteins were separated by gel electrophoresis in an ice bucket at 170V.
Proteins were transferred onto polyvinylidene fluoride membranes at 90V at 4◦C
for 2h. The membranes were washed in Tris-buffered saline (TBS, 1L 1X TBS: 8g
NaCl, 0.2g KCl, 3g Tris-base dissolved in 1L H2O, pH adjusted to 7.4 with HCl)
with 0.1% Tween-20 (TTBS) for 15min and blocked in 5% milk in TTBS for 1h
to block unspecific binding sites on the membranes to prevent antibody binding.
The membranes were incubated with the respective first antibodies (Tab. 3.1) in
5% milk in TTBS for 2h (in case of the Anti-MPA/AcMPAG antibody over night)
and washed 3 times for 10min in TTBS. It was incubated with the respective HRP-
coupled secondary antibodies (Tab. 3.1) in 5% milk in TTBS for 1h and washed
3 times for 10min with TTBS. The membranes were incubated with chemilumi-
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nescence solution (Bio-Rad, Immun-Star HRP Luminol/Enhancer and Immun-Star
HRP Peroxidase Buffer mixed 1:1) for 5min. Films were exposed to the chemilumi-
nescent membranes for varying time periods and developed using an ALLPRO 100
Film Processor. Films were scanned for densitometry using a Kodak Image Station
440CF. Band intensities were determined using 1D Image Station software (Kodak).
Bands were compared within gel and reported as arbitrary units. In cases of compar-
ison among/analysis of bands of different gels, additional samples for normalization
were run.
Table 3.1: Antibodies used for experiments elucidating the mechanisms of MPA
GI toxicity.
Antibody Manufacturer Prod. # Host Dilution/concentration
Anti-ANXA1 Cell Signaling 3299 Rb 1:1000
Anti-ACSL5 Sigma WH0051703M1 Ms 1:1000
Anti-ACSL5 Abcam ab104892 Rb 1:1000
Anti-Caspase-3 Cell Signaling 9662 Rb 1:1000
Anti-CYP3A4 Cell Signaling 12249 Rb 1:1000
Anti-CYP3A5 Sigma C4743 Ms 1:1000
Anti-IL-1β Cell Signaling 2022 Rb 1:1000
Anti-IL-6 Abcam ab6672 Rb 1:1000
Anti-INF-γ Abcam ab9657 Rb 0.2µg/mL
Anti-IMPDH1 Abcam ab33039 Rb 1:1000
Anti-IMPDH2 Abcam ab85702 Goat 1:1000
Anti-MDR1 Abcam ab80594 Ms 1:1000
Anti-MPA/AcMPAG Fisher Scientific custom Ms 1µg/mL
Anti-MRP1 Abcam ab3368 Rat 1:500
Anti-MRP2 Cell Signaling 4446 Rb 1:1000
Anti-Na+-K+-ATPase Cell Signaling 3010 Rb 1:1000
Anti-OAT1B1 Abcam ab103065 Rb 1:1000
Anti-OAT1B3 Novus Biologicals NBP1-45248 Goat 1:1000
Anti-OAT2B1 Abcam ab83532 Rb 1:1000
Anti-PIgR Abcam ab91269 Rb 1:1000
Anti-PXR Abcam ab85451 Rb 1:1000
Anti-REG-4 Abcam ab89917 Ms 1:1000
Anti-SLC12A2 Sigma AV43805 Rb 1:1000
Anti-TNFα Abcam ab9635 Rb 1:1000
Anti-UBC Cell Signaling 3933 Rb 1:1000
Anti-UGT1A7 Abcam ab105685 Rb 1:1000
Anti-UGT1A9 Abcam ab67535 Ms 1:1000
Anti-UGT1A10 Abcam ab76677 Ms 1:1000
Anti-UGT2B7 Fisher Scientific PA5-21507 Rb 1:500
Anti-ZO-1 Cell Signaling 5406 Rb 1:1000
Anti-14-3-3 θ Cell Signaling 9638 Rb 1:1000
Anti-Goat Abcam ab86245 Chicken 1:2000
Anti-Ms Cell Signaling 7076 Horse 1:2000
Anti-Rb Cell Signaling 7074 Goat 1:2000
Anti-Rat Cell Signaling 7077 Goat 1:2000
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3.5.2 QPCR
Primers for QPCR were designed using Beacon Designer software (version 7.7/7.9).
The iScript cDNA Synthesis Kit (Bio-Rad, no. 170-8891) was used to synthesize
cDNA according to the manufacturer’s instructions. Per reaction a total of 1µg of
RNA was pipetted into a 500µL centrifuge tube to which nuclease-free water was
added to bring the volume to 15µL. 5µL of a master mix (4µL 5X iScript Reac-
tion Mix + 1µL of iScript Reverse Transcriptase). Tubes were incubated using an
Eppendorf Mastercycler (iScript program according to the manufacturer’s instruc-
tions: 5min at 25◦C, 30min at 42◦C, 5min at 85◦C, samples held at 4◦C in the
end). Following cDNA synthesis samples were diluted 1:3 using nuclease-free water.
Reactions were prepared using a 96-well semi-skirted plate (AB gene, no. AB-0900,
suitable for use in a Bio-Rad iCycler). Each reaction consisted of 12.5µL 2X SYBR
Green Supermix (Bio-Rad, no. 170-8890) + 0.175µL of each forward and reverse
primer (10µM, final concentration 70nM) + 9.65µL nuclease-free water. Reaction
conditions were based on the annealing temperature of the primer set (generally
60◦C). The protocol was run for 55 cycles. Initial QPCR runs were followed by
analysis of the expected amplicon (product) on 1.2% agarose gel.
mRNA expression was quantified using Bio-Rad iQ5 software. mRNA levels of re-
spective genes were normalized based on mRNA levels of β-actin. All samples were
amplified in triplicates. Human kidney/liver tissue (Biochain) served as positive
control. Samples/diluted samples were used for calibration purposes since human
kidney/liver tissue did not provide mRNA leves high enough for comparison with
levels in LS180 cells.
Table 3.2: QPCR primers and conditions for sample analysis.
Target Annealing Amplicon No. of
transcript Primer set temp. [◦C] size cycles
UGT1A8 F: 5’ ACT TAC TCA ACC TCA TAC ACT 3’ 60 120 55
R: 5’ ACC ATT GGA TGA ACT CAG A 3’ 60 120 55
BCRP F: 5’ GAG GAA CTG GGT AGG ATT T 3’ 60 123 55
R: 5’ TAA GGA TGT AAA TGT TGG GAT 3’ 60 123 55
β-actin F: 5’ GTT CAA GCG ATT CTC CTG 3’ 60 106 55
R: 5’ GAT GAA ACC TTG TCT CTA CTA AA 3’ 60 106 55
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3.6 NMR analysis
3.6.1 Processing of cell extracts, media, and pellets
Lyophilized cell extracts were reconstituted in 600µL D2O and centrifuged (20min,
1450g, 20◦C). Supernatants were collected in NMR tubes and pH values were ad-
justed to pH 7 with deuterated hydrochloric adid (DCl) and deuterated sodium
hydroxide (NaOD).
Lyophilized media were reconstituted in 800µL D2O and prepared for NMRmeasure-
ments as cell extracts.
Lyophilized protein-lipid samples were reconstituted in 900µL deuterated chloro-
form (CDCl3)/deuterated methanol (CD3OD) (2:1) and transferred into glass tubes.
Tubes were plugged and centrifuged (20min, 1450g, 20◦C). Supernatants (lipid ex-
tracts) were transferred into NMR tubes. The protein pellet was not continued to
be used for protein determination since measured metabolite concentrations were
normalized to cell wet weight as determined during sample preparation after PCA
extraction.
3.6.2 Acquisition and processing parameters of NMR spectra
NMR spectra were recorded on a Bruker DRX 600 spectrometer (Bremen, Ger-
many) equipped with a 5-mm HCN probe (1H spectra of hydrophilic cell extracts
and lipids and 2D spectra) or a 5-mm 1H/13C dual probe (13C spectra) at frequencies
of 600MHz (1H) and 150MHz (13C). Spectra of hydrophilic and lipophilic extracts
were recorded using established puls sequences with water saturation independent
of d1 time (d1 = 5*T1).
Spectra were processed using MestRe-C software (version 4.9.9.9). Zero-filling to
32K was applied to all spectra. For 1H NMR spectra a gaussian apodisiation func-
tion (1-2Hz) was used, for 13C NMR spectra an exponential multiplication (varying
parameters) was used.
1H NMR parameters
Table 3.3 lists the parameters used for recording of 1H NMR spectra of hydrophilic
cell extracts and lipid extracts.
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Table 3.3: Parameters for the recording of 1H NMR spectra
Hydrophilic Lipophilic
Parameter extracts extracts
NMR probe 5-mm HCN inverse 5-mm HCN inverse
Temperature [K] 300 300
Spectral width [Hz/ppm] 9.50/150 9.50/150
Number of scans 400 300
Flip angle 40◦ 40◦
Repetition time [s] 17.2 17.2
Data size 16k 16k
13C NMR parameters
Table 3.4 lists the parameters used for recording of 13C NMR spectra of hydrophilic
cell extracts.
Table 3.4: Parameters for the recording of 13C NMR spectra
Cell
Parameter extracts
NMR probe 5-mm 1H/13C dual
Temperature [K] 300
Spectral width [Hz/ppm] 24154.59/160
Number of scans 20,000
Flip angle 27◦
Repetition time [s] 3
Data size 16k
1H-13C HSQC NMR parameters
Several 1H-13C HSQC NMR spectra of LS180 hydrophilic cell extracts and lipid ex-
tracts were recorded for signal assignment in 1D NMR spectra as well as to check for
compounds eventually arising due to MPA treatment or accumulating during MPA
treatment.
Table 3.5 shows the settings for the recording of 1H-13C HSQC NMR spectra. The
resolution in F1 and the number of scans was defined by aquisition time, metabolite
concentration, and desired resolution. 90◦ pulses were determined for each sample
individually. Representative values are listed.
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Table 3.5: Parameters of 1H-13C HSQC NMR spectra
Parameter Cell Lipid
extracts extracts
NMR probe 5-mm HCN inverse 5-mm HCN inverse
Temperature [K] 300 300
Spectral width F2 [Hz/ppm] 6009.62/10.01 6009.62/10.01
Spectral width F1 [Hz/ppm] 24154.59/160 24154.59/160
Number of scans 80 32
3.6.3 Quantitative analysis of NMR spectra
Quantification of metabolite concentrations from 1H NMR spectra
For 1H NMR spectra of hydrophilic extracts a capillary containing 3-(trimethylsilyl)-
2,2,3,3-d4 propionic acid (TSP) in D2O was used as an external standard for absolute
quantification of metabolites. A solution of saccharose and glutamine of known con-
centration served for determination of the TSP concentration inside the capillary.
For 1H NMR spectra of lipid extracts a TSP capillary of known TSP concentration
was used as standard (dissolved in CDCl3/CD3OD 2:1).
For calibration of the NMR spectra the TSP signal was set to 0.00ppm.
For quantification of glutamate, glutamine, and glutamate in GSH/GSSG from
1H NMR spectra C4 signals were integrated due to a complete overlap of C2 signals
and interference of C3 signals of glutamine and glutamate in GSH/GSSG (please
see 1H-13C HSQC spectra in Figure 2.58 and Figure 4.33 and 1H NMR spectra in
Figure 2.48).
Aspartate C3 signals from 1H NMR spectra were not integrated due to an often
insufficient S/N ratio and overlap with a peak of unknown origin at 2.721 ppm (13C:
39.905ppm, please see Section 3.6.3).
For quantitation of Cr and PCr CH2 signals at 3.93ppm and 3.95ppm, respectively,
were integrated due to an overlap of CH3 signals at 3.03ppm (the
1H-13C HSQC
NMR spectrum is shown in Figure 4.33 and the 1H NMR spectrum in Figure 2.48).
Quantification of concentrations of lipophilic compounds from 1H NMR
spectra
Due to varying chain lengths of lipids and overlaps of signals an absolute quan-
tification of lipophilic compounds was not possible and lipophilic compounds were
therefore quantified as % of controls only. As cholesterol signals overlapped with
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multiple other signals in lipid spectra (Fig 4.35) respective compounds were cor-
rected according to the number of protons contributing to the respective cholesterol
signals. Values calculated from the isolated cholesterol C18 signal served as correc-
tion factors.
Calculation of fractional 13C enrichment from 1H NMR spectra and amount
of 13C-labeled metabolites from 13C NMR spectra
13C enrichments in C3 lactate (ELac) were calculated from
1H NMR spectra accord-
ing to Zwingmann et al. [102] using peak areas of the [1H-12C] signal (I (1H-12C))
and the [1H-13C] satellite signals (I (1H-13C)) of lactate C3:
ELac [frac] =
I (1H −13 C)
I (1H −12 C) + I (1H −13 C)
. (3.1)
1.1% natural abundance of 13C was taken into account.
From lactate concentrations [Lac] and ELac from
1H spectra the natural abundances
of metabolites (In.a.(Met)) can be calculated from integrals of
13C spectra, In.a.(Met)
being the fraction of the integral representing the metabolite’s natural abundance:
In.a.(Met) =
I (13C − Lac) ∗ [Met]
(ELac + 1) ∗ [Lac]
. (3.2)
While I (13C-Lac) is the peak area of the [3-13C]lactate signal from 13C spectra, the
concentrations of lactate and the respective metabolite [Met] are calculated from 1H
spectra. Knowing In.a.(Met) the metabolite’s
13C enrichment EMet can be assessed
in %:
E(Met) [%] =
I (13C −Met)− In.a.(Met)] ∗NOE
(In.a.(Met)
. (3.3)
Here I (13C-Met) is the peak area of the metabolite of interest from 13C spectra
and the factor termed Nuclear Overhauser Enhancement (NOE) a correction factor
to adjust intensity gain or loss of signals due to suppression of C-H coupling and
saturation effects. The final concentration of metabolites from 13C spectra c (13C-
Met) is given by equation 3.4, which needs to be corrected by factor 100 due to
E(Met) given in %:
c (13C −Met) =
I (13C −Met)− In.a.(Met)] ∗NOE
(In.a.(Met)
. (3.4)
13C enrichments in alanine (C3) were calculated accordingly.
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Quantification of metabolic fluxes and TCA cycle ratios from 13C NMR
spectra
For determination of metabolic fluxes (PDH/PC ratios) the ratio of the C4 signal
to the C2 signal (C4/C2) of glutamate and glutamine were used.
Mono and double labels of metabolites were quantified separately to determine TCA
cycle ratios and an eventual increase/decrease in TCA cycle speed. The labeling pat-
tern of C4 of glutamate served for determination of these parameters by calculating
the ratio of doubly-labeled to mono-labeled signals.
1H-13C HSQC NMR spectra
Compounds were identified using published databases [349, 350].
Noticeable signals of unknown origin occured at 0.880ppm (t1)/15.916ppm (t2)
and 2.721ppm (t1)/ 39.905ppm (t2), signals not shown/not visible due to low sig-
nal intensity in Figure 2.58). Database searches did not yield reasonable results
(compounds of respective ppm values found in databases were of exogenous source
and/or associated signals of respective compounds were missing). Since no signifi-
cant changes in concentrations of the unknown compounds were seen after quanti-
tative analysis of 1H NMR spectra identification of compounds was not persued any
further.
As mentioned above (Sec. 3.6.3) calculation of fractional 13C enrichment of lactate
and amounts of 13C-labeled metabolites relied on quantitation of peak areas of [1H-
12C] signals of lactate C3 from 1H spectra. Using 2D NMR spectroscopy for a survey
of signals/compounds and signal assignment considerable overlays of the lactate C3
signal with other signals, i.e. N-acetyl-L-alanine, threonine, and acetoin, became
apparent (Fig. 2.58). Since related signals of these compounds at other ppm regions
exhibited severe overlaps with other signals, it was not possible to calculate and sub-
tract compound concentrations from lactate concentrations derived from lactate C3
signals. This needs to be kept in mind looking at fractional 13C enrichments of lac-
tate and amounts of 13C-labeled metabolites, as contribution of N-acetyl-L-alanine,
threonine, and acetoin to the lactate C3 signal is likely to result in underestima-
tion of fractional 13C enrichments in lactate as well as overestimation of 13C-labeled
metabolite concentrations. Additionally, concentrations of N-acetyl-L-alanine, thre-
onine, and acetoin possibly change with MPA concentrations. This possibly results
in under- and/or overestimation of changes or even compensation of changes.
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3.7 Measurement of high-energy phosphate levels
Samples were extracted as described in Section 3.4. Lyophilized cell extracts were
reconstituted in 500µL H2O. Samples were diluted 1:10 (100µL sample + 900µL
HPLC H2O) with a final internal standard concentration of 0.5µM (10mM stock).
A nucleotide mix containing all analytes in 0.5mM concentrations served for prepa-
ration of the calibration curve (0.03125-16µM). N6-(6-aminohexyl)adenosine 3’,5’-
diphosphate (6-aminohexyl-ADP) was used as internal standard.
HPLC-MS measurements were performed on an API 4000 triple quadrupole (AB
Sciex) with adjustments to the method which was previously published by Klawit-
ter et al. for nucleotide measurements using a 1946D Agilent mass selective detec-
tor [160]. The instrument was operated in the negative MRM mode with ESI source
and was equipped with an Agilent 1100 HPLC system. Analytes were extracted
using a ZORBAX C18, 5µm (4.6mm x 5mm) column (Agilent Technologies) column
and separated using a Phenomenex Synergy Hydro C18, 3µm (4.6mm x 250mm)
column (Phenomenex, Torrance, CA, USA).
The solvents were 2mM/4mM dibutylammonium formate (DBAF, mobile phase A)
and methanol + 0.1% FA (mobile phase B). The gradient used for inline extraction
was: 0.0-0.7min 3% 4mM DBAF buffer at a flow rate of 1000µL/min, 0.7-0.8min
3-100% 4mM DBAF buffer at a flow rate of 1000µL/min, 0.8-14.0min 100% 4mM
DBAF buffer at a flow rate of 100µL/min, 14.0-16.0min 100% 4mM DBAF buffer at
a flow rate of 1000µL/min, 16.0-16.1min 100-3% 4mM DBAF buffer at a flow rate of
1000µL/min, 16.1-18.0min 3% 4mM DBAF buffer at a flow rate of 1000µL/min for
re-equilibration to starting conditions. The gradient used for separation (at a con-
stant flow rate of 700µL/min) was: 0.0-1.0min 5% 2mM DBAF buffer, 1.0-3.0min
5-20% 2mM DBAF buffer, 3.0-10.0min 20-40% 2mM DBAF buffer, 10.0-13.0min
40-52% 2mM DBAF buffer, 13.0-14.0min 52-80% 2mM DBAF buffer, 14.0-14.8min
80-5% 2mM DBAF buffer, 14.-18.0min 5% 2mM DBAF buffer for re-equilibration
to starting conditions. Nitrogen was used as drying gas and collision gas.
The MS parameters were adjusted to: ion transition ATP: m/z = 506.3 [M-H]− →
408.2 with 40msec dwell time, with -83V DP, -28V CE, and -13V CXP; ion transition
ADP: m/z = 426.3 [M-H]− → 328.2 with 40msec dwell time, with -90V DP, -23V
CE, and -15V CXP; ion transition AMP: m/z = 346.2 [M-H]− → 79.0 with 40msec
dwell time, with -80V DP, -42V CE, and -5V CXP; ion transition GTP: m/z = 522.2
[M-H]− → 424.2 with 80msec dwell time, with -85V DP, -30V CE, and -15V CXP;
ion transition GDP: m/z = 442.2 [M-H]− → 344.2 with 80msec dwell time, with
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-85V DP, -30V CE, and -15V CXP; ion transition GMP: m/z = 362.2 [M-H]− → 79
with 80msec dwell time, with -85V DP, -42V CE, and -7V CXP; ion transition UTP:
m/z = 483.2 [M-H]− → 385.3 with 80msec dwell time, with -90V DP, -32V CE, and
-14V CXP; ion transition UDP: m/z = 403.2 [M-H]− → 79.0 with 80msec dwell
time, with -90V DP, -45V CE, and -15V CXP; ion transition UMP: m/z = 323.2
[M-H]− → 79 with 80msec dwell time, with -90V DP, -41V CE, and -6V CXP; ion
transition CTP: m/z = 482.3 [M-H]− → 384.1 with 80msec dwell time, with -80V
DP, -32V CE, and -15V CXP; ion transition CDP: m/z = 402.2 [M-H]− → 304.1
with 100msec dwell time, with -80V DP, -28V CE, and -13V CXP; ion transition
CMP: m/z = 322.1 [M-H]− → 79.0 with 80msec dwell time, with -80V DP, -42V CE,
and -8V CXP; ion transition NAD+: m/z = 662.1 [M-H]− → 540.4 with 100msec
dwell time, with -75V DP, -21V CE, and -10V CXP; ion transition NADP+: m/z =
742.1 [M-H]− → 620.5 with 120msec dwell time, with -65V DP, -22V CE, and -17V
CXP; ion transition FAD: m/z = 784.0 [M-H]− → 346.1 with 80msec dwell time,
with -140V DP, -40V CE, and -13V CXP; ion transition 6-aminohexyl-ADP: m/z =
525.0 [M-H]− → 233 with 40msec dwell time, with -90V DP, -36V CE, and -19V
CXP. The source temperature was set to 500◦C with a capillary voltage of -4200V
and CAD set to 12. The column oven temperature was set to 45±1◦C. The injection
volume was 100µL. Total run time was 18min.
For quantitation Analyst software (version 1.5.1) was used. Analytes were quantified
without using the internal standard due to the occurence of severe ion suppression
and the achievement of more resonable results not taking the internal standard into
account.
3.8 HPLC-MS assay development
3.8.1 HPLC-MS conditions
An HPLC-MS method for quantification of MPA, MMF, and their metabolites was
developed. Method development, conditions, and parameters are described in Sec-
tion 2.6.1. Due to problems with the stability of certain analytes and unexpected
matrix effects the method was not validated, only limits of detection (defined as a
S/N ratio of 3:1) in MeOH/H2O (1:1) were deterimined.
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3.8.2 Stability experiments
Stability experiments performed to identify possible pH- and matrix component-
dependency of the stability of AcMPAG and MPAG are described in Section 2.6.2.
3.9 Proteomics
3.9.1 Labeling of LS180 cells for SILAC experiments
Cells were labeled with heavy lysine ([U-13C6]-L-lysine, MW = 152.1259; stable iso-
tope of [12C6]-L-lysine) or light lysine ([
12C6]-L-lysine, MW = 146.1055) according
to the manufacturer’s instructions (Invitrogen, SILAC Protein Identification and
Quantification Kits, manual part no. 25-0841).
Labeling with heavy lysine (no double labeling, e.g. with lysine and arginine) was
used to determine differences in expression levels of proteins in LS180 cells. LS180
cells of sets labeled with heavy and light lysine were treated as described for other
experiments (1000µM guanosine, no FBS, 72h treatment, redosed every 24h). For
extraction cells were washed with 5mL PBS 3 times prior to removal from plates
using ESPG solution as for subcultivation. Cells were washed (pelleted and resus-
pended) 5 times with 3mL PBS to assure complete media removal and lysed using
300µL lysis buffer (Cell Signaling, containing AEBSF) as for western blot experi-
ments (Sec. 3.4).
3.9.2 IP using an anti-MPA/AcMPAG antibody
LS180 cells were incubated with drugs for 72h without FBS and were redosed ev-
ery 24h. Extraction and IP with an anti-MPA/AcMPAG antibody (kind gift of
Thermo Scientific) were performed using the Pierce Classic IP Kit (Thermo Scien-
tific) according to the protocol. A total amount of 1mg of total protein was used
per IP reaction (suggested amount 0.5-1mg) and 10µg of affinity-purified antibody
(suggested amount 2-10µg). Incubation time to form the immune complex was 24h
with gentle end-over-end mixing at 4◦C. Capture of the immune complex was per-
formed according to protocol. The complex was eluted (3 times using 50µL buffer,
respectively) using the low-pH elution option described in the protocol.
1D gel electrophoresis
Samples were prepared to contain 40µg protein per sample (20µg of H/L-labeled
protein each) in NuPAGE LDS sample buffer (4X, diluted with water) to yield a
184
3.9 Proteomics
final volume of 20µL. Samples were heated for 10min under shaking at 90◦C and
loaded onto NuPAGE Bis-Tris 4-20% gradient gels (Invitrogen), which were run
using MES SDS running buffer and an X-Cell II Mini Gel System (Invitrogen) at
200V, 120mA, 25W per gel for 30min. BenchMark Protein Ladder (Invitrogen) was
used as a protein molecular mass marker. After visualizing proteins using Coomassie
Blue (Invitrogen), each lane of the gel was cut into 25 bands of equal size always
covering the same molecular weight ranges for all samples.
Tryptic digestion
Trypsin is widely used to break up proteins into peptides for MS analysis [384].
Tryptic cleavage occurs at the C-terminus of arginine and lysine residues and cleav-
age of isotopically labeled proteins yields labeled peptides. Analyzing mixtures of
labeled and non-labeled peptides with C-terminal lysine, peptides show up in “peak
pairs” of 6.0204Da difference.
In-gel tryptic digestion The first three cut out bands of each sample were cut into
cubes and combined in one 0.6mL microcentrifuge tube. Consecutively, always two
bands were cut into cubes and combined yielding 12 tubes/samples per lane. Gel
bands were destained in 150µL 50% acetonitrile (ACN)/25mM ammonium bicarbon-
ate (ABC) overnight. After removing the supernatant 150µL 50% ACN/25mM ABC
were added and samples were vortexed on the shaker at medium speed for 15min.
After the supernatant was removed a third washing step with 100% ACN was per-
formed (150µL, 15min, vortexing). Disulfide bonds in proteins were reduced in-
cubating with 100µL 10mM dithiothreitol (DTT) at 60◦C for 30min and cysteine
residues were alkylated with 100µL 20mM iodoacetamide (IAA) in the dark for
45min. Gel pieces were washed with distilled water for 15min twice, then washed
once with ACN. The ACN was removed and the gel pieces were dried on a speed
vac (Savant, Thermo Fischer). 100ng of trypsin were added to each sample and left
at 4◦C for 30min to rehydrate the gel plugs and then incubated at room tempera-
ture overnight. Tryptic digests were acidified with FA up to a final concentration
of 1%. After vortexing for 15min, the digest solution was transferred to 0.65mL
siliconized tubes. Peptides were extracted from the gel pieces two more times using
60µL 1% FA in 50% ACN and extracts were combined with the respective initial
digestion supernatants. Samples were concentrated in a speed vac to the desired
volume of 1˜2µL, analyzed by LC-MS, and if necessary, stored at -20◦C.
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In-solution tryptic digestion 50µL/sample (to check for incorporation efficiency,
sample volume was brought up to 50µL/sample with 50mMABC) and 150µL/sample
(for the IP experiment) were used for in-solution tryptic digestion (due to the IP
the protein content was below the detection limits and the maximal amount of
150µL/sample was used). Digestion was performed following a modified Promega
ProteaseMAX Surfactant (Trypsin Enhancer) protocol adjusted to a final volume
of 50µL/sample and 150µL/sample instead of 100µL/sample for the assessment of
incorporation efficiency and IP experiments, respectively. pH values of IP sam-
ples (eluted with low-pH elution buffer, Pierce Classic IP Kit) were adjusted to
the optimal pH for trypsin digestion (pH 7.8-8.7) using 1M TRIS (pH 8.5, about
20µL/sample). Disulfide bonds in proteins were reduced by adding DTT to a fi-
nal concentration of 20mM (stock 200mM) and heating at 56◦C for 5min. Samples
were cooled down on ice. Cystein residues were alkylated by adding IAA to a fi-
nal concentration of 20mM (stock 200mM in 25mM ABC). Samples were vortexed,
spun down, and incubated for 45min in the dark. 1% ProteaseMAX Surfactant
and 1µg/µL trypsin (stock 1µg/µL in 50mM acetic acid) were added to final con-
centrations of 0.01% and 0.01µg/µL per sample, respectively. It was digested at
37◦C overnight. FA was added to a concentration of 0.1% (stock 5% FA, about
4µL/sample).
For IP samples after trypsin digestion and addition of FA to a concentration of
0.1%, the pH of the samples was checked and more FA was added if necessary to
adjust the pH to <4 to optimize sample binding to the resin of ZipTip Pipette
Tips (Millipore). Samples were vortexed for 10min. ZipTip Pipette Tips (10µL)
were activated by washing 3-4 times with 100% ACN and 3-4 times with 0.1% FA.
Activated ZipTip Pipette Tips were used on 200µL pipettes on top of a 200µL tip
and the complete sample was drawn through the Ziptip Pipette Tip multiple times.
ZipTip Pipette Tips were put back onto a 10µL pipette, washed once with 0.1% FA
and the sample was eluted from the ZipTip Pipette Tips by drawing up the elution
buffer (50% ACN, 1% FA, 20µL/sample were pipetted into siliconized tubes) about
20 times while transferring the samples to siliconized tubes. Sample volumes were
reduced using a speed vac until about 2µL/sample were left. About 10µL of 0.1% FA
was added per sample to a final volume of 12µL. Samples were stored at -20◦C until
MS analysis.
HPLC-MS analysis
SILAC SILAC/Gel-C MS samples, samples of the initial screen, and a set of sam-
ples to guarantee sufficient incorporation of heavy lysine were analyzed on a LTQ-FT
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Ultra hybrid mass spectrometer (Thermo Scientific). Peptide desalting and separa-
tion was achieved using a dual capillary/nano pump HPLC system (Agilent 1200,
Palo Alto, CA). On this system 8µL of sample were loaded onto a ZORBAX 300SB-
C18, 5µm (5x0.3mm) column (Agilent Technologies) to extract analytes and washed
with 5% ACN + 0.1% FA at a flow rate of 15µL/min for 5min. The extraction col-
umn was switched online with the nano pump at a flow rate of 350nL/min. An
85min gradient from 8% ACN to 40% ACN was used to separate the peptides. The
column was made from an in-house-pulled 360/100nm (outer/inner diameter) fused
silica capillary packed with Jupiter C18 resin (Phenomenex, Torrance, CA). The
column was kept at 40◦C using an in-house-built column heater. Data acquisition
was performed using Xcalibur software (version 2.0.6). The LC runs were monitored
in positive ion mode by sequentially recording survey MS scans (m/z = 400-2000),
in the ion cyclotron resonance cell, while three MS2 were obtained in the ion trap
via CID for the most intense ions. After two acquisitions of a given ion within 45s
the ion was excluded for 150s.
IP experiment IP samples were analyzed on a LTQ Orbitrap XL mass spectrom-
eter (Thermo Fisher Scientific) coupled to an Eksigent nanoLC-2D system through
a nano ESI LC-MS interface. 8µL of sample were injected into a 10µL loop using
the autosampler. To desalt the sample material was flushed out of the loop and
loaded onto a ZORBAX 300SB-C18, 5µm (5x0.3mm) column (Agilent Technolo-
gies) for extraction of analytes and washed with 5% ACN + 0.1% FA at a flow rate
of 1µL/min for 10min. The extraction column was switched online with the nano-
pump at a flow rate of 350nL/min. The solvents were water + 0.1% FA (mobile
phase A) and 99.9% ACN + 0.1% FA (mobile phase B). A 90min gradient from
6% ACN to 40% ACN was used to separate peptides. Peptides were separated on
a house-made 100µm (inner diameter) x 150mm fused silica capillary packed with
Jupiter C18 resin (Phenomex, Torrace, CA). Data aquisition was performed using
Xcalibur software. The mass spectrometer was operated in the positive ion mode.
The peptide ion masses were measured in the Orbitrap mass analyzer, whereas the
peptide fragmentation was performed by CID in the linear ion trap analyzer using
default settings. The ten most intense ions were selected for fragmentation in each
scan cycle. Fragmented masses were excluded from further sequencing for 90s.
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Database searching, protein identification, identification of covalent
modifications
MS/MS spectra were extracted from raw data files and converted into mgf files using
an in-house script. Mascot (Matrix Science Inc., London, UK; version 2.2) served to
perform database searches against the human subset SwissProt database of the ex-
tracted MS/MS data. Peptide tolerance was set to ±15ppm with MS/MS tolerance
set to ±0.6Da (spectra acquired from the LTQ-FT and LTQ Orbitrap). Full trypsin
specificity was required and one missed cleavage was allowed. Carbamidomethy-
lation on cysteine was defined as fixed modification, methionine oxidation and N-
terminal acetylation were defined as variable modifications in the database search.
For identification of covalent modifications of proteins by MPA/MPA metabolites
Thermo Proteome Discoverer Deamon software (Thermo Scientific, version 1.1.0)
was used in combination with Mascot which served to perform database searches.
The modifications listed in Table 2.15 were defined as additional fixed modifications.
The search was performed for potential modifications on all amino acids in groups
of 5 amino acids per each run.
Scaffold Proteome software was used to validate MS/MS-based peptide and pro-
tein identifications. For each sample (12 samples a 2 bands) all Mascot DAT files
were loaded together as one biological sample within Scaffold. Peptide identifica-
tions were accepted, if they could be established at greater than 95% probability as
specified by the Peptide Prophet algorithm. Protein identifications were accepted,
if they could be established at greater than 99% probability and contained at least
one identified unique peptide.
MaxQuant software settings
Analysis of SILAC/GelC-MS data was performed using the MaxQuant software
package (Max Planck Institute of Biochemistry, Martinsried, Germany, version 1.2.2.5).
Parameters for “Peptide identification and quantification” were set as follows: Pep-
tide false discorvery rate (FDR): 0.01, Site FDR: 0.01, Max. peptide posterior error
probability (PEP): 1, Min. peptides: 2, Min. razor + unique peptides: 1, Min. unique
peptides: 1 (at greater than 99% probability). Only unmodified peptides were used
and the modifications “Oxidation (M)”, “Acetyl (Protein N-term)”, and “Gln →
pyro-Glu”. Protein FDR was set to 0.01 and min. peptide length to 6 amino acids.
Parameters for “MS/MS & sequences” were set to ±15ppm and ±0.6Da for MS/MS
tolerance. As fixed modification “Carbamidomethyl (C)” was used. The human
subset of the FASTA database (version 3.87) was used for MaxQuant analysis of
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sequences.
DAVID/PANTHER software settings
(1) Employing DAVID’s Functional Annotation tool (comprehending the three tools
1A-1C) default settings for annotations as of which databases to search were used,
but the output was modified for further analysis using the provided tools.
(1A) LS180 cell and rat model data: For Functional Annotation Clustering Classi-
fication Stringency was customized (default medium): Kappa Similarity: Similarity
Term Overlap = 4 (default 3 for medium), Similarity Threshold = 1.00 (default
0.50); Classification: Initial Group Membership = 4 (default 3), Final Group Mem-
bership = 4 (default 3), Multiple Linkage Threshold = 0.50 (default 0.50); Enrich-
ment Thresholds: EASE score = 0.05.
(1A) Human non-cancer cell model data: For Functional Annotation Clustering,
Classification Stringency was customized (default medium): Kappa Similarity: Sim-
ilarity Term Overlap = 4 (default 3 for medium), Similarity Threshold = 1.00 (de-
fault 0.50); Classification: Initial Group Membership = 4 (default 3), Final Group
Membership = 4 (default 3), Multiple Linkage Threshold = 0.50 (default 0.50); En-
richment Thresholds: EASE score = 0.05.
(1B) For the Functional Annotation Chart thresholds were customized: Count: 10,
EASE: 0.05 (default 0.1).
(1C) Default settings were used, no customization possible.
(2) Using DAVID’s Functional Classification tool Classification Stringency/search
was customized: Kappa Similarity: Similarity Term Overlap = 4 (default 4), Simi-
larity Threshold = 0.30 (default 0.35); Classification: Initial Group Membership = 4
(default 4), Final Group Membership = 3 (default 4), Multiple Linkage Threshold =
0.50 (default 0.50).
DAVID, PANTHER, and Pathway Palette analyses were performed in September
2012. As databases get continously updated results may vary dependent on the time
of analysis.
Statistics for analysis of proteomics data/EASE scores
Expression Analysis Systematic Explorer (EASE) is a customizable software appli-
cation for biological data interpretation of gene lists resulting from high-throughput
data sets generated by e.g. proteomics or microarray analysis [385]. The EASE
method provides rapid, systematic, and robust analysis of given lists of genes and
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is featured in DAVID analysis tools. A p-value of 0.05 is widely used as threshold
for statistic significance of changes in data sets and is equivalent to 1.3 on a minus
log scale [299] as which the EASE scores in DAVID are presented.
3.10 In vitro gut inflammation model
3.10.1 Cultivation of LS180 cells on cell culture inserts and
TEER measurements
LS180 cells were cultivated on transwell inserts (Millipore, no. PIHT30R48) with a
pore size of 0.4µM that were used in combination with 6-well cell culture multiwell
plates (Millipore, no. PIMWS0650). LS180 cells were seeded onto inserts in different
densities and grown for 1-7 days. Daily TEER measurements were performed using
an EVOM2 Epithelial Voltohmmeter for TEER (World Precision Instruments) ac-
cording to the manufacturer’s instructions.
As TEER values indicated a not confluent monolayer at all times transwell inserts
were coated with two different matrices to improve cell adhesion and growth char-
acteristics. Human fibronection (BD Biosciences) and rat tail collagen (BD Bio-
sciences) served matrices. Inserts were coated according to the manufacturer’s in-
structions.
Human fibronectin was used at different concentrations of 1-5µg/cm2. 1mg (1mg/vial)
was resuspended in sterile distilled H2O, diluted to the desired concentration using
serum-free, Ca2+/Mg2+-free culture medium (pH 7.4), added to the wells in ap-
propriate amounts, and incubated at room temperature for 1h. The medium was
aspirated and inserts rinsed with PBS.
Rat tail collagen was used at a concentration of 5µg/cm2. The stock (3.8mg/mL)
was diluted to 25µg/mL using 0.02N acetic acid. The diluted material was added
to inserts in appropriate amounts, inserts were incubated at room temperature for
1h, and the solution aspirated. Inserts were rinsed with PBS.
LS180 cells were seeded and grown on coated inserts as described before. Despite the
coating TEER measurements indicated that LS180 cells do not grow into a confluent
monolayer.
3.10.2 Treatment of RAW 264.7 cells
For western blot analysis RAW 264.7 cells were grown on standard cell culture
dishes and not in 6-well plate due to the amount of material needed for the required
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number of western blots. Only 8mL cell culture media per dish were used for incu-
bations with test compounds to maintain the growth area to volume ratio that was
dictated by the used 6-well plates in combination with the transwell inserts, that
were planned to be used in following experiments. Cells were incubated with test
compounds for 4h (media also contained 1000µM guanosine and no FBS) in phenol
red-free media (as phenol red interferes with components of the BCA assay used
for protein determination) and 7mL of cell culture media per plate were collected
for western blot analysis (N=3). Cells were extracted for western blot analysis to
measure β-actin. As no appropriate loading control (as which β-actin served for
intracellular proteins) exists for proteins secreted into cell culture media a β-actin
control was used for normalization. Cell lysates were assayed using the BCA assay
for an estimate of concentration (concentrations were all within the same range) but
were used unadjusted in terms of protein content (the same amount of lysate was
used for all samples for the preparation for western blot analysis) so that normal-
ization based on β-actin would at least account for deviances in cell number among
samples.
3.10.3 Preparation of cell culture media for western blot analysis
Cell culture media were lyophilyzed and subsequently reconstituted in 500µL H2O.
BCA assays were run to determine the protein content of samples as described
in Section 3.3. Samples were prepared for western blot analysis as described in
Section 3.4 containing protein concentrations of 175µg/15µL to be able to load
175µg of protein per well for gel electrophoresis.
3.11 Statistics
Numerical data is presented as means ± standard deviations. For statistical analysis
SPSS software (versions 19 and 21) was used. Prior to statistical tests outliers and
extreme values (analysis by boxplots) were removed. One-way analysis of variance
(ANOVA) was used for comparison of more than two groups. To test for significant
changes inbetween groups Scheffe’s tests (unequal sample sizes due to removal of
outliers and extreme values) were used as post-hoc tests. Significance levels were set
at p<0.05 (∗), p<0.01 (∗∗), and p<0.001 (∗ ∗ ∗).
EASE scores for data analysis of proteomics data as used by several ones of the
online tools are described in Section 3.9.2.
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Fig. 4.1: Adenosine triphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.2: Adenosine diphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
245
4
A
p
p
en
d
ix
Fig. 4.3: Adenosine monophosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses
of test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
24
6
Fig. 4.4: Guanosine triphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.5: Guanosine diphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.6: Guanosine monophosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses
of test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.7: Uridine triphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.8: Uridine diphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.9: Uridine monophosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
25
2
Fig. 4.10: Cytidine triphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.11: Cytidine diphosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
25
4
Fig. 4.12: Cytidine monophosphate levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses
of test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.13: NAD+ levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of test compounds.
Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA combined with
Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.14: NADP+ levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of test compounds.
Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA combined with Scheffe’s
post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.15: FAD levels of LS180 cells after 12h, 24h, and 48h of treatment with single doses of test compounds.
Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA combined with
Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.16: Adenylate energy charge of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.17: Guanylate energy charge of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.18: Uridylate energy charge of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.19: Cytidylate energy charge of LS180 cells after 12h, 24h, and 48h of treatment with single doses of
test compounds. Values are given as means of % of controls (N=4). Significance was determined using one-way ANOVA
combined with Scheffe’s post − hoc test with ∗: p<0.05; ∗∗: p<0.005; ∗ ∗ ∗: p<0.001 versus controls.
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Fig. 4.20: PANTHER chart of differentially expressed proteins involved in lipid metabolism in LS180 cells after
MPA treatment. The x-axis shows the fold increase (uploaded value) of a respective protein as determined by SILAC and
GelC-MS, the y-axis shows the cumulative fraction (e.g. data point x=1.4, y=0.75: 75% of uploaded values have a value of
1.4 or smaller).
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Fig. 4.21: PANTHER chart of differentially expressed proteins involved in carbohydrate metabolism in LS180
cells after MPA treatment. The x-axis shows the fold increase (uploaded value) of a respective protein as determined by
SILAC and GelC-MS, the y-axis shows the cumulative fraction (e.g. data point x=1.4, y=0.75: 75% of uploaded values have
a value of 1.4 or smaller).
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Fig. 4.22: PANTHER chart of differentially expressed proteins involved in developmental processes in LS180 cells
after MPA treatment. The x-axis shows the fold increase (uploaded value) of a respective protein as determined by SILAC
and GelC-MS, the y-axis shows the cumulative fraction (e.g. data point x=1.4, y=0.75: 75% of uploaded values have a value
of 1.4 or smaller).
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Fig. 4.23: PANTHER chart of differentially expressed proteins involved in transport processes in LS180 cells after
MPA treatment. The x-axis shows the fold increase (uploaded value) of a respective protein as determined by SILAC and
GelC-MS, the y-axis shows the cumulative fraction (e.g. data point x=1.4, y=0.75: 75% of uploaded values have a value of
1.4 or smaller).
26
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Fig. 4.24: PANTHER chart of differentially expressed proteins according to protein class in LS180 cells after MPA
treatment. Shown protein classes were selected from a larger pool of protein classes. The x-axis shows the fold increase
(uploaded value) of a respective protein as determined by SILAC and GelC-MS, the y-axis shows the cumulative fraction (e.g.
data point x=1.4, y=0.75: 75% of uploaded values have a value of 1.4 or smaller).
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Table 4.1: Proteins/genes identified in [175, 176, 294] to be affected by MPA
treatment in rats. Proteins/genes are listed with their abbreviations, Uniprot identifiers
and reference. For their physiological functions, please see the references.
# Protein Abbr. Uniprot Acc. Ref.
1 Actin, cytoplasmic 1 (β-actin) ACTB P60711 [175]
Actb
2 L-lactate dehydrogenase B chain LDH-B P42123 [175]
Ldhb
3 Aldose reductase AR P07943 [175]
Akr1b1
4 Glyceraldehyde-3-phosphate dehydrogenase GAPDH P04797 [175]
Gapdh
5 Heat shock cognate 71 kDa protein HSPA8 P63018 [175]
(Heat shock 70 kDa protein 8) Hspa8/Hsc70
6 Gluthtione synthetase GSH-S P46413 [175]
Gss
7 Glycine amidinotransferase, mitochondrial AGAT P50442 [175]
Gatm/Agat
8 Alpha-enolase ENO1 P04764 [175]
Eno1
9 Hydroxyacid oxidase 2 HAOX2 Q07523 [175]
Hao2
10 Selenium-binding protein 1 SBP56 Q8VIF7 [175]
Selenbp1
11 Protein-disulfide-isomerase A3 PDIA3 P11598 [175]
Pdia3
12 ATP synthase subunit β, mitochondrial ATP5B P10719 [175]
Atp5b
13 Phosphotriesterase-related protein PTER Q63530 [175]
Pter
14 Aminoacylase-1A ACY-1A Q6PTT1 [175]
Acy1a
15 Pyridoxal kinase ALDH1 O35331 [175]
Pdxk
16 Aldehyde dehydrogenase, mitochondrial ALDH1 P11884 [175]
Aldh2
17 Peroxiredoxin-3 PRDX3 G3V7I0 [175]
Prdx3
18 Triosephosphate isomerase TIM P48500 [175]
Tpi1
19 Peroxiredoxin-6 PRDX6 O35244 [175]
Prdx6
20 Tropomyosin α-1 chain TM-1 P04692 [175]
Tpm1
21 Tropomyosin α-4 chain TM-4 P09495 [175]
Tpm4
22 Sodium/potassium-transporting ATPase subunit α-1 xxxATP1A1xxx
xxxAtp1a1xxx
P06685 [175]
23 Elongation factor 1-α 1 EF-1-α-1 P62630 [175]
Eef1a1
Continued on next page.
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Proteins/genes identified in [175, 176, 294] to be affected by MPA
treatment in rats, continued from previous page.
# Protein Abbr. Uniprot Acc. Ref.
24 Heat shock protein HSP 90-β HSP84 P34058 [175]
(Heat shock 84 kDa, HSP84) Hsp90ab1
25 Kynurenine/alpha-aminoadipate aminotransferase,
mitochondrial
KAT/AadAT
Kat2/Aadat
Q64602 [175]
26 Long-chain specific acyl-CoA dehydrogenase,
mitochondrial
xxxLCADxxx
Acadl
P15650 [175]
27 Aspartate aminotransferase, cytoplasmic GOT1 P13221 [175]
Got1
28 Pyruvate dehydrogenase E1 component subunit β,
mitochondrial
xxPDHE1-Bxx
Pdhb
P49432 [175]
29 Ester hydrolase C11orf54 homolog - Q5U2Q3 [175]
-
30 Sulfotransferase 1C2A ST1C2A Q9WUW9 [175]
Sult1c2a
31 Thiomorpholine-carboxylate dehydrogenase CRYM Q9QYU4 [175]
Crym
32 Methylmalonate-semialdehyde dehydrogenase
[acylating], mitochondrial
xxxMMSDHxxx
Aldh6a1
Q02253 [175]
33 4-hydroxyphenylpyruvate dioxygenase 4HPPD P32755 [175]
Hpd
34 Malate dehydrogenase, mitochondrial MDH2 P04636 [175]
Mdh2
35 Gamma-glutamyltranspeptidase 1 GGT1 P07314 [175]
Ggt1
36 Carbonic anhydrase 2 CA-II P27139 [175]
Ca2
37 Enoyl-CoA delta isomerase 1, mitochondrial ECI1 P23965 [175]
Eci1
38 14-3-3 protein θ YWHAZ P63102 [175]
Ywhaz
39 Pro-cathepsin H CTSH P00786 [175]
Ctsh
40 4-trimethylaminobutyraldehyde dehydrogenase TMABADH Q9JLJ3 [175]
Aldh9a1
41 Glutathione S-transferase α-1 GST1-1 P00502 [175]
Gsta1
42 Aquaporin-1 AQP-1 P29975 [175]
Aqp1
43 Cytochrome c oxidase subunit 2 MTCO2 P00406 [175]
Mtco2
44 Fructose-bisphosphate aldolase B ALDOB P00884 [175]
Aldob
45 Glutathione S-transferase α-4 GST 8-8 P14942 [175]
Gsta4
46 Hemoglobin subunit β-1 HBB P02091 [175]
Hbb
47 Hemoglobin subunit α-1/2 HBA1 P01946 [175]
Hba1
48 Cytochrome c oxidase subunit 4 isoform 1,
mitochondrial
xxxCOX IV-1xxx
Cox4i1
P10888 [175]
Continued on next page.
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Proteins/genes identified in [175, 176, 294] to be affected by MPA
treatment in rats, continued from previous page.
# Protein Abbr. Uniprot Acc. Ref.
49 Ribonuclease UK114 HRSP12 P52759 [175]
Hrsp12
50 Voltage-dependent anion-selective channel protein 1 VDAC-1 Q9Z2L0 [175]
Vdac1
51 Sodium/potassium-transporting ATPase subunit β-1 xxxATP1B1xxx
Atp1b1
P07340 [175]
52 Protein disulfide-isomerase A3 PDIA3 P11598 [176]
Pdia3
53 Selenium-binding protein 1 SELENBP1 Q8VIF7 [176]
Selenbp1
54 ATP synthase subunit β, mitochondrial ATP5B P10719 [176]
Atp5b
55 ATP synthase subunit α, mitochondrial ATP5A1 P15999 [176]
Atp5a1
56 Catalase CAT P04762 [294]
Cat
57 Dynein light chain 1, cytoplasmic DYNLL1 P63170 [294]
Dynll1
58 Cytochrome c oxidase subunit 1 MTCO1 P05503 [294]
Mtco1
59 Lipopolysaccharide-binding protein LBP Q63313 [294]
Lbp
60 Polymeric immunoglobulin receptor PIgR P15083 [294]
Pigr
61 Sphingosine 1-phosphate receptor 1 S1P1 P48303 [294]
S1pr1
62 Hepatocyte nuclear factor 4-α HNF-4-α P22449 [294]
Hnf4a
63 Lipolysis-stimulated lipoprotein receptor LSR Q9WU74 [294]
Lsr
64 Retinoic acid receptor α1 RARA Q9QWT4 [294]
Rara
65 CCAAT/enhancer-binding protein α C/EBPα P05554 [294]
Cebpa
66 Serine/threonine-protein phosphatase PP1-α
catalytic subunit
xxxPP-1Axxx
Ppp1ca
P62138 [294]
67 Galectin-9 Gal-9 P97840 [294]
Lgals9
68 Vascular endothelial growth factor A VEGF-A P16612 [294]
Vegfa
69 Solute carrier family 22 member 2 SLC22A2 Q9R0W2 [294]
Slc22a2
70 Sodium-coupled neutral amino acid transporter 3 SLC38A3 Q9JHZ9 [294]
Slc38a3
71 Sulfated glycoprotein 1 SGP-1 P10960 [294]
Psap
72 Hemoglobin subunit α-1/2 HBA1 P01946 [294]
Hba1
73 Syndecan-1 SYND1 P26260 [294]
Sdc1
Continued on next page.
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Proteins/genes identified in [175, 176, 294] to be affected by MPA
treatment in rats, continued from previous page.
# Protein Abbr. Uniprot Acc. Ref.
74 Actin, cytoplasmic 2 ACTG1 P63259 [294]
Actg1
75 Endoplasmin/Heat shock protein 90 kDa β member 1 xxxHSP90B1xxx
Hsp90b1
Q66HD0 [294]
76 Acyl-CoA desaturase 1 SCD1 P07308 [294]
Scd1
77 Stress-associated endoplasmic reticulum protein 1 SERP1 Q9R2C1 [294]
Serp1
78 Epoxide hydrolase 1 EPHX1 P07687 [294]
Ephx1
79 Fatty acid synthase FASN P12785 [294]
Fasn
80 3-oxo-5-alpha-steroid 4-dehydrogenase 1 SRD5A1 P24008 [294]
Srd5a1
Three Uniprot accessions, i.e. G3V7I0 (#17), P00406 (#43), P05503 (#58), were
unknown by DAVID and were therefore removed from the gene list for analy-
sis. Four genes/proteins were found repeatedly (in several publications) so that
73 genes/proteins constituted the gene list for analysis.
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Table 4.2: Proteins/genes identified in [295, 296] to be affected by MPA treat-
ment in HEK-293 and CCRF-CEM cells, respectively. Proteins/genes are listed
with their abbreviations, Uniprot identifiers and reference. For their physiological func-
tions, please see the references.
# Protein Abbr. Uniprot Acc. Ref.
1 Protein SET SET Q01105 [295]
SET
2 Complement component 1 Q subcomponent- C1qBP Q07021 [295]
binding protein, mitochondrial C1QBP
3 Electron transfer flavoprotein β-ETF P38117 [295]
subunit β ETFB
4 Cytochrome b-c1 complex subunit RISP P47985 [295]
Rieske, mitochondrial UQCRFS1
5 Peroxiredoxin-1 PRDX1 Q06830 [295]
PRDX1
6 Stathmin STMN1 P16949 [295]
STMN1
7 Thioredoxin domain-containing protein 12 ERp18 O95881 [295]
TXNDC12
8 Myosin regulatory light chain 12B MLC-2 O14950 [295]
MYL12B
9 Histone H2B type 1-A HIST1H2BA Q96A08 [295]
HIST1H2BA
10 Histone H2B type 1-C/E/F/G/I H2B.1 A P62807 [295]
HIST1H2BC
11 40S ribosomal protein S12 RPS12 P25398 [295]
RPS12
12 Profilin-1 PFN1 P07737 [295]
PFN1
13 Endoplasmin/Heat shock protein 90 kDa β member 1
(Human)
HSP90B1
HSP90B1
P14625 [296]
14 Cofilin-1 CFL1 P45592 [296]
Cfl1
15 Rho GDP-dissociation inhibitor 2 Rho GDI 2 P52566 [296]
ARHGDIB
16 Proliferating cell nuclear antigen PCNA P04961 [296]
Pcna
17 Acidic leucine-rich nuclear phosphoprotein 32 family
member B
xxxANP32Bxxx
Anp32b
Q9EST6 [296]
18 Deoxyuridine 5’-triphosphate nucleotidohydrolase dUTPase P70583 [296]
Dut
19 Serine/arginine-rich splicing factor 2 SRSF2 Q6PDU1 [296]
Srsf2
20 ATP synthase subunit β, mitochondrial ATP5B Q5M860 [296]
Atp5b
21 Prostaglandin E synthase 3 PTGES3 P83868 [296]
Ptges3
22 Peptidyl-prolyl cis-trans isomerase A PPIase A P10111 [296]
Ppia
23 Rho GDP-dissociation inhibitor 2 Rho GDI 2 P52566 [296]
ARHGDIB
One protein was found repeatedly in both publications so that 22 proteins consti-
tuted the gene list for analysis.
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Table 4.3: Functional Annotation Clustering of 74 genes/proteins affected by
MPA treatment in rats. Genes/proteins taken from [175, 176, 294]. Functional Anno-
tation Clustering was performed using customized options as described in Section 2.7.1,
3 annotation clusters were found (# 1-3). A representative annotation term was as-
signed to characterize grouping terms as comprehensively as possible (for specification
of most important other terms contributing to an annotation cluster/gene functional
group please see footnotes). Enrichment scores are given ranking biological significance
of gene groups based on overall EASE scores of all enriched annotation terms (for ex-
planation please see Section 3.9.2). The number of genes/proteins in each cluster is
given (Count) as well as the Uniprot accessions of genes/proteins from each cluster. 104
terms were not clustered.
Enr. Proteins encoded
# Rep. ann. term score Count by analyzed genes
1 Carbohydrate catabolic process 1 5.83 7 P00884, P04764,
P42123, P04636,
P49432, P04797,
P48500
2 Nicotinamide nucleotide metabolic 2.57 4 P00884, P42123,
process 2 P04636, P48500
3 Purine nucleoside triphosphate/ATP 1.6 4 P15999, P10719,
metabolic process 3 P06685, P07340
1 Glycolysis, glucose catabolic process, hexose catabolic process, monosaccharide catabolic process, cellular carbohydrate
catabolic process, alcohol catabolic process
2 Nicotinamide metabolic process, alkaloid metabolic process, pyridine nucleotide metabolic process, oxidoreduction coen-
zyme metabolic process, secondary metabolic process
3 ATPase activity, coupled to (transmembrane) movement of ions/substances; ATPase biosynthetic/metabolic process;
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substances, (purine) ribonucleo-
side/ribonucleotide triphosphate biosynthetic process; P-P-bond-hydrolysis driven/primary active transmembrane trans-
porter activity
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Table 4.4: Pathway Enrichment Analysis of 74 proteins/genes affected by MPA
treatment in rats. Proteins/genes taken from [175, 176, 294]. The KEGG database
and DAVID’s Functional Annotation Chart tool were used and customized as described
in Section 2.7.1. 11 records were found. The number of proteins/genes in each cluster
is given (Count) as well as the Uniprot accessions of genes/proteins from each cluster.
55 genes from the list were not in the output.
# Term Count Uniprot acc. P-value
1 Glycolysis/ 8 P11884, Q9JLJ3, 1.7E-5
gluconeogenesis P00884, P04764,
P42123, P49432,
P04797, P48500
2 Pyruvate metabolism 6 P11884, Q9JLJ3, 3.7E-5
P07943, P42123,
P04636, P49432
3 Arginine and proline 5 P11884, Q9JLJ3, 1.8E-3
metabolism Q6PTT1, P13221,
P50442
4 Propanoate 4 P11884, Q02253, 4.2E-3
metabolism Q9JLJ3, P42123
5 Cardiac muscle 5 P06685, P07340, 7.4E-3
contraction p10888, P04692,
P09495
6 Fatty acid 4 P15650, P11884, 3.8E-3
metabolism Q9JLJ3, P23965
7 Tryptophan 4 P11884, Q9JLJ3, 8.9E-3
metabolism Q64602, P04762
8 Phenylalanine 3 P32755, P13221, 1.1E-2
metabolism O35244
9 Glutathione 4 P07314, P00502, 1.2E-1
metabolism P14942, P46413
10 Fructose and 3 P07943, P00884, 4.0E-2
mannose metabolism P48500
11 Butanoate 3 P11884, Q9JLJ3, 4.3E-2
metabolism P49432
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Table 4.5: Functional Annotation Clustering of 22 proteins affected by MPA
treatment in human cells of non-cancerous origin. Proteins taken from [295, 296].
Functional Annotation Clustering was performed using customized options as described
in Section 2.7.1. Customization differed from customization for LS180 cell and rat model
analyses due to the insufficient amount of data which did not allow to restrict param-
eters as done previously. 4 annotation clusters were found (# 1-4). A representative
annotation term was assigned to characterize grouping terms as comprehensively as pos-
sible (for specification of all terms contributing to an annotation cluster/gene functional
group see footnotes). Enrichment scores are given ranking biological significance of gene
groups based on overall EASE scores of all enriched annotation terms (for explanation,
please see Section 3.9.2). The number of proteins/genes in each cluster is given (Count)
as well as the Uniprot accessions of proteins/genes from each cluster. 18 terms were not
clustered.
Enr. Proteins encoded
# Rep. ann. term score Count by analyzed genes
1 Organelle lumen 1 2.22 9 Q01105, O95881,
P23528, Q07021,
P38117, P14625,
P12004, Q01130,
O95881
2 Cellular macromolecular complex 2.19 3/4 Q01105, O95881,
subunit organization 2 Q96A08, P62807
3 Regulation of apoptosis 3 1.54 4/5 O95881, P23528,
P14625, Q06830,
O95881
4 Actin cytoskeleton organization 4 1.42 3/4 P52566, P23528,
P07737, P16949
1 Intracellular organelle lumen, organelle lumen, membrane-enclosed lumen
2 DNA packaging, nucleosome assembly, chromatin asembly, protein-DNA complex assembly, nucleosome organization,
chromatin assembly or disassembly, cellular macromolecular complex subunit organization
3 Regulation of apoptosis, regulation of programmed cell death, regulation of cell death, cellular homeostasis
4 cytoskeleton organization, actin cytoskeleton organization, actin filament-based process
Pathway enrichment analysis of 22 proteins affected by MPA treatment in human
cells of non-cancerous origin (Proteins taken from [295, 296]) using the KEGG
database and DAVID’s Functional Annotation Chart tool customized as described
in section 2.7.1 did not yield any enriched pathways.
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Fig. 4.25: KEGG pathway map 00071: Fatty acid metabolism. EC numbers of proteins significantly affected by MPA
treatment in LS180 cells are circled in red and specified in the red box.
27
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Fig. 4.26: KEGG pathway map 00280: Valine, leucine, and isoleucine degra-
dation. EC numbers of proteins significantly affected by MPA treatment in LS180 cells
are circled in red and specified in the red box.
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Fig. 4.27: KEGG pathway map 05130: Pathogenic Escherichia Coli infection. Proteins significantly affected by MPA
treatment in LS180 cells are circled in red and specified in the red box.
27
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Fig. 4.28: KEGG pathway map 04540: Gap junction. Proteins significantly affected
by MPA treatment in LS180 cells are circled in red and specified in the red box.
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ix Fig. 4.29: KEGG pathway map 00640: Propanoate metabolism. EC numbers of proteins significantly affected by MPA
treatment in LS180 cells are circled in red and specified in the red box.
28
0
Fig. 4.30: KEGG pathway map 00062: Fatty acid elongation. EC numbers of
proteins significantly affected by MPA treatment in LS180 cells are circled in red and
specified in the red box.
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4 Appendix
Fig. 4.31: KEGG pathway map 03320: PPAR signaling pathway. Proteins signifi-
cantly affected by MPA treatment in LS180 cells are circled in red. Protein abbreviations
in this figure were assigned by KEGG, proteins abbreviated differently in prior chapters
were renamed in red.
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Unique peptides identifying ACSL5 and immunogen sequences of the
used anti-ACSL5 antibodies
As a representative example the sequence of the NP 976313.1 variant of isoform
b (683 aa protein) for ACSL5 is shown below (taken from PubMed, numbers indi-
cate numbers of first amino acids of each block). ACSL5 was identified by 18 unique
peptides (Tab. 2.3), which are marked by bold letters in brackets in the amino acid
sequence. Immunogen sequences of antibody 1 (Sigma, WH0051703M1, marked in
red) and antibody 2 (Abcam, ab104892, marked in blue) are marked.
aa1 mlfifnflfsplptpaliciltfgaaiflwlitrpqpvlplldlnnqsvgieggarkgvs
a61 qknndltsccfsdak{tmyevfqr}glavsdngpclgyrkpnqpyrwlsykqvsdraeylgs
121 cllhkgyksspdqfvgifaqnrpewiiselacytysmvavplydtlgpeaivhivnk{adi
181 amvicdtpqk}{alvlignvek}gftpslk{viilmdpfdddlkqr}gek{sgieilslydaenlg
241 k}ehfr{kpvppspedlsvicftsgttgdpk}gamithqnivsnaaaflk{cvehayeptpddv
301 aisylplahmfer}{ivqavvyscgar}{vgffqgdir}lladdmk{tlkptlfpavpr}llnriyd
361 kvqneaktplkkfllklavsskfkelqkgiirhdsfwdklifakiqdslggrvr{vivtga
421 apmstsvmtffr}aamgcqvyeaygqtectggctftlpgdwtsghvgvplacnyvkledva
481 dmnyftvnnegevcikgtnvfkgylkdpek{tqealdsdgwlhtgdigr}wlpngtlkiidr
541 kknifk{laqgeyiapek}ieniynr{sqpvlqifvhgeslr}{sslvgvvvpdtdvlpsfaak}l
601 gvk{gsfeelcqnqvvr}eailedlqkigkesglktfeqvk{aiflhpepfsienglltptlk}
661 akrgelskyfr{tqidslyehiqd}
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Unique peptides identifying ANXA1 and immunogen sequence of the
used anti-ANXA1 antibody
As a representative example the sequence of the NP 000691.1 variant (646 aa pro-
tein) of ANXA1 is shown below (taken from PubMed, numbers indicate numbers
of first amino acids of each block). ANXA1 was identified by 14 unique peptides
(Tab. 2.3), which are marked by bold letters in brackets in the amino acid se-
quence (the unique peptide mygislcqaildetkgdyek comprises the unique peptide my-
gislcqaildetk of which both sequences served for identification of ANXA1 and only
13 peptides are marked in the amino acid sequence below). The immunogen se-
quence against which the used anti-ANXA1 (Cell signaling, #3299) antibody was
raised is undisclosed by the manufacturer. Amino acid (aa) 207 (in human; aa 206
in rabbit/host; tyrosine, y) is included in the immunogen and marked in red in the
sequence below.
aa1 m{amvseflk}{qawfieneeqeyvqtvk}ssk{ggpgsavspyptfnpssdvaalhk}aimvk{gv
a61 deatiidiltk}rnnaqrqqikaaylqetgkpldetlkk{altghleevvlallk}{tpaqfda
121 delr}aamk{glgtdedtlieilasr}tnkeirdinrvyreelkrdlak{ditsdtsgdfr}nal
181 lslakgdr{sedfgvnedladsdar}alyeagerrk{gtdvnvfntilttr}sypqlrrvfqky
241 tkyskhdmnk{vldlelkgdiek}cltaivkcatskpaffaeklhqamkgvgtrhkalirim
301 vsrseidmndikafyqk{mygislcqaildetkgdyek}{ilvalcggn}
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Unique peptides identifying SLC12A2 and immunogen sequence of the
used anti-SLC12A2 antibody
As a representative example the sequence of the AAI 46840.1 variant (1196 aa pro-
tein) of SLC12A2 is shown below (taken from PubMed, numbers indicate numbers
of first amino acids of each block). SLC12A2 was identified by 30 unique peptides
(Tab. 2.5), which are marked by bold letters in brackets in the amino acid se-
quence (the unique peptides lkegldishlqgqeellssqek and keniiafeeiiepyr comprise the
unique peptides egldishlqgqeellssqek and eniiafeeiiepyr respectively of which both
sequences served for identification of ANXA11. Only 28 peptides are marked in the
amino acid sequence below). The immunogen sequence of the used anti-SLC12A2
antibody (Sigma, AV43805) is marked in red.
aa1 mepr{ptapssgapglagvgetpsaaalaaar}{velpgtavssvpedaapasr}{dgggvrdeg
a61 paaagdglgrplgptpsqsr}{fqvdlvsenagr}{aaaaaaaaaaaaaaagagagak}qtpadg
121 easgesepakgseeakgrfrvnfvdpaasssaedslsdaagvgvdgpnvsfqnggdtvls
181 egsslhsgggggsghhqhyyydthtntyylr{tfghntmdavpr}idhyrhtaaqlgekllr
241 pslaelhdelekepfedgfangeestptr{davvtytaesk}gvvkfgwikgvlvrcmlniw
301 gvmlfirlswivgqagiglsvlvimmatvvttitglstsaiatngfvr{gggayylisr}sl
361 gpefggaiglifafanavavamyvvgfaetvvellkehsilmideindiriigaitvvil
421 lgisvagmeweakaqivllvilllaigdfvigtfipleskkpkgffgyksei{fnenfgpd
481 fr}eeetffsvfaiffpaatgilaganisgdladpqsaipkgtllailittlvyvgiavsv
541 gscvvrdatgnvydtivteltnctsaacklnfdfsscesspcsyglmnnfqvmsmvsgft
601 plisagifsatlssalaslvsapkifqalck{dniypafqmfak}gygknneplrgyiltfl
661 ialgfiliaelnviapiisnﬄasyalinfsvfhaslakspgwrpafkyynmwisllga
721 ilccivmfvinwwaalltyvivlglyiyvtyk{kpdvnwgsstqaltylnalqhsir}lsgv
781 edhvk{nfrpqclvmtgapnsr}{pallhlvhdftk}{nvglmicghvhmgpr}rqamkemsidqa
841 kyqrwliknkmk{afyapvhaddlr}{egaqylmqaaglgr}mkpntlvlgfkk{dwlqadmr}dv
901 dmyinlfhdafdiqygvvvir{lkegldishlqgqeellssqek}spgtk{dvvvsveysk}ks
961 dldtskplsekpithkesk{gpivplnvadqk}{lleastqfqk}kqgkntidvwwlfddgglt
1021 llipyllttkkkwkdckirvfiggkinridhdrramatllskfr{idfsdimvlgdintkp
1081 k}{keniiafeeiiepyr}lheddkeqdiadkmkedepwr{itdnelelyk}tktyrqirlnell
1141 k{ehsstaniivmslpvar}{kgavssalymawlealsk}{dlppillvr}{gnhqsvltfys}
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Unique peptides identifying PIgR and immunogen sequence of the used
anti-PIgR antibody
As a representative example the sequence of the AAI 10495.1 variant (764 aa pro-
tein) of PIgR is shown below (taken from PubMed, numbers indicate numbers of first
amino acids of each block). PIgR was identified by 13 unique peptides (Tab. 2.5),
which are marked by bold letters in brackets in the amino acid sequence. The im-
munogen sequence against which the used anti-PIgR antibody (Abcam, ab91269)
was raised is undisclosed by the manufacturer. The anti-PIgR antibody was raised
against a synthetic peptide selected from the C-terminal region (red) of human PIgR
(the amino acid sequence is displayed from N- to C-terminus as conventional).
(N-terminus)
aa1 mllfvltcllavfpaistkspifgpeevnsvegnsvsitcyypptsvnrhtrkywcrqga
a61 r{ggcitlissegyvssk}yagranltnfpengtfvvniaqlsqddsgrykcglginsrgls
121 fdvslevsqgpgllndtkvytvdlgrtvtincpfktenaqkrkslykqiglypvlvidss
181 gyvnpnytgrirldiqgtgqllfsvvinqlrlsdagqylcqagddsnsnkk{nadlqvlkp
241 epelvyedlr}{gsvtfhcalgpevanvak}flcr{qssgencdvvvntlgk}rapafegrilln
301 pqdk{dgsfsvvitglr}kedagr{ylcgahsdgqlqegspiqawqlfvneestipr}sptvvk
361 gvaggsvavlcpynrkesksik{ywclwegaqngr}{cpllvdsegwvk}aqyegrlslleepg
421 ngtftvilnqltsrdagfywcltngdtlwrttveikiiegepnlkvpgnvtavlgetlkv
481 pchfpckfssyekywckwnntgcqalpsqdegpskafvncdensr{lvsltlnlvtr}{adeg
541 wywcgvk}{qghfygetaavyvaveer}kaagsrdvslakadaapdekvldsgfreienkaiq
601 dprlfaeekavadtrdqadgsrasvdsgsseeqggssr{alvstlvplglvlavgavavgv
661 ar}arhrknvdrvsirsyrtdismsdfensrefgandnmgassitqetslggk{eefvatte
721 sttetk}epkkakrsskeeaemaykdfllqsstvaaeaqdgpqea (C-terminus)
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Unique peptides identifying REG-4 and immunogen sequence of the used
anti-REG-4 antibody
As a representative example the sequence of the AAH 17089 variant (158 aa protein)
of REG-4 is shown below (taken from PubMed, numbers indicate numbers of first
amino acids of each block). REG-4 was identified by 8 unique peptides (Tab. 2.5),
which are marked by bold letters in brackets in the amino acid sequence (the unique
peptide sqpiwiglhdpqkr comprises the unique peptide sqpiwiglhdpqk of which both
sequences served for identification of the protein and only 7 peptides are marked
in the amino acid sequence below). As immunogen to raise the used anti-REG-4
antibody (Abcam, ab89917) served recombinant human full length REG-4 protein.
aa1 masrsmrlllllsclaktgvlgdiimr{pscapgwfyhk}{sncygyfr}klr{nwsdaelecqs
a61 ygngahlasilslk}{eastiaeyisgyqr}{sqpiwiglhdpqkr}{qqwqwidgamylyr}swsg
121 ksmggnk{hcaemssnnnfltwssnecnk}rqhflckyrp
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Fig. 4.32: Metabolic fate of the 13C label of [1-13C]glucose. Label distribution
in glycolytic and TCA cycle intermediates during metabolism of [1-13C]glucose. For
label distribution via PC into glutamine and glutamate only one TCA cycle turn is
concidered, for metabolism via PDH label distribution after one and two TCA cycle
turns are presented. The fate of the 13C label form [1-13C]glucose is indicated by circles;
black circles: 13C-label position in glycolytic products (lactate and alanine synthesized via
LDH and ALAT, respectively) and in TCA cycle-related metabolites synthesized via PC
and PDH during the first TCA cycle turn (for other isotopomers, please see Table 2.17);
gray circles: 13C-label position due to equilibration of PC-derived axaloacetate with
fumarate and 13C-label positions within the second TCA cycle turn via PDH. ALAT:
alanine aminotransferase, GDH: glutamate dehydrogenase, LDH: lactate dehydrogenase,
PC: pyruvate carboxylase, PDH: pyruvate dehydrogenase. Graph and caption taken
from [102], modified.
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Fig. 4.33: 1H-13C HSQC spectrum of ppm regions 2.9-5.0 (t1) and 33-80 (t2) of
an LS180 cell extract. Compounds were identified using published databases [349, 350]
and were compared to 1H and 13C NMR spectra of cell extracts of same experimental con-
ditions (controls). Amino acid abbreviations are based on IUPAC nomenclature. cAMP:
cyclic adenosine monophosphate, Cr: creatine, Glc: glucose, GSH: reduced glutathione,
GSSG: oxidized glutathione, Ins: inositol, Nuc: nucleotides, OAA: oxaloacetate, PC:
phosphocoline, PCr: phosphocreatine, R-N+(CH3)3: trimethyl ammonium compounds,
Tau: taurine. ppm regions 0.0-3.0 (t1)/10-40 (t2) and 4.0-6.5 (t1)/80-110 (t2) of the
same 1H-13C HSQC spectrum are shown in Figure 2.58 and Figure 4.34.
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Fig. 4.34: 1H-13C HSQC spectrum of ppm regions 4.0-6.5 (t1) and 80-110 (t2)
of an LS180 cell extracts. Compounds were identified using published databases [349,
350] and were compared to 1H and 13C NMR spectra of cell extracts of same experimental
conditions (controls). Glc: glucose, Nuc: nucleotides, UDP: uridine diphosphate. ppm
regions 0.0-3.0 (t1)/10-40 (t2) and 2.9-5.0 (t1)/33-80 (t2) of the same 1H-13C HSQC
spectrum are shown in Figure 2.58 and Figure 4.33.
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Fig. 4.35: 1H-13C HSQC spectrum of ppm regions 0.0-3.0 (t1)/10-60 (t2)
of a lipophilic LS180 cell extract. Compounds were identified using published
databases [349, 350] and were compared to 1H and 13C NMR spectra of lipid extracts
of same experimental conditions (controls). Chol: cholesterol/cholesterolester, F: fatty
acid, Fα/β: carbon atom in α/β-position to carboyl carbon atom, F∆: carbon atom
at a double bond, Fω: terminal carbon atom, PE: phosphatidylethanolamine, PtdCho:
phosphatidylcholine, SPH: sphingomyeline. ppm regions 3.0-5.5 (t1)/40-75 (t2) and 5.0-
5.5 (t1)/120-135 (t2) of the same 1H-13C HSQC spectrum are shown in Figure 4.36.
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Fig. 4.36: 1H-13C HSQC spectrum of ppm regions 3.0-5.5 (t1)/40-75 (t2)
and 5.0-5.5 (t1)/120-135 (t2) of a lipophilic LS180 cell extract. Compounds
were identified using published databases [349, 350] and were compared to 1H and
13C NMR spectra of lipid extracts of same experimental conditions (controls). Chol:
cholesterol/cholesterolester, DAG: diacylglycerols, R-N+(CH3)3: trimethyl ammonium
compounds, PE: phosphatidylethanolamine, plas: plasmalogen, PtdCho: phosphatidyl-
choline, SPH: sphingomyeline, TAG: triacyl glycerols, TDB: total number of double
bonds. ppm regions 0.0-3.0 (t1)/10-60 (t2) of the same 1H-13C HSQC spectrum are
shown in Figure 4.36.
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Fig. 4.37: Western blot of LS180 cell lysates after 72h of MPA and/or flucona-
zole treatment in FBS-free media and incubation with an anti-MPA/AcMPAG
antibody. A film developed after a shorter exposure time is shown in Figure 2.46 to
facilitate visualization of proteins at the medium molecular weight range. A western blot
of the same experiment run with FBS is shown in Figure 2.45.
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Fig. 4.38: Effects of fluconazole treatment on LS180 cell number and LDH
activity in LS180 cell culture media after 72h (redosed every 24h). Values are
given as means of % of controls with standard deviations (N=6). Significance was deter-
mined using one-way ANOVA combined with Scheffe’s post − hoc test with ∗: p<0.05;
∗∗: p<0.01; ∗ ∗ ∗: p<0.001 versus controls. Values were calculated from fluorescence
intensities using the CyQUANT R© NF Cell Proliferation Assay for assessment of cell num-
ber and calculated from LDH activities and normalized to fuorescence intensities using
the CyQUANT R© NF Cell Proliferation Assay for assessment of extracellular LDH. LDH
activities represent only the incubation time of 48h to 72h (24h total) due to media
renewal every 24h.
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